CAMK2B
Normalized values from positional scanning peptide array
Phospho-serine (pS) is a duplicate of phospho-tyrosine (pT) in PSPA
Position-wise Probabilities
Log-Odds: Probabilities / STY Background
Sites with acceptor types representing >8% and count ≥10 are included
S Sites Probabilities
T Sites Probabilities
Log-Odds: S Sites / S Background
Log-Odds: T Sites / T Background
Sites with acceptor types representing >8% and count ≥10 are included
Motif clusters with count ≥ 10 are shown
Download
| substrate_uniprot | site | source | substrate_genes | site_seq |
|---|---|---|---|---|
| A0A2R8Y4L2 | S95 | Sugiyama | HNRNPA1L3 HNRNPA1P48 | RPHKVDGRVVEPKRAVSREDsQRPDAHLTVKKIFVGGIKED |
| O00273 | S28 | Sugiyama | DFFA DFF1 DFF45 H13 | GVPESGEIRTLKPCLLRRNysREQHGVAAsCLEDLRSKACD |
| O00488 | S93 | Sugiyama | ZNF593 ZT86 | STNLKTHFRSKDHKKRLKQLsVEPysQEEAERAAGMGSYVP |
| O00488 | Y97 | Sugiyama | ZNF593 ZT86 | KTHFRSKDHKKRLKQLsVEPysQEEAERAAGMGSYVPPRRL |
| O14974 | S910 | Sugiyama | PPP1R12A MBS MYPT1 | yETssTsAGDRyDsLLGRsGsysYLEERKPYSSRLEKDDST |
| O14974 | S995 | Sugiyama | PPP1R12A MBS MYPT1 | ADRSLLEMEKRERRALERRIsEMEEELKMLPDLKADNQRLK |
| O15067 | S215 | Sugiyama | PFAS KIAA0361 | LDSWDLDFYTKRFQELQRNPstVEAFDLAQsNsEHSRHWFF |
| O15212 | T38 | Sugiyama | PFDN6 HKE2 PFD6 | QLQKDLSKSMSGRQKLEAQLtENNIVKEELALLDGsNVVFK |
| O15460 | T532 | Sugiyama | P4HA2 UNQ290/PRO330 | WVSNKWFHERGQEFLRPCGstEVD_________________ |
| O43399 | S166 | Sugiyama | TPD52L2 | tVGsAIsRKLGDMRNsAtFKsFEDRVGtIKSKVVGDRENGs |
| O43399 | T163 | Sugiyama | TPD52L2 | ALstVGsAIsRKLGDMRNsAtFKsFEDRVGtIKSKVVGDRE |
| O43823 | S323 | Sugiyama | AKAP8 AKAP95 | RKRKQFQLyEEPDtKLARVDsEGDFsENDDAAGDFRsGDEE |
| O43852 | S44 | Sugiyama | CALU | KKDRVHHEPQLsDKVHNDAQsFDyDHDAFLGAEEAKtFDQL |
| O60266 | S1076 | ELM | ADCY3 KIAA0511 | ARKPHYDIWGNTVNVASRMEsTGVMGNIQVVEETQVILREY |
| O60664 | S148 | Sugiyama | PLIN3 M6PRBP1 TIP47 | KVsGAQEMVssAKDTVAtQLsEAVDATRGAVQSGVDKTKsV |
| O60814 | S39 | Sugiyama | H2BC12 H2BFT HIRIP1 HIST1H2BK | VTKAQKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIssKA |
| O60841 | S107 | Sugiyama | EIF5B IF2 KIAA0741 | NEEEFtsKDKKKKGQKGKKQsFDDNDsEELEDKDsKSKKTA |
| O60841 | S182 | Sugiyama | EIF5B IF2 KIAA0741 | DGsEEDEDNsKKIKERsRINssGEsGDEsDEFLQsRKGQKK |
| O60841 | S183 | Sugiyama | EIF5B IF2 KIAA0741 | GsEEDEDNsKKIKERsRINssGEsGDEsDEFLQsRKGQKKN |
| O60841 | S186 | Sugiyama | EIF5B IF2 KIAA0741 | EDEDNsKKIKERsRINssGEsGDEsDEFLQsRKGQKKNQKN |
| O60841 | S66 | Sugiyama | EIF5B IF2 KIAA0741 | KEKKKQDFDEDDILKELEELsLEAQGIKADREtVAVKPTEN |
| O60927 | T75 | Sugiyama | PPP1R11 HCGV TCTE5 | RRssKCCCIyEKPRAFGEsstEsDEEEEEGCGHtHCVRGHR |
| O75534 | T761 | Sugiyama | CSDE1 D1S155E KIAA0885 NRU UNR | GPKAVAAPRPDRLVNRLKNItLDDAsAPRLMVLRQPRGPDN |
| O75821 | S189 | Sugiyama | EIF3G EIF3S4 | CPYKDtLGPMQKELAEQLGLstGEKEKLPGELEPVQAtQNK |
| O76070 | S124 | GPS6|EPSD | SNCG BCSG1 PERSYN PRSN | APQQEGEAsKEKEEVAEEAQsGGD_________________ |
| O95071 | S327 | Sugiyama | UBR5 EDD EDD1 HYD KIAA0896 | LLRERESVLRLRERRWLDGAsFDNERGSTSKEGEPNLDKKN |
| O95155 | S105 | Sugiyama | UBE4B HDNB1 KIAA0684 UFD2 | LsssPsNsLEtQsQsLsRsQsMDIDGVSCEKsMsQVDVDsG |
| O95218 | S188 | Sugiyama | ZRANB2 ZIS ZNF265 | KLDEDEDEDDADLsKyNLDAsEEEDsNKKKSNRRSRSKSRS |
| O95678 | S162 | Sugiyama | KRT75 K6HF KB18 | IQRVRAEEREQIKTLNNKFAsFIDKVRFLEQQNKVLETKWA |
| O95999 | S138 | GPS6 | BCL10 CIPER CLAP | KCSSCEPFPDGAtNNLsRsNsDEsNFsEKLRASTVMYHPEG |
| O96013 | S41 | Sugiyama | PAK4 KIAA1142 | VHTGFDQHEQKFTGLPRQWQsLIEESARRPKPLVDPACITS |
| P02538 | S176 | Sugiyama | KRT6A K6A KRT6D | IQRVRAEEREQIKTLNNKFAsFIDKVRFLEQQNKVLETKWT |
| P04075 | S336 | Sugiyama | ALDOA ALDA | GKKENLKAAQEEYVKRALANsLACQGKytPsGQAGAAAsEs |
| P04075 | S36 | Sugiyama | ALDOA ALDA | LsDIAHRIVAPGKGILAADEstGsIAKRLQsIGtENtEENR |
| P04075 | S39 | Sugiyama | ALDOA ALDA | IAHRIVAPGKGILAADEstGsIAKRLQsIGtENtEENRRFy |
| P04075 | S46 | Sugiyama | ALDOA ALDA | PGKGILAADEstGsIAKRLQsIGtENtEENRRFyRQLLLtA |
| P04075 | T37 | Sugiyama | ALDOA ALDA | sDIAHRIVAPGKGILAADEstGsIAKRLQsIGtENtEENRR |
| P04075 | T49 | Sugiyama | ALDOA ALDA | GILAADEstGsIAKRLQsIGtENtEENRRFyRQLLLtADDR |
| P04259 | S176 | Sugiyama | KRT6B K6B KRTL1 | IQRVRAEEREQIKTLNNKFAsFIDKVRFLEQQNKVLDTKWT |
| P04406 | S210 | Sugiyama | GAPDH GAPD CDABP0047 OK/SW-cl.12 | GPsGKLWRDGRGALQNIIPAstGAAKAVGKVIPELNGKLtG |
| P04406 | S241 | Sugiyama | GAPDH GAPD CDABP0047 OK/SW-cl.12 | IPELNGKLtGMAFRVPtANVsVVDLtCRLEKPAKyDDIKKV |
| P04406 | S321 | Sugiyama | GAPDH GAPD CDABP0047 OK/SW-cl.12 | IALNDHFVKLIsWyDNEFGysNRVVDLMAHMAsKE______ |
| P04406 | T211 | Sugiyama | GAPDH GAPD CDABP0047 OK/SW-cl.12 | PsGKLWRDGRGALQNIIPAstGAAKAVGKVIPELNGKLtGM |
| P04406 | T237 | Sugiyama | GAPDH GAPD CDABP0047 OK/SW-cl.12 | VGKVIPELNGKLtGMAFRVPtANVsVVDLtCRLEKPAKyDD |
| P04406 | Y314 | Sugiyama | GAPDH GAPD CDABP0047 OK/SW-cl.12 | tFDAGAGIALNDHFVKLIsWyDNEFGysNRVVDLMAHMAsK |
| P04792 | S78 | Sugiyama | HSPB1 HSP27 HSP28 | LPPAAIEsPAVAAPAYsRALsRQLssGVsEIRHtADRWRVs |
| P04792 | S82 | Sugiyama | HSPB1 HSP27 HSP28 | AIEsPAVAAPAYsRALsRQLssGVsEIRHtADRWRVsLDVN |
| P04792 | S83 | Sugiyama | HSPB1 HSP27 HSP28 | IEsPAVAAPAYsRALsRQLssGVsEIRHtADRWRVsLDVNH |
| P05386 | S101 | Sugiyama | RPLP1 RRP1 | APstAAAPAEEKKVEAKKEEsEEsDDDMGFGLFD_______ |
| P05386 | S104 | Sugiyama | RPLP1 RRP1 | tAAAPAEEKKVEAKKEEsEEsDDDMGFGLFD__________ |
| P05387 | S102 | Sugiyama | RPLP2 D11S2243E RPP2 | PAAGsAPAAAEEKKDEKKEEsEEsDDDMGFGLFD_______ |
| P05387 | S105 | Sugiyama | RPLP2 D11S2243E RPP2 | GsAPAAAEEKKDEKKEEsEEsDDDMGFGLFD__________ |
| P05455 | S325 | Sugiyama | SSB | VLEGEVEKEALKKIIEDQQEsLNKWKSKGRRFKGKGKGNKA |
| P05556 | T788 | PSP | ITGB1 FNRB MDF2 MSK12 | KEKMNAKWDtGENPIyKsAVttVVNPKyEGK__________ |
| P05556 | T789 | PSP | ITGB1 FNRB MDF2 MSK12 | EKMNAKWDtGENPIyKsAVttVVNPKyEGK___________ |
| P05783 | S53 | ELM | KRT18 CYK18 PIG46 | AsVyAGAGGsGsRIsVsRstsFRGGMGsGGLAtGIAGGLAG |
| P05787 | S104 | Sugiyama | KRT8 CYK8 | IQAVRTQEKEQIKTLNNKFAsFIDKVRFLEQQNKMLETKWS |
| P05787 | S432 | GPS6|EPSD | KRT8 CYK8 | HtKTTSGYAGGLSSAYGGLtsPGLSYSLGSSFGSGAGSSSF |
| P06733 | T205 | Sugiyama | ENO1 ENO1L1 MBPB1 MPB1 | GAEVyHNLKNVIKEKyGKDAtNVGDEGGFAPNILENKEGLE |
| P07101 | S19 | ELM | TH TYH | __MPTPDATTPQAKGFRRAVsELDAKQAEAIMVRGQGAPGP |
| P07195 | S303 | Sugiyama | LDHB | GIENEVFLSLPCILNARGLtsVINQKLKDDEVAQLKKsADt |
| P07195 | T302 | Sugiyama | LDHB | YGIENEVFLSLPCILNARGLtsVINQKLKDDEVAQLKKsAD |
| P07195 | T323 | Sugiyama | LDHB | sVINQKLKDDEVAQLKKsADtLWDIQKDLKDL_________ |
| P07237 | S427 | Sugiyama | P4HB ERBA2L PDI PDIA1 PO4DB | WDKLGEtyKDHENIVIAKMDstANEVEAVKVHsFPtLKFFP |
| P07237 | T453 | Sugiyama | P4HB ERBA2L PDI PDIA1 PO4DB | EAVKVHsFPtLKFFPAsADRtVIDyNGERtLDGFKKFLESG |
| P07737 | T65 | Sugiyama | PFN1 | PAEVGVLVGKDRssFyVNGLtLGGQKCsVIRDsLLQDGEFs |
| P07737 | Y60 | Sugiyama | PFN1 | FVNITPAEVGVLVGKDRssFyVNGLtLGGQKCsVIRDsLLQ |
| P07900 | S399 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | PEYLNFIRGVVDsEDLPLNIsREMLQQsKILKVIRKNLVKK |
| P07900 | S468 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | GIHEDsQNRKKLsELLRyytsAsGDEMVsLKDYCTRMKENQ |
| P07900 | S52 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | LIINtFySNKEIFLRELIsNssDALDKIRyEsLtDPsKLDs |
| P07900 | T195 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | DTGEPMGRGTKVILHLKEDQtEyLEERRIKEIVKKHSQFIG |
| P08238 | S391 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | PEYLNFIRGVVDsEDLPLNIsREMLQQsKILKVIRKNIVKK |
| P08238 | S460 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | GIHEDstNRRRLsELLRyHtsQsGDEMtsLsEyVsRMKEtQ |
| P08238 | S462 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | HEDstNRRRLsELLRyHtsQsGDEMtsLsEyVsRMKEtQKs |
| P08238 | T190 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | DHGEPIGRGTKVILHLKEDQtEyLEERRVKEVVKKHsQFIG |
| P08238 | T297 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | IDQEELNKtKPIWtRNPDDItQEEyGEFyKsLtNDWEDHLA |
| P08238 | T459 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | LGIHEDstNRRRLsELLRyHtsQsGDEMtsLsEyVsRMKEt |
| P08621 | S410 | Sugiyama | SNRNP70 RNPU1Z RPU1 SNRP70 U1AP1 | DEARGGGGGQDNGLEGLGNDsRDMYMESEGGDGYLAPENGY |
| P08670 | S39 | GPS6|EPSD | VIM | GtAsRPsssRsYVttsTRtYsLGsALRPstsRsLyAssPGG |
| P08729 | S104 | Sugiyama | KRT7 SCL | LQRVRQEESEQIKTLNNKFAsFIDKVRFLEQQNKLLETKWT |
| P09234 | S48 | Sugiyama | SNRPC | RKHKENVKDYYQKWMEEQAQsLIDKTTAAFQQGKIPPTPFS |
| P09417 | S223 | ELM | QDPR DHPR SDR33C1 | TPLEFLVETFHDWITGKNRPsSGsLIQVVTTEGRTELTPAY |
| P09651 | S95 | Sugiyama | HNRNPA1 HNRPA1 | RPHKVDGRVVEPKRAVsREDsQRPGAHLtVKKIFVGGIKED |
| P10412 | S89 | Sugiyama | H1-4 H1F4 HIST1H1E | AGyDVEKNNSRIKLGLKsLVsKGtLVQtKGtGAsGsFKLNK |
| P10412 | T92 | Sugiyama | H1-4 H1F4 HIST1H1E | DVEKNNSRIKLGLKsLVsKGtLVQtKGtGAsGsFKLNKKAA |
| P10636 | S733 | GPS6|EPSD | MAPT MAPTL MTBT1 TAU | sPVVsGDtsPRHLsNVsstGsIDMVDsPQLAtLADEVSASL |
| P11717 | S1378 | Sugiyama | IGF2R MPRI | QYACPPFDLTECSFKDGAGNsFDLsSLSRYSDNWEAITGTG |
| P12035 | S211 | Sugiyama | KRT3 | IGQVKAQEREQIKTLNNKFAsFIDKVRFLEQQNKVLETKWN |
| P12268 | S416 | Sugiyama | IMPDH2 IMPD2 | APGEYFFSDGIRLKKyRGMGsLDAMDKHLssQNRyFsEADK |
| P12955 | S162 | Sugiyama | PEPD PRD | SVLLTLRGVNTDSGSVCREAsFDGISKFEVNNTILHPEIVE |
| P13489 | S290 | Sugiyama | RNH1 PRI RNH | AKGCGDLCRVLRAKESLKELsLAGNELGDEGARLLCETLLE |
| P13639 | S732 | Sugiyama | EEF2 EF2 | DAIHRGGGQIIPtARRCLyAsVLtAQPRLMEPIyLVEIQCP |
| P13639 | T5 | Sugiyama | EEF2 EF2 | ________________MVNFtVDQIRAIMDKKANIRNMsVI |
| P13639 | T735 | Sugiyama | EEF2 EF2 | HRGGGQIIPtARRCLyAsVLtAQPRLMEPIyLVEIQCPEQV |
| P13639 | Y730 | Sugiyama | EEF2 EF2 | HADAIHRGGGQIIPtARRCLyAsVLtAQPRLMEPIyLVEIQ |
| P13647 | S181 | Sugiyama | KRT5 | IQRVRTEEREQIKTLNNKFAsFIDKVRFLEQQNKVLDTKWT |
| P13861 | S99 | Sugiyama | PRKAR2A PKR2 PRKAR2 | EsEEDEDLEVPVPsRFNRRVsVCAEtyNPDEEEEDTDPRVI |
| P14136 | S13 | ELM | GFAP | ________MERRRItsAARRsYVssGEMMVGGLAPGRRLGP |
| P14136 | S17 | ELM | GFAP | ____MERRRItsAARRsYVssGEMMVGGLAPGRRLGPGTRL |
| P14136 | S38 | ELM | GFAP | GEMMVGGLAPGRRLGPGTRLsLARMPPPLPTRVDFSLAGAL |
| P14921 | S251 | SIGNOR|iPTMNet | ETS1 EWSR2 | VTPDNMCMGRTSRGKLGGQDsFEsIEsYDSCDRLtQsWssQ |
| P14921 | S257 | SIGNOR|iPTMNet | ETS1 EWSR2 | CMGRTSRGKLGGQDsFEsIEsYDSCDRLtQsWssQssFNsL |
| P14921 | S282 | SIGNOR|iPTMNet | ETS1 EWSR2 | DRLtQsWssQssFNsLQRVPsyDsFDsEDYPAALPNHKPKG |
| P14921 | S285 | SIGNOR|iPTMNet | ETS1 EWSR2 | tQsWssQssFNsLQRVPsyDsFDsEDYPAALPNHKPKGTFK |
| P15311 | S249 | Sugiyama | EZR VIL2 | EKDDKLtPKIGFPWSEIRNIsFNDKKFVIKPIDKKAPDFVF |
| P15311 | S535 | Sugiyama | EZR VIL2 | EKRITEAEKNERVQRQLLtLssELsQARDENKRTHNDIIHN |
| P15311 | S539 | Sugiyama | EZR VIL2 | TEAEKNERVQRQLLtLssELsQARDENKRTHNDIIHNENMR |
| P15336 | S62 | Sugiyama | ATF2 CREB2 CREBP1 | LAVHKHKHEMtLKFGPARNDsVIVADQtPtPtRFLKNCEEV |
| P15531 | S122 | Sugiyama | NME1 NDPKA NM23 | GtIRGDFCIQVGRNIIHGsDsVEsAEKEIGLWFHPEELVDy |
| P16070 | S71 | Sugiyama | CD44 LHR MDU2 MDU3 MIC4 | DLCKAFNSTLPTMAQMEKALsIGFEtCRyGFIEGHVVIPRI |
| P16083 | S80 | Sugiyama | NQO2 NMOR2 | LSNPEVFNyGVEtHEAyKQRsLAsDITDEQKKVREADLVIF |
| P16220 | S142 | ELM | CREB1 | KILNDLssDAPGVPRIEEEKsEEETSAPAITTVTVPTPIYQ |
| P16401 | S92 | Sugiyama | H1-5 H1F5 HIST1H1B | GGYDVEKNNSRIKLGLKsLVsKGtLVQtKGtGAsGsFKLNK |
| P16401 | T95 | Sugiyama | H1-5 H1F5 HIST1H1B | DVEKNNSRIKLGLKsLVsKGtLVQtKGtGAsGsFKLNKKAA |
| P16402 | S90 | Sugiyama | H1-3 H1F3 HIST1H1D | AGyDVEKNNSRIKLGLKsLVsKGtLVQtKGtGAsGsFKLNK |
| P16402 | T93 | Sugiyama | H1-3 H1F3 HIST1H1D | DVEKNNSRIKLGLKsLVsKGtLVQtKGtGAsGsFKLNKKAA |
| P16403 | S89 | Sugiyama | H1-2 H1F2 HIST1H1C | AGyDVEKNNSRIKLGLKsLVsKGtLVQtKGtGAsGsFKLNK |
| P16403 | T92 | Sugiyama | H1-2 H1F2 HIST1H1C | DVEKNNSRIKLGLKsLVsKGtLVQtKGtGAsGsFKLNKKAA |
| P16615 | S38 | ELM | ATP2A2 ATP2B | VNESTGLSLEQVKKLKERWGsNELPAEEGKTLLELVIEQFE |
| P16949 | S16 | SIGNOR|EPSD|PSP | STMN1 C1orf215 LAP18 OP18 | _____MAssDIQVKELEKRAsGQAFELILsPRsKEsVPEFP |
| P17096 | S103 | Sugiyama | HMGA1 HMGIY | PRGRPKKLEKEEEEGIsQEssEEEQ________________ |
| P17544 | S44 | Sugiyama | ATF7 ATFA | LAVHKHKHEMTLKFGPARtDsVIIADQtPtPtRFLKNCEEV |
| P17600 | S568 | GPS6|EPSD | SYN1 | PPAsPsPQRQAGPPQATRQTsVSGPAPPKASGAPPGGQQRQ |
| P17600 | S605 | GPS6|EPSD | SYN1 | QQRQGPPQKPPGPAGPTRQAsQAGPVPRTGPPTTQQPRPSG |
| P17676 | S325 | ELM | CEBPB TCF5 PP9092 | ELTAENERLQKKVEQLSRELsTLRNLFKQLPEPLLAssGHC |
| P17987 | S544 | Sugiyama | TCP1 CCT1 CCTA | ILRIDDLIKLHPESKDDKHGsyEDAVHsGALND________ |
| P18615 | S115 | Sugiyama | NELFE RD RDBP | KLKDPEKGPVPTFQPFQRsIsADDDLQEsSRRPQRKsLyEs |
| P18615 | S135 | Sugiyama | NELFE RD RDBP | sADDDLQEsSRRPQRKsLyEsFVsssDRLRELGPDGEEAEG |
| P18621 | S5 | Sugiyama | RPL17 | ________________MVRysLDPENPtKsCKSRGSNLRVH |
| P18859 | S57 | Sugiyama | ATP5PF ATP5A ATP5J ATPM | DPIQKLFVDKIREYKSKRQTsGGPVDAssEyQQELERELFK |
| P19338 | S460 | Sugiyama | NCL | ADAEKTFEEKQGtEIDGRsIsLyytGEKGQNQDYRGGKNST |
| P19338 | S580 | Sugiyama | NCL | PRGsPNARSQPSKTLFVKGLsEDttEEtLKEsFDGsVRARI |
| P21333 | S2523 | ELM | FLNA FLN FLN1 | GPYHIGGsPFKAKVTGPRLVsNHsLHEtsSVFVDsLtKATC |
| P22090 | S204 | Sugiyama | RPS4Y1 RPS4Y PRO2646 | IGGANLGRVGVITNRERHPGsFDVVHVKDANGNSFATRLSN |
| P22314 | S46 | Sugiyama | UBA1 A1S9T UBE1 | AQsVLsEVPSVPTNGMAKNGsEADIDEGLysRQLyVLGHEA |
| P22626 | S189 | Sugiyama | HNRNPA2B1 HNRPA2B1 | IVLQKyHtINGHNAEVRKALsRQEMQEVQssRsGRGGNFGF |
| P22626 | S212 | Sugiyama | HNRNPA2B1 HNRPA2B1 | EMQEVQssRsGRGGNFGFGDsRGGGGNFGPGPGsNFRGGsD |
| P22626 | T140 | Sugiyama | HNRNPA2B1 HNRPA2B1 | KEDTEEHHLRDyFEEYGKIDtIEIItDRQsGKKRGFGFVtF |
| P23588 | S207 | Sugiyama | EIF4B | DRNRDsDKtDTDWRARPAtDsFDDyPPRRGDDsFGDKYRDR |
| P23588 | S597 | Sugiyama | EIF4B | KKPEENPASKFssASKyAALsVDGEDENEGEDyAE______ |
| P24534 | S141 | Sugiyama | EEF1B2 EEF1B EF1B | ERLAQYESKKAKKPALVAKssILLDVKPWDDEtDMAKLEEC |
| P25705 | S76 | Sugiyama | ATP5F1A ATP5A ATP5A1 ATP5AL2 ATPM | EERILGADtsVDLEETGRVLsIGDGIARVHGLRNVQAEEMV |
| P26038 | S249 | Sugiyama | MSN | EQNDRLTPKIGFPWSEIRNIsFNDKKFVIKPIDKKAPDFVF |
| P26038 | S527 | Sugiyama | MSN | ERTTEAEKNERVQKHLKALtsELANARDEsKKTANDMIHAE |
| P26038 | S576 | Sugiyama | MSN | YKtLRQIRQGNTKQRIDEFEsM___________________ |
| P26038 | T526 | Sugiyama | MSN | EERTTEAEKNERVQKHLKALtsELANARDEsKKTANDMIHA |
| P26358 | S91 | Sugiyama | DNMT1 AIM CXXC9 DNMT | EELSEEGYLAKVKSLLNKDLsLENGAHAYNREVNGRLENGN |
| P26373 | S181 | Sugiyama | RPL13 BBC1 OK/SW-cl.46 | YKKEKARVItEEEKNFKAFAsLRMARANARLFGIRAKRAKE |
| P26373 | S77 | Sugiyama | RPL13 BBC1 OK/SW-cl.46 | PIVRCPTVRYHTKVRAGRGFsLEELRVAGIHKKVARTIGIs |
| P26373 | T107 | Sugiyama | RPL13 BBC1 OK/SW-cl.46 | HKKVARTIGIsVDPRRRNKstEsLQANVQRLKEYRSKLILF |
| P26373 | T148 | Sugiyama | RPL13 BBC1 OK/SW-cl.46 | PRKPSAPKKGDssAEELKLAtQLtGPVMPVRNVYKKEKARV |
| P26373 | T151 | Sugiyama | RPL13 BBC1 OK/SW-cl.46 | PSAPKKGDssAEELKLAtQLtGPVMPVRNVYKKEKARVItE |
| P26678 | T17 | GPS6|EPSD | PLN PLB | ____MEKVQYLTRSAIRRAstIEMPQQARQKLQNLFINFCL |
| P27348 | S45 | Sugiyama | YWHAQ | CMKAVtEQGAELsNEERNLLsVAyKNVVGGRRSAWRVIsSI |
| P27797 | S52 | Sugiyama | CALR CRTC | GWtsRWIEsKHKSDFGKFVLssGKFyGDEEKDKGLQTSQDA |
| P27797 | T34 | Sugiyama | CALR CRTC | LAVAEPAVYFKEQFLDGDGWtsRWIEsKHKSDFGKFVLssG |
| P28340 | S1064 | Sugiyama | POLD1 POLD | LNALEERFSRLWTQCQRCQGsLHEDVICTSRDCPIFyMRKK |
| P29692 | S86 | Sugiyama | EEF1D EF1D | GPGAssGtsGDHGELVVRIAsLEVENQsLRGVVQELQQAIs |
| P30040 | T62 | Sugiyama | ERP29 C12orf8 ERP28 | DtVtFyKVIPKSKFVLVKFDtQyPyGEKQDEFKRLAENSAS |
| P30050 | S138 | Sugiyama | RPL12 | HRSLARELsGtIKEILGtAQsVGCNVDGRHPHDIIDDINsG |
| P30050 | S157 | Sugiyama | RPL12 | QsVGCNVDGRHPHDIIDDINsGAVECPAs____________ |
| P30101 | T485 | Sugiyama | PDIA3 ERP57 ERP60 GRP58 | KKyEGGRELsDFIsyLQREAtNPPVIQEEKPKKKKKAQEDL |
| P30533 | S247 | Sugiyama | LRPAP1 A2MRAP | KLRsINQGLDRLRRVsHQGystEAEFEEPRVIDLWDLAQSA |
| P30626 | S111 | Sugiyama | SRI | GFNEFKELWAVLNGWRQHFIsFDTDRSGTVDPQELQKALtt |
| P31943 | S23 | Sugiyama | HNRNPH1 HNRPH HNRPH1 | LGTEGGEGFVVKVRGLPWsCsADEVQRFFSDCKIQNGAQGI |
| P31946 | S47 | Sugiyama | YWHAB | AMKAVtEQGHELsNEERNLLsVAyKNVVGARRSsWRVIsSI |
| P31947 | S45 | Sugiyama | SFN HME1 | FMKGAVEKGEELsCEERNLLsVAyKNVVGGQRAAWRVLSsI |
| P31947 | S64 | Sugiyama | SFN HME1 | LsVAyKNVVGGQRAAWRVLSsIEQKsNEEGsEEKGPEVREY |
| P31947 | S69 | Sugiyama | SFN HME1 | KNVVGGQRAAWRVLSsIEQKsNEEGsEEKGPEVREYREKVE |
| P32119 | S112 | Sugiyama | PRDX2 NKEFB TDPX1 | KEGGLGPLNIPLLADVTRRLsEDyGVLKTDEGIAYRGLFII |
| P32119 | T142 | Sugiyama | PRDX2 NKEFB TDPX1 | EGIAYRGLFIIDGKGVLRQItVNDLPVGRsVDEALRLVQAF |
| P33176 | S950 | Sugiyama | KIF5B KNS KNS1 | PAAsPtHPSAIRGGGAFVQNsQPVAVRGGGGKQV_______ |
| P33527 | S915 | Sugiyama | ABCC1 MRP MRP1 | QMENGMLVTDsAGKQLQRQLsssssysGDISRHHNstAELQ |
| P35222 | S552 | SIGNOR | CTNNB1 CTNNB OK/SW-cl.35 PRO2286 | AIPRLVQLLVRAHQDtQRRtsMGGtQQQFVEGVRMEEIVEG |
| P35222 | T332 | SIGNOR | CTNNB1 CTNNB OK/SW-cl.35 PRO2286 | KLIILASGGPQALVNIMRTytyEKLLWTTSRVLKVLSVCSs |
| P35222 | T472 | SIGNOR | CTNNB1 CTNNB OK/SW-cl.35 PRO2286 | LRAGDREDITEPAICALRHLtSRHQEAEMAQNAVRLHyGLP |
| P35241 | S249 | Sugiyama | RDX | EHDDKLTPKIGFPWSEIRNIsFNDKKFVIKPIDKKAPDFVF |
| P35241 | S533 | Sugiyama | RDX | ERVTETQKNERVKKQLQALssELAQARDETKKTQNDVLHAE |
| P35269 | T154 | Sugiyama | GTF2F1 RAP74 | AFEAFPVHNWYNFTPLARHRtLtAEEAEEEWERRNKVLNHF |
| P35269 | T156 | Sugiyama | GTF2F1 RAP74 | EAFPVHNWYNFTPLARHRtLtAEEAEEEWERRNKVLNHFSI |
| P35270 | S213 | GPS6|EPSD | SPR | VLNYAPGPLDTDMQQLARETsVDPDMRKGLQELKAKGKLVD |
| P35579 | S1943 | Sugiyama | MYH9 | RGDLPFVVPRRMARKGAGDGsDEEVDGKADGAEAKPAE___ |
| P35637 | S340 | Sugiyama | FUS TLS | PMINLyTDRETGKLKGEAtVsFDDPPsAKAAIDWFDGKEFs |
| P35637 | T338 | Sugiyama | FUS TLS | GQPMINLyTDRETGKLKGEAtVsFDDPPsAKAAIDWFDGKE |
| P35908 | S191 | Sugiyama | KRT2 KRT2A KRT2E | IQNVKAQEREQIKTLNNKFAsFIDKVRFLEQQNQVLQTKWE |
| P36578 | S365 | Sugiyama | RPL4 RPL1 | RNHKLRVDKAAAAAAALQAKsDEKAAVAGKKPVVGKKGKKA |
| P37108 | T45 | Sugiyama | SRP14 | sVyItLKKYDGRTKPIPKKGtVEGFEPADNKCLLRATDGKK |
| P37802 | S163 | Sugiyama | TAGLN2 KIAA0120 CDABP0035 | LFsGDPNWFPKKSKENPRNFsDNQLQEGKNVIGLQMGtNRG |
| P37802 | S185 | Sugiyama | TAGLN2 KIAA0120 CDABP0035 | NQLQEGKNVIGLQMGtNRGAsQAGMtGyGMPRQIL______ |
| P37802 | T180 | Sugiyama | TAGLN2 KIAA0120 CDABP0035 | RNFsDNQLQEGKNVIGLQMGtNRGAsQAGMtGyGMPRQIL_ |
| P38646 | T398 | Sugiyama | HSPA9 GRP75 HSPA9B mt-HSP70 | SDIGEVILVGGMTRMPKVQQtVQDLFGRAPsKAVNPDEAVA |
| P39023 | S13 | Sugiyama | RPL3 OK/SW-cl.32 | ________MSHRKFSAPRHGsLGFLPRKRSSRHRGKVKSFP |
| P39023 | S265 | Sugiyama | RPL3 OK/SW-cl.32 | HRGLRKVACIGAWHPARVAFsVARAGQKGYHHRTEINKKIY |
| P39023 | S304 | Sugiyama | RPL3 OK/SW-cl.32 | IYKIGQGyLIKDGKLIKNNAstDyDLSDKSINPLGGFVHYG |
| P40818 | S719 | Sugiyama | USP8 KIAA0055 UBPY | KPQIPAERDREPSKLKRsyssPDItQAIQEEEKRKPTVtPT |
| P41091 | T464 | Sugiyama | EIF2S3 EIF2G | SRRVEKHWRLIGWGQIRRGVtIKPtVDDD____________ |
| P41091 | T468 | Sugiyama | EIF2S3 EIF2G | EKHWRLIGWGQIRRGVtIKPtVDDD________________ |
| P41236 | S121 | Sugiyama | PPP1R2 IPP2 | ARKLAAAEGLEPKyRIQEQEssGEEDsDLsPEEREKKRQFE |
| P41236 | S122 | Sugiyama | PPP1R2 IPP2 | RKLAAAEGLEPKyRIQEQEssGEEDsDLsPEEREKKRQFEM |
| P41236 | Y114 | Sugiyama | PPP1R2 IPP2 | AMAPDILARKLAAAEGLEPKyRIQEQEssGEEDsDLsPEER |
| P42224 | S727 | SIGNOR | STAT1 | IsVsEVHPSRLQttDNLLPMsPEEFDEVSRIVGsVEFDSMM |
| P42261 | S849 | ELM | GRIA1 GLUA1 GLUH1 GLUR1 | CYKsRsEsKRMKGFCLIPQQsINEAIRTStLPRNsGAGASS |
| P42677 | S78 | Sugiyama | RPS27 MPS1 | GCSTVLCQPTGGKARLtEGCsFRRKQH______________ |
| P42766 | T59 | Sugiyama | RPL35 | GAASKLsKIRVVRKSIARVLtVINQtQKENLRKFYKGKKyK |
| P42766 | T64 | Sugiyama | RPL35 | LsKIRVVRKSIARVLtVINQtQKENLRKFYKGKKyKPLDLR |
| P43034 | S152 | Sugiyama | PAFAH1B1 LIS1 MDCR MDS PAFAHA | IKVWDyEtGDFERtLKGHtDsVQDIsFDHsGKLLASCSADM |
| P43034 | S157 | Sugiyama | PAFAH1B1 LIS1 MDCR MDS PAFAHA | yEtGDFERtLKGHtDsVQDIsFDHsGKLLASCSADMTIKLW |
| P43243 | S188 | Sugiyama | MATR3 KIAA0723 | EPPyRVPRDDWEEKRHFRRDsFDDRGPsLNPVLDyDHGsRs |
| P43487 | S60 | Sugiyama | RANBP1 | TLEEDEEELFKMRAKLFRFAsENDLPEWKERGTGDVKLLKH |
| P46013 | S1098 | Sugiyama | MKI67 | PAARVTGMKKWPRtPKEEAQsLEDLAGFKELFQtPGPsEEs |
| P46776 | S68 | Sugiyama | RPL27A | yHPGyFGKVGMKHYHLKRNQsFCPtVNLDKLWtLVsEQtRV |
| P46777 | S224 | Sugiyama | RPL5 MSTP030 | VADyMRyLMEEDEDAyKKQFsQyIKNsVtPDMMEEMyKKAH |
| P46937 | S109 | Sugiyama | YAP1 YAP65 | RKLPDsFFKPPEPKsHsRQAstDAGtAGALtPQHVRAHssP |
| P48668 | S176 | Sugiyama | KRT6C KRT6E | IQRVRAEEREQIKTLNNKFAsFIDKVRFLEQQNKVLDTKWT |
| P49736 | S139 | Sugiyama | MCM2 BM28 CCNL1 CDCL1 KIAA0030 | QRDREAGRGLGRMRRGLLyDsDEEDEERPARKRRQVERAtE |
| P49840 | S21 | SIGNOR | GSK3A | MsGGGPsGGGPGGsGRARtssFAEPGGGGGGGGGGPGGsAs |
| P51116 | S601 | Sugiyama | FXR2 FMR1L2 | RPQRRNRSRRRRNRGNRtDGsIsGDRQPVtVADyIsRAEsQ |
| P52272 | S528 | Sugiyama | HNRNPM HNRPM NAGR1 | IERMGsGVERMGPAIERMGLsMERMVPAGMGAGLERMGPVM |
| P52272 | S618 | Sugiyama | HNRNPM HNRPM NAGR1 | PALGAGIERMGLAMGGGGGAsFDRAIEMERGNFGGsFAGsF |
| P52298 | S13 | Sugiyama | NCBP2 CBP20 PIG55 | ________MSGGLLKALRsDsyVELSQYRDQHFRGDNEEQE |
| P53396 | S455 | Sugiyama | ACLY | ANFLLNAsGststPAPsRtAsFsEsRADEVAPAKKAKPAMP |
| P53999 | S118 | Sugiyama | SUB1 PC4 RPO2TC1 | PGRKGIsLNPEQWsQLKEQIsDIDDAVRKL___________ |
| P53999 | S12 | Sugiyama | SUB1 PC4 RPO2TC1 | _________MPKSKELVsssssGsDsDsEVDKKLKRKKQVA |
| P57053 | S39 | Sugiyama | H2BC12L H2BFS H2BS1 | VTKAQKKDGRKRKRSRKEsysVyVyKVLKQVHPDTGIssKA |
| P58876 | S39 | Sugiyama | H2BC5 H2BFB HIRIP2 HIST1H2BD | VTKAQKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIssKA |
| P60174 | S198 | Sugiyama | TPI1 TPI | TPQQAQEVHEKLRGWLKsNVsDAVAQstRIIyGGsVtGAtC |
| P60174 | S212 | Sugiyama | TPI1 TPI | WLKsNVsDAVAQstRIIyGGsVtGAtCKELASQPDVDGFLV |
| P60174 | T217 | Sugiyama | TPI1 TPI | VsDAVAQstRIIyGGsVtGAtCKELASQPDVDGFLVGGAsL |
| P60660 | T85 | Sugiyama | MYL6 | LDFEHFLPMLQTVAKNKDQGtyEDyVEGLRVFDKEGNGtVM |
| P60709 | S199 | Sugiyama | ACTB | DLAGRDLTDyLMKILtERGysFtttAEREIVRDIKEKLCyV |
| P60709 | S52 | Sugiyama | ACTB | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKYPIE |
| P61247 | S236 | Sugiyama | RPS3A FTE1 MFTL | KMLKKPKFELGKLMELHGEGsssGKAtGDEtGAKVERADGy |
| P61254 | T8 | Sugiyama | RPL26 | _____________MKFNPFVtsDRsKNRKRHFNAPsHIRRK |
| P61313 | S100 | Sugiyama | RPL15 EC45 TCBAP0781 | tyGKPVHHGVNQLKFARsLQsVAEERAGRHCGALRVLNsyW |
| P61353 | S86 | Sugiyama | RPL27 | SKIKSFVKVyNyNHLMPtRysVDIPLDKtVVNKDVFRDPAL |
| P61978 | S420 | Sugiyama | HNRNPK HNRPK | GsIIGKGGQRIKQIRHEsGAsIKIDEPLEGsEDRIITItGt |
| P61978 | S75 | Sugiyama | HNRNPK HNRPK | GAVIGKGGKNIKALRtDyNAsVsVPDssGPERILsISADIE |
| P61981 | S46 | Sugiyama | YWHAG | AMKNVtELNEPLsNEERNLLsVAyKNVVGARRSsWRVIsSI |
| P61981 | T31 | Sugiyama | YWHAG | ARLAEQAERyDDMAAAMKNVtELNEPLsNEERNLLsVAyKN |
| P62072 | S48 | Sugiyama | TIMM10 TIM10 | ACHRKCVPPHYKEAELSKGEsVCLDRCVSKYLDIHERMGKK |
| P62249 | S9 | Sugiyama | RPS16 | ____________MPsKGPLQsVQVFGRKKTATAVAHCKRGN |
| P62258 | S148 | Sugiyama | YWHAE | YHRyLAEFAtGNDRKEAAENsLVAyKAAsDIAMtELPPTHP |
| P62258 | S46 | Sugiyama | YWHAE | SMKKVAGMDVELTVEERNLLsVAyKNVIGARRASWRIIssI |
| P62258 | T229 | Sugiyama | YWHAE | LsEEsyKDstLIMQLLRDNLtLWtsDMQGDGEEQNKEALQD |
| P62263 | S139 | Sugiyama | RPS14 PRO2640 | LARSGMKIGRIEDVtPIPsDstRRKGGRRGRRL________ |
| P62277 | S12 | Sugiyama | RPS13 | _________MGRMHAPGKGLsQsALPyRRsVPtWLKLTsDD |
| P62280 | T15 | Sugiyama | RPS11 | ______MADIQTERAyQKQPtIFQNKKRVLLGEtGKEKLPR |
| P62280 | T28 | Sugiyama | RPS11 | RAyQKQPtIFQNKKRVLLGEtGKEKLPRYYKNIGLGFKtPK |
| P62701 | S204 | Sugiyama | RPS4X CCG2 RPS4 SCAR | tGGANLGRIGVITNRERHPGsFDVVHVKDANGNSFATRLsN |
| P62736 | S54 | Sugiyama | ACTA2 ACTSA ACTVS GIG46 | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIE |
| P62807 | S39 | Sugiyama | H2BC4 H2BFL HIST1H2BC; H2BC6 H2BFH HIST1H2BE; H2BC7 H2BFG HIST1H2BF; H2BC8 H2BFA HIST1H2BG; H2BC10 H2BFK HIST1H2BI | VTKAQKKDGKKRKRsRKEsysVyVyKVLKQVHPDTGIssKA |
| P62826 | T66 | Sugiyama | RAN ARA24 OK/SW-cl.81 | EVHPLVFHTNRGPIKFNVWDtAGQEKFGGLRDGYYIQAQCA |
| P62899 | S15 | Sugiyama | RPL31 | ______MAPAKKGGEKKKGRsAINEVVtREytINIHKRIHG |
| P62899 | T26 | Sugiyama | RPL31 | KGGEKKKGRsAINEVVtREytINIHKRIHGVGFKKRAPRAL |
| P62906 | S64 | Sugiyama | RPL10A NEDD6 | QKDKRFsGTVRLKSTPRPKFsVCVLGDQQHCDEAKAVDIPH |
| P62917 | S130 | Sugiyama | RPL8 | GTIVCCLEEKPGDRGKLARAsGNyAtVIsHNPEtKKtRVKL |
| P62917 | S138 | Sugiyama | RPL8 | EKPGDRGKLARAsGNyAtVIsHNPEtKKtRVKLPSGSKKVI |
| P62917 | S14 | Sugiyama | RPL8 | _______MGRVIRGQRKGAGsVFRAHVKHRKGAARLRAVDF |
| P62917 | T135 | Sugiyama | RPL8 | CLEEKPGDRGKLARAsGNyAtVIsHNPEtKKtRVKLPSGSK |
| P62917 | Y133 | Sugiyama | RPL8 | VCCLEEKPGDRGKLARAsGNyAtVIsHNPEtKKtRVKLPSG |
| P62942 | T22 | Sugiyama | FKBP1A FKBP1 FKBP12 | GVQVEtIsPGDGRtFPKRGQtCVVHytGMLEDGKKFDSSRD |
| P62979 | S123 | Sugiyama | RPS27A UBA80 UBCEP1 | LKYYKVDENGKIsRLRRECPsDECGAGVFMAsHFDRHyCGK |
| P62979 | S134 | Sugiyama | RPS27A UBA80 UBCEP1 | IsRLRRECPsDECGAGVFMAsHFDRHyCGKCCLtyCFNKPE |
| P63104 | S28 | Sugiyama | YWHAZ | QKAKLAEQAERyDDMAACMKsVtEQGAELsNEERNLLsVAy |
| P63104 | S45 | Sugiyama | YWHAZ | CMKsVtEQGAELsNEERNLLsVAyKNVVGARRssWRVVssI |
| P63167 | S14 | Sugiyama | DYNLL1 DLC1 DNCL1 DNCLC1 HDLC1 | _______MCDRKAVIKNADMsEEMQQDsVECAtQALEKYNI |
| P63167 | S21 | Sugiyama | DYNLL1 DLC1 DNCL1 DNCLC1 HDLC1 | MCDRKAVIKNADMsEEMQQDsVECAtQALEKYNIEKDIAAH |
| P63220 | S65 | Sugiyama | RPS21 | RFNGQFKtyAICGAIRRMGEsDDsILRLAKADGIVSKNF__ |
| P63261 | S199 | Sugiyama | ACTG1 ACTG | DLAGRDLTDyLMKILtERGysFtttAEREIVRDIKEKLCyV |
| P63261 | S52 | Sugiyama | ACTG1 ACTG | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKYPIE |
| P63267 | S53 | Sugiyama | ACTG2 ACTA3 ACTL3 ACTSG | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIE |
| P67809 | S136 | Sugiyama | YBX1 NSEP1 YB1 | GEKGAEAANVtGPGGVPVQGsKYAADRNHYRRYPRRRGPPR |
| P67809 | S167 | Sugiyama | YBX1 NSEP1 YB1 | RYPRRRGPPRNyQQNyQNsEsGEKNEGsEsAPEGQAQQRRP |
| P67809 | S209 | Sugiyama | YBX1 NSEP1 YB1 | RRRRFPPyyMRRPYGRRPQysNPPVQGEVMEGADNQGAGEQ |
| P67809 | T80 | Sugiyama | YBX1 NSEP1 YB1 | LGTVKWFNVRNGyGFINRNDtKEDVFVHQtAIKKNNPRKyL |
| P68032 | S54 | Sugiyama | ACTC1 ACTC | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIE |
| P68133 | S54 | Sugiyama | ACTA1 ACTA | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIE |
| P83731 | S38 | Sugiyama | RPL24 | GRRYARTDGKVFQFLNAKCEsAFLSKRNPRQINWtVLyRRK |
| P84098 | S12 | Sugiyama | RPL19 | _________MSMLRLQKRLAssVLRCGKKKVWLDPNEtNEI |
| P84098 | T29 | Sugiyama | RPL19 | RLAssVLRCGKKKVWLDPNEtNEIANANsRQQIRKLIKDGL |
| Q00341 | S904 | Sugiyama | HDLBP HBP VGL | FHRSVMGPKGSRIQQITRDFsVQIKFPDREENAVHSTEPVV |
| Q00613 | S230 | ELM | HSF1 HSTF1 | PLMLNDsGsAHSMPKYSRQFsLEHVHGSGPYSAPSPAYSSS |
| Q00839 | S59 | Sugiyama | HNRNPU C1orf199 HNRPU SAFA U21.1 | QAALDDEEAGGRPAMEPGNGsLDLGGDsAGRSGAGLEQEAA |
| Q01105 | S161 | Sugiyama | SET | FDENPyFENKVLSKEFHLNEsGDPssKstEIKWKSGKDLTK |
| Q01105 | S168 | Sugiyama | SET | ENKVLSKEFHLNEsGDPssKstEIKWKSGKDLTKRssQTQN |
| Q01105 | T169 | Sugiyama | SET | NKVLSKEFHLNEsGDPssKstEIKWKSGKDLTKRssQTQNK |
| Q01546 | S196 | Sugiyama | KRT76 KRT2B KRT2P | IGQVKAQEREQIKTLNNKFAsFIDKVRFLEQQNKVLETKWE |
| Q01650 | S35 | Sugiyama | SLC7A5 CD98LC LAT1 MPE16 | AAEEKEEAREKMLAAKsADGsAPAGEGEGVtLQRNITLLNG |
| Q01970 | S537 | SIGNOR|ELM|iPTMNet | PLCB3 | PGLSNGEEVGLEKPSLEPQKsLGDEGLNRGPyVLGPADRED |
| Q02539 | S92 | Sugiyama | H1-1 H1F1 HIST1H1A | AGyDVEKNNSRIKLGIKsLVsKGtLVQtKGtGAsGsFKLNK |
| Q02539 | T95 | Sugiyama | H1-1 H1F1 HIST1H1A | DVEKNNSRIKLGIKsLVsKGtLVQtKGtGAsGsFKLNKKAS |
| Q02952 | S248 | Sugiyama | AKAP12 AKAP250 | KESEPKQSTEKPEETLKREQsHAEIsPPAESGQAVEECKEE |
| Q04637 | S1238 | Sugiyama | EIF4G1 EIF4F EIF4G EIF4GI | RDAVKREAALPPVsPLKAALsEEELEKKsKAIIEEyLHLND |
| Q04917 | S46 | Sugiyama | YWHAH YWHA1 | AMKAVtELNEPLsNEDRNLLsVAyKNVVGARRSsWRVIsSI |
| Q05397 | S677 | Sugiyama | PTK2 FAK FAK1 | KCWAYDPSRRPRFTELKAQLsTILEEEKAQQEERMRMEsRR |
| Q06210 | S261 | Sugiyama | GFPT1 GFAT GFPT | GsQGERGKDKKGSCNLsRVDsttCLFPVEEKAVEyyFASDA |
| Q06830 | S152 | Sugiyama | PRDX1 PAGA PAGB TDPX2 | IIDDKGILRQItVNDLPVGRsVDEtLRLVQAFQFtDKHGEV |
| Q06830 | S30 | Sugiyama | PRDX1 PAGA PAGB TDPX2 | HPAPNFKAtAVMPDGQFKDIsLsDyKGKYVVFFFYPLDFTF |
| Q06830 | T143 | Sugiyama | PRDX1 PAGA PAGB TDPX2 | EGIsFRGLFIIDDKGILRQItVNDLPVGRsVDEtLRLVQAF |
| Q07020 | T85 | Sugiyama | RPL18 | RMIRKMKLPGRENKtAVVVGtItDDVRVQEVPKLKVCALRV |
| Q07666 | S20 | Sugiyama | KHDRBS1 SAM68 | _MQRRDDPAARMsRssGRsGsMDPsGAHPsVRQtPsRQPPL |
| Q08AD1 | S1313 | Sugiyama | CAMSAP2 CAMSAP1L1 KIAA1078 | sLNtGDNEsVHsGKRtPRsEsVEGFLsPsRCGsRNGEKDWE |
| Q09028 | S147 | Sugiyama | RBBP4 RBAP48 | VNRARYMPQNPCIIATKtPssDVLVFDyTKHPsKPDPsGEC |
| Q12879 | S1291 | iPTMNet | GRIN2A NMDAR2A | WAQNNALQLQKNKLRISRQHsyDNIVDKPRELDLSRPSRSI |
| Q12904 | S140 | Sugiyama | AIMP1 EMAP2 SCYE1 | EKKAKEKIEKKGEKKEKKQQsIAGsADSKPIDVSRLDLRIG |
| Q12959 | S232 | ELM | DLG1 | YVNGTDADYEYEEITLERGNsGLGFSIAGGTDNPHIGDDSS |
| Q13131 | T183 | SIGNOR|EPSD|PSP | PRKAA1 AMPK1 | NAKIADFGLsNMMsDGEFLRtsCGsPNyAAPEVISGRLYAG |
| Q13206 | S831 | Sugiyama | DDX10 | DMENKISDTKKKQGMKKRsNsEVEDVGPTsHNRKKARWDTL |
| Q13224 | S1303 | SIGNOR|iPTMNet | GRIN2B NMDAR2B | QSPTNSKAQKKNRNKLRRQHsYDTFVDLQKEEAALAPRSVs |
| Q13224 | S383 | iPTMNet | GRIN2B NMDAR2B | VIILLNKERKWERVGKWKDKsLQMKYYVWPRMCPETEEQED |
| Q13442 | S19 | Sugiyama | PDAP1 HASPP28 | __MPKGGRKGGHKGRARQytsPEEIDAQLQAEKQKAREEEE |
| Q13442 | S57 | Sugiyama | PDAP1 HASPP28 | EEEQKEGGDGAAGDPKKEKKsLDsDEsEDEEDDyQQKRKGV |
| Q13442 | S63 | Sugiyama | PDAP1 HASPP28 | GGDGAAGDPKKEKKsLDsDEsEDEEDDyQQKRKGVEGLIDI |
| Q13442 | T18 | Sugiyama | PDAP1 HASPP28 | ___MPKGGRKGGHKGRARQytsPEEIDAQLQAEKQKAREEE |
| Q13554 | S26 | Sugiyama | CAMK2B CAM2 CAMK2 CAMKB | TCTRFTDEYQLYEDIGKGAFsVVRRCVKLCTGHEYAAKIIN |
| Q13554 | S280 | Sugiyama | CAMK2B CAM2 CAMK2 CAMKB | RITAHEALKHPWVCQRstVAsMMHRQEtVECLKKFNARRKL |
| Q13554 | T277 | Sugiyama | CAMK2B CAM2 CAMK2 CAMKB | PAKRITAHEALKHPWVCQRstVAsMMHRQEtVECLKKFNAR |
| Q13554 | T287 | GPS6|SIGNOR|iPTMNet|EPSD|Sugiyama | CAMK2B CAM2 CAMK2 CAMKB | LKHPWVCQRstVAsMMHRQEtVECLKKFNARRKLKGAILtt |
| Q13554 | T306 | Sugiyama | CAMK2B CAM2 CAMK2 CAMKB | EtVECLKKFNARRKLKGAILttMLAtRNFSVGRQTtAPAtM |
| Q13554 | T307 | Sugiyama | CAMK2B CAM2 CAMK2 CAMKB | tVECLKKFNARRKLKGAILttMLAtRNFSVGRQTtAPAtMS |
| Q13554 | T382 | GPS6 | CAMK2B CAM2 CAMK2 CAMKB | SAAATSPKGTLPPAALEPQttVIHNPVDGIKEssDsANttI |
| Q13555 | S26 | Sugiyama | CAMK2G CAMK CAMK-II CAMKG | TCTRFTDDYQLFEELGKGAFsVVRRCVKKTstQEYAAKIIN |
| Q13555 | S280 | Sugiyama | CAMK2G CAMK CAMK-II CAMKG | RITADQALKHPWVCQRstVAsMMHRQEtVECLRKFNARRKL |
| Q13555 | T277 | Sugiyama | CAMK2G CAMK CAMK-II CAMKG | PAKRITADQALKHPWVCQRstVAsMMHRQEtVECLRKFNAR |
| Q13555 | T287 | PSP | CAMK2G CAMK CAMK-II CAMKG | LKHPWVCQRstVAsMMHRQEtVECLRKFNARRKLKGAILtt |
| Q13557 | S26 | Sugiyama | CAMK2D CAMKD | TCTRFTDEyQLFEELGKGAFsVVRRCMKIPTGQEYAAKIIN |
| Q13557 | S280 | Sugiyama | CAMK2D CAMKD | RItAsEALKHPWICQRstVAsMMHRQEtVDCLKKFNARRKL |
| Q13557 | T277 | Sugiyama | CAMK2D CAMKD | PAKRItAsEALKHPWICQRstVAsMMHRQEtVDCLKKFNAR |
| Q13557 | T306 | Sugiyama | CAMK2D CAMKD | EtVDCLKKFNARRKLKGAILttMLAtRNFsAAKsLLKKPDG |
| Q13557 | T307 | Sugiyama | CAMK2D CAMKD | tVDCLKKFNARRKLKGAILttMLAtRNFsAAKsLLKKPDGV |
| Q14126 | S551 | Sugiyama | DSG2 CDHF5 | FSVIDKPPGMAEKWKIARQEstsVLLQQSEKKLGRSEIQFL |
| Q14151 | S613 | Sugiyama | SAFB2 KIAA0138 | ERSSKSQDRKSESKEKRDILsFDKIKEQRERERQRQREREI |
| Q14157 | T239 | Sugiyama | UBAP2L KIAA0144 NICE4 | GNTWNNTGHFEPDDGTSAWRtAtEEWGtEDWNEDLsEtKIF |
| Q14157 | T241 | Sugiyama | UBAP2L KIAA0144 NICE4 | TWNNTGHFEPDDGTSAWRtAtEEWGtEDWNEDLsEtKIFtA |
| Q14157 | T246 | Sugiyama | UBAP2L KIAA0144 NICE4 | GHFEPDDGTSAWRtAtEEWGtEDWNEDLsEtKIFtAsNVss |
| Q14192 | S238 | Sugiyama | FHL2 DRAL SLIM3 | AKKCAGCTNPISGLGGtKyIsFEERQWHNDCFNCKKCsLsL |
| Q14247 | S282 | Sugiyama | CTTN EMS1 | QKDyKTGFGGKFGVQsERQDsAAVGFDyKEKLAKHEsQQDy |
| Q14498 | S337 | Sugiyama | RBM39 HCC1 RNPC2 | AGRPMKVGHVTERtDAssAssFLDsDELERtGIDLGtTGRL |
| Q14524 | S516 | SIGNOR | SCN5A | KsDsEDGPRAMNHLsLTRGLsRTSMKPRssRGsIFTFRRRD |
| Q14524 | S571 | SIGNOR | SCN5A | AGESESHHTSLLVPWPLRRtsAQGQPsPGTSAPGHALHGKK |
| Q14524 | T594 | SIGNOR | SCN5A | GQPsPGTSAPGHALHGKKNStVDCNGVVSLLGAGDPEATSP |
| Q14568 | S52 | Sugiyama | HSP90AA2P HSP90AA2 HSPC2 HSPCAL3 | LIINTFYSNKEIFLRELIsNssDALDKIWYESLTDPSKLDS |
| Q14677 | S166 | Sugiyama | CLINT1 ENTH EPN4 EPNR KIAA0171 | REERKKAKKNKDKyVGVssDsVGGFRysERYDPEPKSKWDE |
| Q14738 | S598 | Sugiyama | PPP2R5D | DVyTIKALEAHKRAEEFLTAsQEAL________________ |
| Q14847 | S99 | Sugiyama | LASP1 MLN50 | ELQsQVRYKEEFEKNKGKGFsVVADtPELQRIKKTQDQIsN |
| Q14966 | S1228 | Sugiyama | ZNF638 NP220 ZFML | DLEKKGAEIINPKTALLPSDsVFAEERNLKGILEEsPsEAE |
| Q14978 | S87 | Sugiyama | NOLC1 KIAA0035 NS5ATP13 | KLQANGPVAKKAKKKAsssDsEDssEEEEEVQGPPAKKAAV |
| Q14CN4 | S138 | Sugiyama | KRT72 K6IRS2 KB35 KRT6 KRT6IRS2 | IQRVRAQEREQIKALNNKFAsFIDKVRFLEQQNQVLETKWN |
| Q15084 | S169 | Sugiyama | PDIA6 ERP5 P5 TXNDC7 | GKQGRSDsSSKKDVIELtDDsFDKNVLDSEDVWMVEFYAPW |
| Q15121 | S116 | ELM | PEA15 | DtKLtRIPsAKKYKDIIRQPsEEEIIKLAPPPKKA______ |
| Q15459 | S690 | Sugiyama | SF3A1 SAP114 | VHPPPPMEDEPTSKKLKTEDsLMPEEEFLRRNKGPVSIKVQ |
| Q15527 | S183 | Sugiyama | SURF2 | sDDsMtDLYPPELFTRKDLGstEDGDGtDDFLtDKEDEKAK |
| Q15527 | T184 | Sugiyama | SURF2 | DDsMtDLYPPELFTRKDLGstEDGDGtDDFLtDKEDEKAKP |
| Q15796 | S240 | EPSD | SMAD2 MADH2 MADR2 | tPPPGYISEDGETSDQQLNQsMDtGsPAELsPTTLsPVNHs |
| Q15906 | T137 | ELM | VPS72 TCFL1 YL1 | LLPLELQDDGsDsRKsMRQStAEHTRQTFLRVQERQGQSRR |
| Q15906 | T168 | ELM | VPS72 TCFL1 YL1 | VQERQGQSRRRKGPHCERPLtQEELLREAKITEELNLRSLE |
| Q15906 | T86 | ELM | VPS72 TCFL1 YL1 | GDEPSsDGEAEEPRRKRRVVtKAYKEPLKSLRPRKVNTPAG |
| Q16513 | S583 | Sugiyama | PKN2 PRK2 PRKCL2 | VTKLDFDLEPEPPPAPPRAssLGEIDEssELRVLDIPGQDs |
| Q16576 | S146 | Sugiyama | RBBP7 RBAP46 | VNRARYMPQNPHIIATKtPssDVLVFDyTKHPAKPDPsGEC |
| Q16625 | S471 | EPSD|PSP | OCLN | DEINKELSRLDKELDDYREEsEEyMAAADEYNRLKQVKGsA |
| Q2VIR3 | T464 | Sugiyama | EIF2S3B | SRRVEKHWRLIGWGQIRRGVtIKPtVDDD____________ |
| Q2VIR3 | T468 | Sugiyama | EIF2S3B | EKHWRLIGWGQIRRGVtIKPtVDDD________________ |
| Q32P51 | S95 | Sugiyama | HNRNPA1L2 HNRNPA1L | TPHKVDGRVVEPKRAVsREDsQRPGAHLtVKKIFVGGIKED |
| Q3SY84 | S143 | Sugiyama | KRT71 K6IRS1 KB34 KRT6IRS1 | IQKVRAQEREQIKALNNKFAsFIDKVRFLEQQNQVLETKWE |
| Q3ZCM7 | S75 | Sugiyama | TUBB8 | SGGRYVPRAVLVDLEPGtMDsVRSGPFGQVFRPDNFIFGQC |
| Q3ZCM7 | T72 | Sugiyama | TUBB8 | NEASGGRYVPRAVLVDLEPGtMDsVRSGPFGQVFRPDNFIF |
| Q53EL6 | S76 | Sugiyama | PDCD4 H731 | NAKAKRRLRKNssRDsGRGDsVsDsGsDALRSGLtVPtsPK |
| Q58FF6 | T165 | Sugiyama | HSP90AB4P | DHGEPIDRDTKVILHLKEDQtEyLEERWVKEVVKKHPQFIG |
| Q58FF7 | T169 | Sugiyama | HSP90AB3P HSP90BC | DHGEPIGRGTKVILHLKEDQtEyLEERRVKEVVKKHsQFIG |
| Q5H9R7 | S579 | Sugiyama | PPP6R3 C11orf23 KIAA1558 PP6R3 SAPL SAPS3 | IDQFGFNDEKFADQDDIGNVsFDRVSDINFTLNTNESGNIA |
| Q5QNW6 | S39 | Sugiyama | H2BC18 HIST2H2BF | VTKVQKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIssKA |
| Q5XKE5 | S155 | Sugiyama | KRT79 K6L KB38 KRT6L | IQRVRTQEREQIKTLNNKFAsFIDKVRFLEQQNKVLETKWA |
| Q6GYQ0 | T798 | Sugiyama | RALGAPA1 GARNL1 KIAA0884 TULIP1 | tGNEVFGALNEEQPLPRssstsDILEPFTVERAKVNKEDMS |
| Q71UM5 | S78 | Sugiyama | RPS27L | GCSTVLCQPTGGKARLtEGCsFRRKQH______________ |
| Q7RTS7 | S153 | Sugiyama | KRT74 K6IRS4 KB37 KRT5C KRT6IRS4 | IQKVRAQEREQIKVLNDKFAsFIDKVRFLEQQNQVLETKWE |
| Q7Z417 | S652 | Sugiyama | NUFIP2 KIAA1321 PIG1 | NtLLGsAKEQRYQRGLERNDsWGsFDLRAAIVYHTKEMEsI |
| Q7Z4V5 | S370 | Sugiyama | HDGFL2 HDGF2 HDGFRP2 HRP2 UNQ785/PRO1604 | KERRRERADRGEAERGsGGssGDELREDDEPVKKRGRKGRG |
| Q7Z794 | S177 | Sugiyama | KRT77 KRT1B | IQRIKTQEREQIMVLNNKFAsFIDKVRFLEQQNQVLQTKWE |
| Q86UE4 | S298 | Sugiyama | MTDH AEG1 LYRIC | NLTVNGGGWNEKSVKLssQIsAGEEKWNsVsPAsAGKRKtE |
| Q86V81 | S239 | Sugiyama | ALYREF ALY BEF THOC4 | tRGGARGRGRGAGRNSKQQLsAEELDAQLDAyNARMDts__ |
| Q86VQ1 | S223 | Sugiyama | GLCCI1 | QTPsCWAEEGAEKRSHQRsAsWGsADQLKEQIAKLRQQLQR |
| Q86Y46 | S145 | Sugiyama | KRT73 K6IRS3 KB36 KRT6IRS3 | IQKVRAQEREQIKVLNNKFAsFIDKVRFLEQQNQVLETKWE |
| Q8N6H7 | S368 | Sugiyama | ARFGAP2 ZNF289 Nbla10535 | VGTFASGPPKYKDNPFsLGEsFGsRWDTDAAWGMDRVEEKE |
| Q8N8S7 | S125 | Sugiyama | ENAH MENA | MHALEVLNSQETGPTLPRQNsQLPAQVQNGPSQEELEIQRR |
| Q8NE71 | S105 | Sugiyama | ABCF1 ABC50 | KKDVDDDGEEKELMERLKKLsVPtsDEEDEVPAPKPRGGKK |
| Q8NE71 | S166 | Sugiyama | ABCF1 ABC50 | EEKHPPKPAKPEKNRINKAVsEEQQPALKGKKGKEEKSKGK |
| Q8NE71 | S595 | Sugiyama | ABCF1 ABC50 | TKEALTRKQQKCRRKNQDEEsQEAPELLKRPKEYTVRFTFP |
| Q8NE71 | T108 | Sugiyama | ABCF1 ABC50 | VDDDGEEKELMERLKKLsVPtsDEEDEVPAPKPRGGKKTKG |
| Q8NEY1 | S808 | Sugiyama | NAV1 KIAA1151 KIAA1213 POMFIL3 STEERIN1 | TAKSFVKPPsLANLDKVNsNsLDLPSSSDTTHASKVPDLHA |
| Q8NFD5 | S1744 | Sugiyama | ARID1B BAF250B DAN15 KIAA1235 OSA2 | ALDTINILLYDDSTVATFNLsQLSGFLELLVEYFRKCLIDI |
| Q8TAM6 | S280 | Sugiyama | ERMN KIAA1189 | TISYRKIRKGNTKQRIDEFEsMMHL________________ |
| Q8TEQ6 | S757 | Sugiyama | GEMIN5 | PKAKPKKKKKPTLRtPVKLEsIDGNEEEsMKENsGPVENGV |
| Q8TEU7 | S1117 | Sugiyama | RAPGEF6 PDZGEF2 | NAKKLYEDAQMARKVKQYLssLDVETDEEKFQMMSLQWEPA |
| Q8WWI1 | S704 | Sugiyama | LMO7 FBX20 FBXO20 KIAA0858 | KKRLMVERLFQKIYGENGsKsMsDVsAEDVQNLRQLRYEEM |
| Q8WWI1 | S709 | Sugiyama | LMO7 FBX20 FBXO20 KIAA0858 | VERLFQKIYGENGsKsMsDVsAEDVQNLRQLRYEEMQKIKS |
| Q8WX93 | S479 | Sugiyama | PALLD KIAA0992 CGI-151 | VLECRVRGAPPLQVQWFRQGsEIQDsPDFRILQKKPRSTAE |
| Q92609 | S541 | Sugiyama | TBC1D5 KIAA0210 | EsMPVQLNKGLSSKNIsssPsVEsLPGGREFtGsPPssAtK |
| Q92804 | S289 | Sugiyama | TAF15 RBP56 TAF2N | PMINLYTDKDTGKPKGEAtVsFDDPPsAKAAIDWFDGKEFH |
| Q92804 | T287 | Sugiyama | TAF15 RBP56 TAF2N | GKPMINLYTDKDTGKPKGEAtVsFDDPPsAKAAIDWFDGKE |
| Q93079 | S39 | Sugiyama | H2BC9 H2BFJ HIST1H2BH | VTKAQKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIssKA |
| Q96AT1 | S146 | Sugiyama | KIAA1143 | VNQDsVKKNSQKQIKNssLLsFDNEDENE____________ |
| Q96CT7 | S141 | Sugiyama | CCDC124 | KsHLEVPLEENVNRRVLEEGsVEARTIEDAIAVLsVAEEAA |
| Q99497 | S57 | Sugiyama | PARK7 | GLAGKDPVQCsRDVVICPDAsLEDAKKEGPyDVVVLPGGNL |
| Q99575 | S816 | Sugiyama | POP1 KIAA0061 | VAATGSHLCVLRSRKLLKQLsAWCGPSSEDSRGGRRAPGRG |
| Q99613 | S865 | Sugiyama | EIF3C EIF3S8 | HRTEPTAQQNLALQLAEKLGsLVENNERVFDHKQGtyGGyF |
| Q99755 | S486 | Sugiyama | PIP5K1A | GssFSRRAGssGNsCItyQPsVsGEHKAQVTTKAEVEPGVH |
| Q99877 | S39 | Sugiyama | H2BC15 H2BFD HIST1H2BN | VTKAQKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIssKA |
| Q99879 | S39 | Sugiyama | H2BC14 H2BFE HIST1H2BM | INKAQKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIssKA |
| Q99880 | S39 | Sugiyama | H2BC13 H2BFC HIST1H2BL | VTKAQKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIssKA |
| Q9BTE6 | S174 | Sugiyama | AARSD1 | IEQSVNEKIRDRLPVNVRELsLDDPEVEQVsGRGLPDDHAG |
| Q9BY44 | S526 | Sugiyama | EIF2A CDA02 MSTP004 MSTP089 | sPDLAPtPAPQstPRNtVsQsIsGDPEIDKKIKNLKKKLKA |
| Q9C0C2 | S1621 | Sugiyama | TNKS1BP1 KIAA1741 TAB182 | DsDAHLFQDSTEPRAsRVPssDEEVVEEPQsRRTRMsLGTK |
| Q9C0C2 | S221 | Sugiyama | TNKS1BP1 KIAA1741 TAB182 | TyGtTTAPRDEDGstLFRGWsQEGPVKsPAECREEHsKtPE |
| Q9C0C2 | S899 | Sugiyama | TNKS1BP1 KIAA1741 TAB182 | RDVsLGDWEFGKRDsLGAyAsQDANEQGQDLGKRDHHGRys |
| Q9H1E3 | S113 | Sugiyama | NUCKS1 NUCKS JC7 | RQAASKAASKQREMLMEDVGsEEEQEEEDEAPFQEKDsGsD |
| Q9H6L5 | S151 | SIGNOR|PSP | RETREG1 FAM134B JK1 | QIIKDMVLSRTRGAQLWRSLsEsWEVINSKPDERPRLSHCI |
| Q9H6S3 | S693 | Sugiyama | EPS8L2 EPS8R2 PP13181 | EGVRVySQLTMQKAFLEKQQsGSELEELMNKFHSMNQRRGE |
| Q9H788 | S315 | Sugiyama | SH2D4A PPP1R38 SH2A | LNSGAYPQKPLRNQGVVRtLsssAQEDIIRWFKEEQLPLRA |
| Q9NQC7 | S362 | SIGNOR | CYLD CYLD1 KIAA0849 HSPC057 | STSDPGNRNRSELFYTLNGSsVDSQPQSKSKNTWYIDEVAE |
| Q9NQC7 | S418 | SIGNOR | CYLD CYLD1 KIAA0849 HSPC057 | ssPPLQPPPVNSLTTENRFHsLPFsLtKMPNTNGsIGHsPL |
| Q9NQC7 | S772 | SIGNOR | CYLD CYLD1 KIAA0849 HSPC057 | LIIQMPRFGKDFKLFKKIFPsLELNITDLLEDTPRQCRICG |
| Q9NQZ2 | T397 | Sugiyama | UTP3 CRLZ1 SAS10 | KYYKEIEDRQKLKRKKEENstEEQALEDQNAKRAItyQIAK |
| Q9NSB2 | S178 | Sugiyama | KRT84 KRTHB4 | AQRVKKDEKEQIKTLNNKFAsFIDKVRFLEQQNKLLETKWS |
| Q9NUU7 | T467 | Sugiyama | DDX19A DDX19L | SMNILNRIQEHFNKKIERLDtDDLDEIEKIAN_________ |
| Q9NYF8 | S198 | Sugiyama | BCLAF1 BTF KIAA0164 | PLKsKsQEEPKDtFEHDPsEsIDEFNKssAtsGDIWPGLsA |
| Q9NZV8 | S438 | ELM | KCND2 KIAA1044 | RADKRRAQKKARLARIRAAKsGSANAYMQSKRNGLLSNQLQ |
| Q9NZV8 | S459 | ELM | KCND2 KIAA1044 | GSANAYMQSKRNGLLSNQLQsSEDEQAFVSKSGSSFETQHH |
| Q9UBS5 | S868 | SIGNOR | GABBR1 GPRC3A | TLVVLFVPKMRRLITRGEWQsEAQDtMKTGSstNNNEEEKS |
| Q9UBS5 | T873 | SIGNOR | GABBR1 GPRC3A | FVPKMRRLITRGEWQsEAQDtMKTGSstNNNEEEKSRLLEK |
| Q9UI15 | S185 | Sugiyama | TAGLN3 NP25 | EQLRQGQNVIGLQMGSNKGAsQAGMtGyGMPRQIM______ |
| Q9UII2 | S63 | Sugiyama | ATP5IF1 ATPI ATPIF1 | AGGAFGKREQAEEERyFRAQsREQLAALKKHHEEEIVHHKK |
| Q9UKV8 | S387 | Sugiyama | AGO2 EIF2C2 | ATARSAPDRQEEISKLMRsAsFNTDPyVREFGIMVKDEMTD |
| Q9ULD2 | S1203 | Sugiyama | MTUS1 ATBP ATIP GK1 KIAA1288 MTSG1 | QENEELKARMDKHMAISRQLstEQAVLQESLEKESKVNKRL |
| Q9ULD2 | T1204 | Sugiyama | MTUS1 ATBP ATIP GK1 KIAA1288 MTSG1 | ENEELKARMDKHMAISRQLstEQAVLQESLEKESKVNKRLs |
| Q9UMR2 | T468 | Sugiyama | DDX19B DBP5 DDX19 TDBP | SMNILNRIQEHFNKKIERLDtDDLDEIEKIAN_________ |
| Q9UNX3 | T8 | Sugiyama | RPL26L1 RPL26P1 | _____________MKFNPFVtsDRsKNRKRHFNAPSHVRRK |
| Q9UNZ2 | S192 | Sugiyama | NSFL1C UBXN2C | KRQHssQDVHVVLKLWKsGFsLDNGELRSyQDPsNAQFLEs |
| Q9UPQ0 | S201 | Sugiyama | LIMCH1 KIAA1102 | DCWDsERsDsLsPPRHGRDDsFDsLDsFGsRsRQtPsPDVV |
| Q9UQD0 | S561 | SIGNOR | SCN8A MED | sIMNQSLLSIPGSPFLSRHNsKSSIFSFRGPGRFRDPGSEN |
| Q9UQD0 | S641 | SIGNOR | SCN8A MED | SQGSRSSRIFPSLRRSVKRNstVDCNGVVSLIGGPGSHIGG |
| Q9UQD0 | T642 | SIGNOR | SCN8A MED | QGSRSSRIFPSLRRSVKRNstVDCNGVVSLIGGPGSHIGGR |
| Q9UQM7 | S25 | Sugiyama | CAMK2A CAMKA KIAA0968 | TCTRFTEEYQLFEELGKGAFsVVRRCVKVLAGQEYAAKIIN |
| Q9UQM7 | T305 | Sugiyama | CAMK2A CAMKA KIAA0968 | EtVDCLKKFNARRKLKGAILttMLAtRNFsGGKSGGNKKSD |
| Q9UQM7 | T306 | Sugiyama | CAMK2A CAMKA KIAA0968 | tVDCLKKFNARRKLKGAILttMLAtRNFsGGKSGGNKKSDG |
| Q9Y237 | S72 | Sugiyama | PIN4 | MEAMEKLKSGMRFNEVAAQysEDKARQGGDLGWMTRGSMVG |
| Q9Y281 | S24 | ELM | CFL2 | GVtVNDEVIKVFNDMKVRKsstQEEIKKRKKAVLFCLSDDK |
| Q9Y2B0 | S115 | Sugiyama | CNPY2 MSAP TMEM4 ZSIG9 UNQ1943/PRO4426 | QIDPstHRKNYVRVVGRNGEssELDLQGIRIDsDISGtLKF |
| Q9Y2B0 | S63 | Sugiyama | CNPY2 MSAP TMEM4 ZSIG9 UNQ1943/PRO4426 | AQVDPKKTIQMGsFRINPDGsQsVVEVPyARsEAHLtELLE |
| Q9Y2B0 | S65 | Sugiyama | CNPY2 MSAP TMEM4 ZSIG9 UNQ1943/PRO4426 | VDPKKTIQMGsFRINPDGsQsVVEVPyARsEAHLtELLEEI |
| Q9Y2T7 | T115 | Sugiyama | YBX2 CSDA3 MSY2 | LGTVKWFNVRNGyGFINRNDtKEDVFVHQtAIKRNNPRKFL |
| Q9Y3F4 | S153 | Sugiyama | STRAP MAWD UNRIP | EAEPKEISGHTSGIKKALWCsEDKQILsADDKtVRLWDHAT |
| Q9Y3U8 | S91 | Sugiyama | RPL36 | KFIKKRVGTHIRAKRKREELsNVLAAMRKAAAKKD______ |
| Q9Y4W2 | S641 | Sugiyama | LAS1L MSTP060 | ENARLLAQKRGALQGsAWQVssEDVRWDTFPLGRMPGQTED |
| Q9Y4W2 | S642 | Sugiyama | LAS1L MSTP060 | NARLLAQKRGALQGsAWQVssEDVRWDTFPLGRMPGQTEDP |
| Q9Y5S9 | S56 | Sugiyama | RBM8A RBM8 HSPC114 MDS014 | KGRGFGsEEGsRARMREDyDsVEQDGDEPGPQRSVEGWILF |
| Q9Y608 | S18 | Sugiyama | LRRFIP2 | ___MGTPASGRKRTPVKDRFsAEDEALsNIAREAEARLAAK |
| Q9Y6K9 | S196 | Sugiyama | IKBKG FIP3 NEMO | AASEQARQLESEREALQQQHsVQVDQLRMQGQSVEAALRME |
Site Promiscuity
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 0.000004 | 5.352 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 0.000007 | 5.171 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 0.000145 | 3.838 | 1 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 0.000157 | 3.803 | 0 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 0.000396 | 3.403 | 1 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 0.000347 | 3.459 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 0.000302 | 3.521 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 0.000396 | 3.403 | 1 | 1 |
| Post NMDA receptor activation events | R-HSA-438064 | 0.000421 | 3.376 | 1 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 0.000444 | 3.353 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 0.000444 | 3.353 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 0.000435 | 3.362 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 0.000487 | 3.313 | 1 | 0 |
| Nervous system development | R-HSA-9675108 | 0.000617 | 3.210 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 0.000689 | 3.162 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 0.000729 | 3.137 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 0.000810 | 3.092 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 0.000932 | 3.030 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 0.001225 | 2.912 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 0.001488 | 2.827 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 0.001855 | 2.732 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 0.001735 | 2.761 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 0.001860 | 2.730 | 1 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 0.002033 | 2.692 | 1 | 1 |
| Chromatin modifying enzymes | R-HSA-3247509 | 0.002212 | 2.655 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 0.002511 | 2.600 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 0.002666 | 2.574 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 0.002800 | 2.553 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 0.002881 | 2.541 | 0 | 0 |
| Cell Cycle | R-HSA-1640170 | 0.002964 | 2.528 | 0 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 0.003367 | 2.473 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | R-HSA-6804116 | 0.003499 | 2.456 | 0 | 0 |
| TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation | R-HSA-8869496 | 0.005216 | 2.283 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 0.005297 | 2.276 | 1 | 1 |
| G alpha (12/13) signalling events | R-HSA-416482 | 0.005195 | 2.284 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 0.005143 | 2.289 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 0.005385 | 2.269 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 0.005717 | 2.243 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 0.006480 | 2.188 | 1 | 1 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 0.006583 | 2.182 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 0.006583 | 2.182 | 0 | 0 |
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 0.006129 | 2.213 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 0.006547 | 2.184 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 0.006309 | 2.200 | 1 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 0.006480 | 2.188 | 1 | 1 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 0.007017 | 2.154 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 0.007404 | 2.131 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 0.007845 | 2.105 | 0 | 0 |
| Cohesin Loading onto Chromatin | R-HSA-2470946 | 0.008011 | 2.096 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 0.009307 | 2.031 | 1 | 1 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 0.009862 | 2.006 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 0.010453 | 1.981 | 0 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 0.010772 | 1.968 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 0.010933 | 1.961 | 0 | 0 |
| RUNX2 regulates chondrocyte maturation | R-HSA-8941284 | 0.011009 | 1.958 | 0 | 0 |
| RSK activation | R-HSA-444257 | 0.011706 | 1.932 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 0.011706 | 1.932 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 0.011910 | 1.924 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 0.011910 | 1.924 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 0.012889 | 1.890 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 0.012438 | 1.905 | 0 | 0 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 0.013859 | 1.858 | 0 | 0 |
| Processing of Intronless Pre-mRNAs | R-HSA-77595 | 0.015354 | 1.814 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 0.015727 | 1.803 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 0.014808 | 1.829 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 0.014808 | 1.829 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 0.015557 | 1.808 | 1 | 0 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 0.016042 | 1.795 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 0.015401 | 1.812 | 0 | 0 |
| RUNX3 regulates CDKN1A transcription | R-HSA-8941855 | 0.017103 | 1.767 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 0.016528 | 1.782 | 1 | 1 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 0.016843 | 1.774 | 0 | 0 |
| RUNX1 regulates expression of components of tight junctions | R-HSA-8935964 | 0.017103 | 1.767 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 0.018475 | 1.733 | 1 | 1 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 0.018475 | 1.733 | 0 | 0 |
| Calmodulin induced events | R-HSA-111933 | 0.017714 | 1.752 | 1 | 0 |
| CaM pathway | R-HSA-111997 | 0.017714 | 1.752 | 1 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 0.018712 | 1.728 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 0.019068 | 1.720 | 0 | 0 |
| Signaling by FGFR4 in disease | R-HSA-5655291 | 0.023884 | 1.622 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 0.023721 | 1.625 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 0.021127 | 1.675 | 0 | 0 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 0.022702 | 1.644 | 1 | 0 |
| Transport of the SLBP independent Mature mRNA | R-HSA-159227 | 0.022702 | 1.644 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 0.021481 | 1.668 | 1 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 0.020749 | 1.683 | 0 | 0 |
| Regulation of MITF-M dependent genes involved in metabolism | R-HSA-9854907 | 0.023638 | 1.626 | 0 | 0 |
| CREB phosphorylation | R-HSA-199920 | 0.024961 | 1.603 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 0.021173 | 1.674 | 1 | 0 |
| Cellular Senescence | R-HSA-2559583 | 0.020964 | 1.679 | 0 | 0 |
| CaMK IV-mediated phosphorylation of CREB | R-HSA-111932 | 0.022238 | 1.653 | 1 | 1 |
| Death Receptor Signaling | R-HSA-73887 | 0.021357 | 1.670 | 0 | 0 |
| Loss of MECP2 binding ability to 5hmC-DNA | R-HSA-9022534 | 0.024988 | 1.602 | 0 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 0.026347 | 1.579 | 0 | 0 |
| Transport of the SLBP Dependant Mature mRNA | R-HSA-159230 | 0.026347 | 1.579 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 0.026995 | 1.569 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 0.027073 | 1.567 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 0.027220 | 1.565 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 0.027431 | 1.562 | 0 | 0 |
| ChREBP activates metabolic gene expression | R-HSA-163765 | 0.029256 | 1.534 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 0.029467 | 1.531 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 0.029512 | 1.530 | 0 | 0 |
| Activation of gene expression by SREBF (SREBP) | R-HSA-2426168 | 0.029542 | 1.530 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 0.029934 | 1.524 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 0.029934 | 1.524 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 0.029934 | 1.524 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 0.032070 | 1.494 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 0.034409 | 1.463 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 0.034662 | 1.460 | 0 | 0 |
| Role of ABL in ROBO-SLIT signaling | R-HSA-428890 | 0.034678 | 1.460 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 0.034934 | 1.457 | 1 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 0.034934 | 1.457 | 1 | 1 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 0.034934 | 1.457 | 1 | 1 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 0.034934 | 1.457 | 1 | 1 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 0.035233 | 1.453 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 0.035739 | 1.447 | 0 | 0 |
| Transcriptional activation of p53 responsive genes | R-HSA-69560 | 0.037424 | 1.427 | 0 | 0 |
| Transcriptional activation of cell cycle inhibitor p21 | R-HSA-69895 | 0.037424 | 1.427 | 0 | 0 |
| M Phase | R-HSA-68886 | 0.036515 | 1.438 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of cell cycle factors | R-HSA-8866911 | 0.037424 | 1.427 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 0.036322 | 1.440 | 1 | 0 |
| Formation of the dystrophin-glycoprotein complex (DGC) | R-HSA-9913351 | 0.039178 | 1.407 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 0.039760 | 1.401 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 0.039852 | 1.400 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 0.040188 | 1.396 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 0.044844 | 1.348 | 0 | 0 |
| Vpr-mediated nuclear import of PICs | R-HSA-180910 | 0.045117 | 1.346 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 0.042002 | 1.377 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 0.045914 | 1.338 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 0.042820 | 1.368 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 0.045558 | 1.341 | 1 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 0.044073 | 1.356 | 1 | 0 |
| Membrane Trafficking | R-HSA-199991 | 0.042291 | 1.374 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 0.043790 | 1.359 | 0 | 0 |
| Co-stimulation by ICOS | R-HSA-9927354 | 0.046302 | 1.334 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of myeloid cells | R-HSA-8939246 | 0.046302 | 1.334 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 0.047106 | 1.327 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 0.048160 | 1.317 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 0.048830 | 1.311 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 0.050076 | 1.300 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 0.050112 | 1.300 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 0.050722 | 1.295 | 0 | 0 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | R-HSA-5693568 | 0.051269 | 1.290 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 0.053766 | 1.269 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 0.053766 | 1.269 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 0.057026 | 1.244 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 0.054971 | 1.260 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 0.054971 | 1.260 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 0.055831 | 1.253 | 0 | 0 |
| Resolution of D-Loop Structures | R-HSA-5693537 | 0.058142 | 1.236 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 0.054971 | 1.260 | 0 | 0 |
| Lipophagy | R-HSA-9613354 | 0.059831 | 1.223 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 0.063690 | 1.196 | 0 | 0 |
| Polo-like kinase mediated events | R-HSA-156711 | 0.063690 | 1.196 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 0.063690 | 1.196 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition | R-HSA-9926550 | 0.063690 | 1.196 | 0 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 0.064038 | 1.194 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 0.065580 | 1.183 | 1 | 1 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 0.065632 | 1.183 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 0.066396 | 1.178 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 0.066396 | 1.178 | 0 | 0 |
| Regulation of gene expression in beta cells | R-HSA-210745 | 0.066396 | 1.178 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 0.085486 | 1.068 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 0.085486 | 1.068 | 0 | 0 |
| Regulation of cortical dendrite branching | R-HSA-8985801 | 0.085486 | 1.068 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 0.085486 | 1.068 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 0.085486 | 1.068 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 0.085486 | 1.068 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 0.085486 | 1.068 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 0.085486 | 1.068 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 0.085486 | 1.068 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 0.085486 | 1.068 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 0.085486 | 1.068 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 0.085486 | 1.068 | 0 | 0 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | R-HSA-9022537 | 0.074601 | 1.127 | 0 | 0 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 0.075226 | 1.124 | 0 | 0 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | R-HSA-428359 | 0.075226 | 1.124 | 0 | 0 |
| 2-LTR circle formation | R-HSA-164843 | 0.075226 | 1.124 | 0 | 0 |
| Formation of the embryonic stem cell BAF (esBAF) complex | R-HSA-9933946 | 0.083728 | 1.077 | 0 | 0 |
| Impaired BRCA2 binding to PALB2 | R-HSA-9709603 | 0.074619 | 1.127 | 0 | 0 |
| Processing of Capped Intronless Pre-mRNA | R-HSA-75067 | 0.075832 | 1.120 | 0 | 0 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | R-HSA-5619107 | 0.075238 | 1.124 | 0 | 0 |
| IP3 and IP4 transport between cytosol and nucleus | R-HSA-1855196 | 0.084756 | 1.072 | 0 | 0 |
| IP6 and IP7 transport between cytosol and nucleus | R-HSA-1855229 | 0.084756 | 1.072 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 0.073592 | 1.133 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 0.075818 | 1.120 | 0 | 0 |
| Metabolism of non-coding RNA | R-HSA-194441 | 0.068998 | 1.161 | 0 | 0 |
| snRNP Assembly | R-HSA-191859 | 0.068998 | 1.161 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 0.082006 | 1.086 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 0.073369 | 1.134 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 0.075238 | 1.124 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 0.084756 | 1.072 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 0.084756 | 1.072 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 0.073369 | 1.134 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 0.075226 | 1.124 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 0.079123 | 1.102 | 1 | 1 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 0.074619 | 1.127 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 0.077857 | 1.109 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 0.080179 | 1.096 | 1 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 0.079330 | 1.101 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 0.075832 | 1.120 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 0.075832 | 1.120 | 0 | 0 |
| G-protein mediated events | R-HSA-112040 | 0.077588 | 1.110 | 1 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 0.086446 | 1.063 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 0.086446 | 1.063 | 0 | 0 |
| Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | R-HSA-9934037 | 0.086547 | 1.063 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | R-HSA-9701193 | 0.086547 | 1.063 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | R-HSA-9701192 | 0.086547 | 1.063 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | R-HSA-9704646 | 0.086547 | 1.063 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | R-HSA-9704331 | 0.086547 | 1.063 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 0.086547 | 1.063 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 0.087276 | 1.059 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 0.087584 | 1.058 | 1 | 0 |
| Drug resistance of PDGFR mutants | R-HSA-9674415 | 0.114054 | 0.943 | 0 | 0 |
| PDGFR mutants bind TKIs | R-HSA-9674428 | 0.114054 | 0.943 | 0 | 0 |
| Regorafenib-resistant PDGFR mutants | R-HSA-9674403 | 0.114054 | 0.943 | 0 | 0 |
| Sorafenib-resistant PDGFR mutants | R-HSA-9674404 | 0.114054 | 0.943 | 0 | 0 |
| Deletions in the AMER1 gene destabilize the destruction complex | R-HSA-5467343 | 0.114054 | 0.943 | 0 | 0 |
| Sunitinib-resistant PDGFR mutants | R-HSA-9674401 | 0.114054 | 0.943 | 0 | 0 |
| Imatinib-resistant PDGFR mutants | R-HSA-9674396 | 0.114054 | 0.943 | 0 | 0 |
| APC truncation mutants are not K63 polyubiquitinated | R-HSA-5467333 | 0.114054 | 0.943 | 0 | 0 |
| Alternative Lengthening of Telomeres (ALT) | R-HSA-9006821 | 0.215105 | 0.667 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere | R-HSA-9670621 | 0.215105 | 0.667 | 0 | 0 |
| Diseases of Telomere Maintenance | R-HSA-9673013 | 0.215105 | 0.667 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations | R-HSA-9670615 | 0.215105 | 0.667 | 0 | 0 |
| TICAM1 deficiency - HSE | R-HSA-5602566 | 0.215105 | 0.667 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis Due to p14ARF Loss of Function | R-HSA-9645722 | 0.215105 | 0.667 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH6 | R-HSA-5632968 | 0.215105 | 0.667 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations | R-HSA-9670613 | 0.215105 | 0.667 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by DVL-interacting proteins | R-HSA-5368598 | 0.123688 | 0.908 | 0 | 0 |
| Loss of MECP2 binding ability to 5mC-DNA | R-HSA-9022538 | 0.123688 | 0.908 | 0 | 0 |
| Signaling by cytosolic PDGFRA and PDGFRB fusion proteins | R-HSA-9673766 | 0.123688 | 0.908 | 0 | 0 |
| RUNX3 regulates YAP1-mediated transcription | R-HSA-8951671 | 0.097499 | 1.011 | 0 | 0 |
| RAS signaling downstream of NF1 loss-of-function variants | R-HSA-6802953 | 0.097499 | 1.011 | 0 | 0 |
| MECP2 regulates transcription of genes involved in GABA signaling | R-HSA-9022927 | 0.165075 | 0.782 | 0 | 0 |
| TLR3-mediated TICAM1-dependent programmed cell death | R-HSA-9013957 | 0.165075 | 0.782 | 0 | 0 |
| TNFR1-mediated ceramide production | R-HSA-5626978 | 0.165075 | 0.782 | 0 | 0 |
| RUNX2 regulates genes involved in differentiation of myeloid cells | R-HSA-8941333 | 0.165075 | 0.782 | 0 | 0 |
| RUNX3 regulates BCL2L11 (BIM) transcription | R-HSA-8952158 | 0.165075 | 0.782 | 0 | 0 |
| PLCG1 events in ERBB2 signaling | R-HSA-1251932 | 0.165075 | 0.782 | 0 | 0 |
| Defective LFNG causes SCDO3 | R-HSA-5083630 | 0.165075 | 0.782 | 0 | 0 |
| FGFR4 mutant receptor activation | R-HSA-1839128 | 0.304636 | 0.516 | 0 | 0 |
| ARL13B-mediated ciliary trafficking of INPP5E | R-HSA-5624958 | 0.304636 | 0.516 | 0 | 0 |
| Interactions of Tat with host cellular proteins | R-HSA-176034 | 0.304636 | 0.516 | 0 | 0 |
| TRAF3 deficiency - HSE | R-HSA-5602571 | 0.304636 | 0.516 | 0 | 0 |
| Defective PGM1 causes PGM1-CDG | R-HSA-5609974 | 0.304636 | 0.516 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 | R-HSA-9632700 | 0.304636 | 0.516 | 0 | 0 |
| PTEN Loss of Function in Cancer | R-HSA-5674404 | 0.304636 | 0.516 | 0 | 0 |
| Defective SLC20A2 causes idiopathic basal ganglia calcification 1 (IBGC1) | R-HSA-5619111 | 0.304636 | 0.516 | 0 | 0 |
| Defective SLC4A4 causes renal tubular acidosis, proximal, with ocular abnormalities and mental retardation (pRTA-OA) | R-HSA-5619054 | 0.304636 | 0.516 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 | R-HSA-9630794 | 0.304636 | 0.516 | 0 | 0 |
| RUNX3 Regulates Immune Response and Cell Migration | R-HSA-8949275 | 0.122844 | 0.911 | 0 | 0 |
| TRIF-mediated programmed cell death | R-HSA-2562578 | 0.122844 | 0.911 | 0 | 0 |
| Disinhibition of SNARE formation | R-HSA-114516 | 0.122844 | 0.911 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 0.122844 | 0.911 | 0 | 0 |
| PECAM1 interactions | R-HSA-210990 | 0.092408 | 1.034 | 0 | 0 |
| Post-transcriptional silencing by small RNAs | R-HSA-426496 | 0.208423 | 0.681 | 0 | 0 |
| IRS activation | R-HSA-74713 | 0.208423 | 0.681 | 0 | 0 |
| Loss of Function of TGFBR1 in Cancer | R-HSA-3656534 | 0.208423 | 0.681 | 0 | 0 |
| Loss of phosphorylation of MECP2 at T308 | R-HSA-9022535 | 0.208423 | 0.681 | 0 | 0 |
| Type I hemidesmosome assembly | R-HSA-446107 | 0.150277 | 0.823 | 0 | 0 |
| Formation of annular gap junctions | R-HSA-196025 | 0.150277 | 0.823 | 0 | 0 |
| Activation of RAC1 | R-HSA-428540 | 0.111273 | 0.954 | 0 | 0 |
| Signaling by AMER1 mutants | R-HSA-4839748 | 0.111273 | 0.954 | 0 | 0 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | R-HSA-399955 | 0.098511 | 1.007 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 0.131691 | 0.880 | 0 | 0 |
| Gap junction degradation | R-HSA-190873 | 0.179437 | 0.746 | 0 | 0 |
| Inactivation of CDC42 and RAC1 | R-HSA-428543 | 0.179437 | 0.746 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 0.252749 | 0.597 | 0 | 0 |
| CDC6 association with the ORC:origin complex | R-HSA-68689 | 0.252749 | 0.597 | 0 | 0 |
| SLIT2:ROBO1 increases RHOA activity | R-HSA-8985586 | 0.252749 | 0.597 | 0 | 0 |
| RUNX3 regulates RUNX1-mediated transcription | R-HSA-8951911 | 0.383959 | 0.416 | 0 | 0 |
| Glycogen storage disease type XV (GYG1) | R-HSA-3814836 | 0.383959 | 0.416 | 0 | 0 |
| TGFBR1 LBD Mutants in Cancer | R-HSA-3656535 | 0.383959 | 0.416 | 0 | 0 |
| Mitotic Metaphase/Anaphase Transition | R-HSA-68881 | 0.383959 | 0.416 | 0 | 0 |
| Signaling by RAS GAP mutants | R-HSA-9753510 | 0.383959 | 0.416 | 0 | 0 |
| Glycogen storage disease type 0 (muscle GYS1) | R-HSA-3828062 | 0.383959 | 0.416 | 0 | 0 |
| HHAT G278V doesn't palmitoylate Hh-Np | R-HSA-5658034 | 0.383959 | 0.416 | 0 | 0 |
| HDR through MMEJ (alt-NHEJ) | R-HSA-5685939 | 0.153514 | 0.814 | 0 | 0 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | R-HSA-2559584 | 0.153514 | 0.814 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 0.099456 | 1.002 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 0.099456 | 1.002 | 0 | 0 |
| Folding of actin by CCT/TriC | R-HSA-390450 | 0.209962 | 0.678 | 0 | 0 |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | R-HSA-2151209 | 0.209962 | 0.678 | 0 | 0 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | R-HSA-2032785 | 0.176585 | 0.753 | 0 | 0 |
| Small interfering RNA (siRNA) biogenesis | R-HSA-426486 | 0.297265 | 0.527 | 0 | 0 |
| Autointegration results in viral DNA circles | R-HSA-177539 | 0.297265 | 0.527 | 0 | 0 |
| E2F-enabled inhibition of pre-replication complex formation | R-HSA-113507 | 0.297265 | 0.527 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 0.149891 | 0.824 | 0 | 0 |
| Signaling by APC mutants | R-HSA-4839744 | 0.241511 | 0.617 | 0 | 0 |
| APC truncation mutants have impaired AXIN binding | R-HSA-5467337 | 0.241511 | 0.617 | 0 | 0 |
| Truncations of AMER1 destabilize the destruction complex | R-HSA-5467348 | 0.241511 | 0.617 | 0 | 0 |
| AXIN missense mutants destabilize the destruction complex | R-HSA-5467340 | 0.241511 | 0.617 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 0.110059 | 0.958 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 0.110059 | 0.958 | 0 | 0 |
| Signaling by PDGFRA extracellular domain mutants | R-HSA-9673770 | 0.200734 | 0.697 | 0 | 0 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | R-HSA-9673767 | 0.200734 | 0.697 | 0 | 0 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 0.200734 | 0.697 | 0 | 0 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | R-HSA-167242 | 0.169112 | 0.772 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 0.123025 | 0.910 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 0.123025 | 0.910 | 0 | 0 |
| IPs transport between nucleus and cytosol | R-HSA-1855170 | 0.105802 | 0.976 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 0.136732 | 0.864 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 0.160257 | 0.795 | 0 | 0 |
| Transcription of E2F targets under negative control by DREAM complex | R-HSA-1362277 | 0.189231 | 0.723 | 0 | 0 |
| Phosphorylation of the APC/C | R-HSA-176412 | 0.225793 | 0.646 | 0 | 0 |
| Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 | R-HSA-9824878 | 0.273760 | 0.563 | 0 | 0 |
| Phosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promoters | R-HSA-9931512 | 0.273760 | 0.563 | 0 | 0 |
| Signaling by GSK3beta mutants | R-HSA-5339716 | 0.273760 | 0.563 | 0 | 0 |
| MECP2 regulates transcription factors | R-HSA-9022707 | 0.341352 | 0.467 | 0 | 0 |
| MET activates PI3K/AKT signaling | R-HSA-8851907 | 0.341352 | 0.467 | 0 | 0 |
| Regulation of PTEN localization | R-HSA-8948747 | 0.341352 | 0.467 | 0 | 0 |
| VLDL clearance | R-HSA-8964046 | 0.341352 | 0.467 | 0 | 0 |
| Pre-NOTCH Processing in the Endoplasmic Reticulum | R-HSA-1912399 | 0.341352 | 0.467 | 0 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 0.341352 | 0.467 | 0 | 0 |
| Activated NTRK3 signals through PLCG1 | R-HSA-9034793 | 0.454237 | 0.343 | 0 | 0 |
| PLC-gamma1 signalling | R-HSA-167021 | 0.454237 | 0.343 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of other transcription factors | R-HSA-8866906 | 0.454237 | 0.343 | 0 | 0 |
| MET activates PTPN11 | R-HSA-8865999 | 0.454237 | 0.343 | 0 | 0 |
| Loss of Function of KMT2D in Kabuki Syndrome | R-HSA-9944971 | 0.454237 | 0.343 | 0 | 0 |
| Invadopodia formation | R-HSA-8941237 | 0.454237 | 0.343 | 0 | 0 |
| Loss of Function of KMT2D in MLL4 Complex Formation in Kabuki Syndrome | R-HSA-9944997 | 0.454237 | 0.343 | 0 | 0 |
| Defective ABCC2 causes DJS | R-HSA-5679001 | 0.454237 | 0.343 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 0.111408 | 0.953 | 0 | 0 |
| BMAL1:CLOCK,NPAS2 activates circadian expression | R-HSA-1368108 | 0.129466 | 0.888 | 0 | 0 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | R-HSA-5693554 | 0.177518 | 0.751 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 0.122285 | 0.913 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 0.122285 | 0.913 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 0.122285 | 0.913 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 0.251591 | 0.599 | 0 | 0 |
| The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex | R-HSA-9931521 | 0.251591 | 0.599 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 0.195490 | 0.709 | 0 | 0 |
| RUNX3 regulates NOTCH signaling | R-HSA-8941856 | 0.306411 | 0.514 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 0.306411 | 0.514 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 0.306411 | 0.514 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 0.306411 | 0.514 | 0 | 0 |
| Signaling by CTNNB1 phospho-site mutants | R-HSA-4839743 | 0.306411 | 0.514 | 0 | 0 |
| Scavenging by Class F Receptors | R-HSA-3000484 | 0.306411 | 0.514 | 0 | 0 |
| CTNNB1 S33 mutants aren't phosphorylated | R-HSA-5358747 | 0.306411 | 0.514 | 0 | 0 |
| CTNNB1 S45 mutants aren't phosphorylated | R-HSA-5358751 | 0.306411 | 0.514 | 0 | 0 |
| CTNNB1 T41 mutants aren't phosphorylated | R-HSA-5358752 | 0.306411 | 0.514 | 0 | 0 |
| CTNNB1 S37 mutants aren't phosphorylated | R-HSA-5358749 | 0.306411 | 0.514 | 0 | 0 |
| FOXO-mediated transcription of cell cycle genes | R-HSA-9617828 | 0.231772 | 0.635 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 0.169550 | 0.771 | 0 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 0.277959 | 0.556 | 0 | 0 |
| EGFR interacts with phospholipase C-gamma | R-HSA-212718 | 0.384529 | 0.415 | 0 | 0 |
| Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation | R-HSA-9828211 | 0.384529 | 0.415 | 0 | 0 |
| Regulation of NPAS4 mRNA translation | R-HSA-9768778 | 0.384529 | 0.415 | 0 | 0 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 0.384529 | 0.415 | 0 | 0 |
| Activated NTRK2 signals through PI3K | R-HSA-9028335 | 0.384529 | 0.415 | 0 | 0 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 0.384529 | 0.415 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 0.253988 | 0.595 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 0.233302 | 0.632 | 0 | 0 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 0.233302 | 0.632 | 0 | 0 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | R-HSA-9661069 | 0.339195 | 0.470 | 0 | 0 |
| Trafficking of GluR2-containing AMPA receptors | R-HSA-416993 | 0.304736 | 0.516 | 0 | 0 |
| Impaired BRCA2 binding to RAD51 | R-HSA-9709570 | 0.253005 | 0.597 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 0.212805 | 0.672 | 0 | 0 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 0.273143 | 0.564 | 0 | 0 |
| IKK complex recruitment mediated by RIP1 | R-HSA-937041 | 0.331768 | 0.479 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | R-HSA-975163 | 0.371870 | 0.430 | 0 | 0 |
| CRMPs in Sema3A signaling | R-HSA-399956 | 0.371870 | 0.430 | 0 | 0 |
| Estrogen-stimulated signaling through PRKCZ | R-HSA-9634635 | 0.426429 | 0.370 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 0.426429 | 0.370 | 0 | 0 |
| Calcineurin activates NFAT | R-HSA-2025928 | 0.426429 | 0.370 | 0 | 0 |
| ALK mutants bind TKIs | R-HSA-9700645 | 0.426429 | 0.370 | 0 | 0 |
| Activated NTRK2 signals through PLCG1 | R-HSA-9026527 | 0.516502 | 0.287 | 0 | 0 |
| AKT-mediated inactivation of FOXO1A | R-HSA-211163 | 0.516502 | 0.287 | 0 | 0 |
| Inhibition of TSC complex formation by PKB | R-HSA-165181 | 0.516502 | 0.287 | 0 | 0 |
| betaKlotho-mediated ligand binding | R-HSA-1307965 | 0.516502 | 0.287 | 0 | 0 |
| Loss of Function of FBXW7 in Cancer and NOTCH1 Signaling | R-HSA-2644607 | 0.516502 | 0.287 | 0 | 0 |
| TGFBR1 KD Mutants in Cancer | R-HSA-3656532 | 0.516502 | 0.287 | 0 | 0 |
| GRB7 events in ERBB2 signaling | R-HSA-1306955 | 0.516502 | 0.287 | 0 | 0 |
| Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes | R-HSA-69200 | 0.516502 | 0.287 | 0 | 0 |
| FBXW7 Mutants and NOTCH1 in Cancer | R-HSA-2644605 | 0.516502 | 0.287 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 0.268522 | 0.571 | 0 | 0 |
| RNA Polymerase III Abortive And Retractive Initiation | R-HSA-749476 | 0.268522 | 0.571 | 0 | 0 |
| PI-3K cascade:FGFR4 | R-HSA-5654720 | 0.358908 | 0.445 | 0 | 0 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | R-HSA-937072 | 0.404224 | 0.393 | 0 | 0 |
| RIP-mediated NFkB activation via ZBP1 | R-HSA-1810476 | 0.404224 | 0.393 | 0 | 0 |
| Beta-catenin phosphorylation cascade | R-HSA-196299 | 0.404224 | 0.393 | 0 | 0 |
| TICAM1, RIP1-mediated IKK complex recruitment | R-HSA-168927 | 0.404224 | 0.393 | 0 | 0 |
| TNFR1-induced proapoptotic signaling | R-HSA-5357786 | 0.386021 | 0.413 | 0 | 0 |
| APC-Cdc20 mediated degradation of Nek2A | R-HSA-179409 | 0.386021 | 0.413 | 0 | 0 |
| MECP2 regulates transcription of neuronal ligands | R-HSA-9022702 | 0.466784 | 0.331 | 0 | 0 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | R-HSA-9014325 | 0.466784 | 0.331 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 0.466784 | 0.331 | 0 | 0 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | R-HSA-9027277 | 0.466784 | 0.331 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 0.370410 | 0.431 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 0.356623 | 0.448 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 0.356623 | 0.448 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 0.436073 | 0.360 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 0.266923 | 0.574 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 0.251832 | 0.599 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 0.251832 | 0.599 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 0.328181 | 0.484 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 0.318139 | 0.497 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 0.291593 | 0.535 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 0.283699 | 0.547 | 0 | 0 |
| Late endosomal microautophagy | R-HSA-9615710 | 0.417670 | 0.379 | 0 | 0 |
| mRNA decay by 5' to 3' exoribonuclease | R-HSA-430039 | 0.467260 | 0.330 | 0 | 0 |
| RUNX2 regulates genes involved in cell migration | R-HSA-8941332 | 0.505399 | 0.296 | 0 | 0 |
| Regulation of CDH11 mRNA translation by microRNAs | R-HSA-9759811 | 0.505399 | 0.296 | 0 | 0 |
| Activation of AMPA receptors | R-HSA-399710 | 0.571666 | 0.243 | 0 | 0 |
| Signaling by membrane-tethered fusions of PDGFRA or PDGFRB | R-HSA-9673768 | 0.571666 | 0.243 | 0 | 0 |
| NOSIP mediated eNOS trafficking | R-HSA-203754 | 0.571666 | 0.243 | 0 | 0 |
| Defective F9 activation | R-HSA-9673221 | 0.571666 | 0.243 | 0 | 0 |
| Enhanced binding of GP1BA variant to VWF multimer:collagen | R-HSA-9845620 | 0.571666 | 0.243 | 0 | 0 |
| SMAD2/3 Phosphorylation Motif Mutants in Cancer | R-HSA-3304356 | 0.571666 | 0.243 | 0 | 0 |
| Defective binding of VWF variant to GPIb:IX:V | R-HSA-9846298 | 0.571666 | 0.243 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 0.291184 | 0.536 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 0.404799 | 0.393 | 0 | 0 |
| Regulation of PTEN mRNA translation | R-HSA-8943723 | 0.466004 | 0.332 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 0.283224 | 0.548 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 0.497653 | 0.303 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 0.383854 | 0.416 | 0 | 0 |
| Condensation of Prometaphase Chromosomes | R-HSA-2514853 | 0.542147 | 0.266 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 0.460642 | 0.337 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 0.460642 | 0.337 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 0.439414 | 0.357 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 0.408394 | 0.389 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 0.408394 | 0.389 | 0 | 0 |
| RNA Polymerase III Transcription Termination | R-HSA-73980 | 0.527144 | 0.278 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 0.517201 | 0.286 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 0.450476 | 0.346 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 0.444566 | 0.352 | 0 | 0 |
| Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes | R-HSA-9931510 | 0.541922 | 0.266 | 0 | 0 |
| PI-3K cascade:FGFR3 | R-HSA-5654710 | 0.555647 | 0.255 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Cyclin B | R-HSA-174048 | 0.555647 | 0.255 | 0 | 0 |
| NOTCH2 intracellular domain regulates transcription | R-HSA-2197563 | 0.576951 | 0.239 | 0 | 0 |
| RUNX3 regulates p14-ARF | R-HSA-8951936 | 0.576951 | 0.239 | 0 | 0 |
| Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant | R-HSA-2660826 | 0.620539 | 0.207 | 0 | 0 |
| Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant | R-HSA-2660825 | 0.620539 | 0.207 | 0 | 0 |
| Cam-PDE 1 activation | R-HSA-111957 | 0.620539 | 0.207 | 0 | 0 |
| IkBA variant leads to EDA-ID | R-HSA-5603029 | 0.620539 | 0.207 | 0 | 0 |
| Signaling by Overexpressed Wild-Type EGFR in Cancer | R-HSA-5638302 | 0.620539 | 0.207 | 0 | 0 |
| Noncanonical activation of NOTCH3 | R-HSA-9017802 | 0.620539 | 0.207 | 0 | 0 |
| Inhibition of Signaling by Overexpressed EGFR | R-HSA-5638303 | 0.620539 | 0.207 | 0 | 0 |
| Loss-of-function mutations in DBT cause MSUD2 | R-HSA-9865113 | 0.620539 | 0.207 | 0 | 0 |
| Loss-of-function mutations in DLD cause MSUD3/DLDD | R-HSA-9907570 | 0.620539 | 0.207 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 0.553546 | 0.257 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 0.579617 | 0.237 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 0.589318 | 0.230 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 0.606567 | 0.217 | 0 | 0 |
| RNA Polymerase III Transcription | R-HSA-74158 | 0.268522 | 0.571 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 0.332567 | 0.478 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 0.286856 | 0.542 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 0.501954 | 0.299 | 0 | 0 |
| FOXO-mediated transcription of cell death genes | R-HSA-9614657 | 0.304736 | 0.516 | 0 | 0 |
| RNA Polymerase III Transcription Initiation | R-HSA-76046 | 0.441102 | 0.355 | 0 | 0 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 0.439677 | 0.357 | 0 | 0 |
| VxPx cargo-targeting to cilium | R-HSA-5620916 | 0.189231 | 0.723 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | R-HSA-5358565 | 0.277959 | 0.556 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 0.557191 | 0.254 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 0.524449 | 0.280 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 0.436073 | 0.360 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 0.179437 | 0.746 | 0 | 0 |
| Platelet sensitization by LDL | R-HSA-432142 | 0.149891 | 0.824 | 0 | 0 |
| NOTCH4 Intracellular Domain Regulates Transcription | R-HSA-9013695 | 0.210152 | 0.677 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 0.511302 | 0.291 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 0.441102 | 0.355 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 0.427358 | 0.369 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 0.253988 | 0.595 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 0.517201 | 0.286 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 0.297309 | 0.527 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 0.207660 | 0.683 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 0.363578 | 0.439 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 0.184357 | 0.734 | 0 | 0 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | R-HSA-936964 | 0.467260 | 0.330 | 0 | 0 |
| TICAM1-dependent activation of IRF3/IRF7 | R-HSA-9013973 | 0.542147 | 0.266 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 0.440216 | 0.356 | 0 | 0 |
| Fanconi Anemia Pathway | R-HSA-6783310 | 0.460642 | 0.337 | 0 | 0 |
| Integration of provirus | R-HSA-162592 | 0.111273 | 0.954 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 0.133711 | 0.874 | 0 | 0 |
| Acetylcholine regulates insulin secretion | R-HSA-399997 | 0.467260 | 0.330 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 0.458833 | 0.338 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 0.494351 | 0.306 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 0.423440 | 0.373 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 0.408885 | 0.388 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 0.609776 | 0.215 | 0 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 0.250320 | 0.602 | 0 | 0 |
| Activation of RAC1 downstream of NMDARs | R-HSA-9619229 | 0.179437 | 0.746 | 0 | 0 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 0.209962 | 0.678 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 0.273143 | 0.564 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 0.246719 | 0.608 | 0 | 0 |
| Josephin domain DUBs | R-HSA-5689877 | 0.466784 | 0.331 | 0 | 0 |
| DARPP-32 events | R-HSA-180024 | 0.417670 | 0.379 | 0 | 0 |
| Golgi Cisternae Pericentriolar Stack Reorganization | R-HSA-162658 | 0.609776 | 0.215 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 0.595336 | 0.225 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 0.611797 | 0.213 | 0 | 0 |
| Signaling by BMP | R-HSA-201451 | 0.214107 | 0.669 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 0.383029 | 0.417 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 0.503756 | 0.298 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 0.120802 | 0.918 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 0.399147 | 0.399 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 0.149580 | 0.825 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 0.280382 | 0.552 | 0 | 0 |
| Muscarinic acetylcholine receptors | R-HSA-390648 | 0.208423 | 0.681 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 0.181967 | 0.740 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 0.466784 | 0.331 | 0 | 0 |
| WNT5A-dependent internalization of FZD4 | R-HSA-5099900 | 0.436073 | 0.360 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 0.344205 | 0.463 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 0.255685 | 0.592 | 0 | 0 |
| Regulation of localization of FOXO transcription factors | R-HSA-9614399 | 0.505399 | 0.296 | 0 | 0 |
| POLB-Dependent Long Patch Base Excision Repair | R-HSA-110362 | 0.542147 | 0.266 | 0 | 0 |
| SHC-related events triggered by IGF1R | R-HSA-2428933 | 0.576951 | 0.239 | 0 | 0 |
| PKA-mediated phosphorylation of key metabolic factors | R-HSA-163358 | 0.620539 | 0.207 | 0 | 0 |
| NPAS4 regulates expression of target genes | R-HSA-9768919 | 0.553546 | 0.257 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 0.609438 | 0.215 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 0.108000 | 0.967 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 0.149891 | 0.824 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 0.181288 | 0.742 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 0.368687 | 0.433 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 0.490480 | 0.309 | 0 | 0 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 0.417670 | 0.379 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 0.574711 | 0.241 | 0 | 0 |
| Sensing of DNA Double Strand Breaks | R-HSA-5693548 | 0.542147 | 0.266 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 0.360566 | 0.443 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 0.170135 | 0.769 | 0 | 0 |
| SARS-CoV-2 targets PDZ proteins in cell-cell junction | R-HSA-9705677 | 0.165075 | 0.782 | 0 | 0 |
| Activation of NIMA Kinases NEK9, NEK6, NEK7 | R-HSA-2980767 | 0.297265 | 0.527 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 0.108709 | 0.964 | 1 | 1 |
| Regulation of CDH1 Function | R-HSA-9764561 | 0.102417 | 0.990 | 0 | 0 |
| Sodium/Proton exchangers | R-HSA-425986 | 0.384529 | 0.415 | 0 | 0 |
| Nef mediated downregulation of MHC class I complex cell surface expression | R-HSA-164940 | 0.384529 | 0.415 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 0.138820 | 0.858 | 0 | 0 |
| Synaptic adhesion-like molecules | R-HSA-8849932 | 0.304736 | 0.516 | 0 | 0 |
| AMPK inhibits chREBP transcriptional activation activity | R-HSA-163680 | 0.426429 | 0.370 | 0 | 0 |
| Unwinding of DNA | R-HSA-176974 | 0.426429 | 0.370 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 0.516502 | 0.287 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 0.243025 | 0.614 | 0 | 0 |
| Phosphorylation and nuclear translocation of BMAL1 (ARNTL) and CLOCK | R-HSA-9931529 | 0.571666 | 0.243 | 0 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 0.359642 | 0.444 | 0 | 0 |
| NF-kB is activated and signals survival | R-HSA-209560 | 0.542147 | 0.266 | 0 | 0 |
| PKA activation | R-HSA-163615 | 0.527144 | 0.278 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 0.502653 | 0.299 | 0 | 0 |
| Role of second messengers in netrin-1 signaling | R-HSA-418890 | 0.576951 | 0.239 | 0 | 0 |
| GLI proteins bind promoters of Hh responsive genes to promote transcription | R-HSA-5635851 | 0.620539 | 0.207 | 0 | 0 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 0.574711 | 0.241 | 0 | 0 |
| PINK1-PRKN Mediated Mitophagy | R-HSA-5205685 | 0.589318 | 0.230 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 0.473829 | 0.324 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 0.094946 | 1.023 | 0 | 0 |
| Nuclear RNA decay | R-HSA-9930044 | 0.198286 | 0.703 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 0.298678 | 0.525 | 1 | 1 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 0.299791 | 0.523 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 0.103323 | 0.986 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 0.099129 | 1.004 | 0 | 0 |
| Activated NTRK2 signals through FRS2 and FRS3 | R-HSA-9028731 | 0.576951 | 0.239 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 0.565977 | 0.247 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 0.616798 | 0.210 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 0.511302 | 0.291 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 0.195126 | 0.710 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 0.511302 | 0.291 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 0.553710 | 0.257 | 0 | 0 |
| p75NTR signals via NF-kB | R-HSA-193639 | 0.404224 | 0.393 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 0.559081 | 0.253 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 0.417615 | 0.379 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 0.535895 | 0.271 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 0.535895 | 0.271 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 0.110341 | 0.957 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 0.303782 | 0.517 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 0.143940 | 0.842 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 0.349276 | 0.457 | 1 | 0 |
| Negative feedback regulation of MAPK pathway | R-HSA-5674499 | 0.252749 | 0.597 | 0 | 0 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 0.110059 | 0.958 | 0 | 0 |
| RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | R-HSA-9933387 | 0.151149 | 0.821 | 0 | 0 |
| Adrenoceptors | R-HSA-390696 | 0.384529 | 0.415 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 0.276696 | 0.558 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 0.273143 | 0.564 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 0.267250 | 0.573 | 0 | 0 |
| HDR through Single Strand Annealing (SSA) | R-HSA-5685938 | 0.335455 | 0.474 | 0 | 0 |
| Resolution of AP sites via the single-nucleotide replacement pathway | R-HSA-110381 | 0.571666 | 0.243 | 0 | 0 |
| Activation of AKT2 | R-HSA-165158 | 0.571666 | 0.243 | 0 | 0 |
| Modulation of host responses by IFN-stimulated genes | R-HSA-9909505 | 0.497653 | 0.303 | 0 | 0 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | R-HSA-176407 | 0.497653 | 0.303 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 0.423440 | 0.373 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 0.503756 | 0.298 | 0 | 0 |
| p75NTR recruits signalling complexes | R-HSA-209543 | 0.576951 | 0.239 | 0 | 0 |
| GRB2 events in EGFR signaling | R-HSA-179812 | 0.576951 | 0.239 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 0.563338 | 0.249 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 0.560649 | 0.251 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 0.578460 | 0.238 | 0 | 0 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | R-HSA-450321 | 0.609438 | 0.215 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 0.331714 | 0.479 | 1 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 0.589424 | 0.230 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 0.099479 | 1.002 | 0 | 0 |
| Mismatch Repair | R-HSA-5358508 | 0.304736 | 0.516 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 0.372548 | 0.429 | 1 | 1 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 0.253005 | 0.597 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 0.280382 | 0.552 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 0.615809 | 0.211 | 1 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 0.183073 | 0.737 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 0.306411 | 0.514 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 0.371870 | 0.430 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 0.140038 | 0.854 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 0.198485 | 0.702 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 0.546249 | 0.263 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 0.247594 | 0.606 | 0 | 0 |
| CHL1 interactions | R-HSA-447041 | 0.122844 | 0.911 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 0.341352 | 0.467 | 0 | 0 |
| SARS-CoV-1-mediated effects on programmed cell death | R-HSA-9692913 | 0.516502 | 0.287 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 0.238227 | 0.623 | 0 | 0 |
| Dopamine Neurotransmitter Release Cycle | R-HSA-212676 | 0.439677 | 0.357 | 0 | 0 |
| LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | R-HSA-3134973 | 0.571666 | 0.243 | 0 | 0 |
| Toxicity of botulinum toxin type E (botE) | R-HSA-5250992 | 0.620539 | 0.207 | 0 | 0 |
| Aryl hydrocarbon receptor signalling | R-HSA-8937144 | 0.620539 | 0.207 | 0 | 0 |
| S Phase | R-HSA-69242 | 0.539271 | 0.268 | 0 | 0 |
| Processing of SMDT1 | R-HSA-8949664 | 0.609776 | 0.215 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 0.237072 | 0.625 | 1 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 0.528254 | 0.277 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 0.528481 | 0.277 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 0.479775 | 0.319 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 0.485915 | 0.313 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 0.183188 | 0.737 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 0.335455 | 0.474 | 0 | 0 |
| PTK6 Regulates Proteins Involved in RNA Processing | R-HSA-8849468 | 0.208423 | 0.681 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 0.113321 | 0.946 | 0 | 0 |
| Regulation of NFE2L2 gene expression | R-HSA-9818749 | 0.297265 | 0.527 | 0 | 0 |
| ERK/MAPK targets | R-HSA-198753 | 0.210152 | 0.677 | 0 | 0 |
| ROBO receptors bind AKAP5 | R-HSA-9010642 | 0.384529 | 0.415 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 0.331768 | 0.479 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 0.150262 | 0.823 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 0.570904 | 0.243 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 0.595336 | 0.225 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 0.616798 | 0.210 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 0.124999 | 0.903 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 0.252949 | 0.597 | 1 | 0 |
| MAP kinase activation | R-HSA-450294 | 0.457066 | 0.340 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 0.460642 | 0.337 | 0 | 0 |
| Regulation of FOXO transcriptional activity by acetylation | R-HSA-9617629 | 0.306411 | 0.514 | 0 | 0 |
| Diseases of DNA Double-Strand Break Repair | R-HSA-9675136 | 0.377875 | 0.423 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 0.558917 | 0.253 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 0.583095 | 0.234 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 0.502653 | 0.299 | 0 | 0 |
| HDMs demethylate histones | R-HSA-3214842 | 0.517201 | 0.286 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 0.498735 | 0.302 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 0.620390 | 0.207 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 0.372548 | 0.429 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 0.105802 | 0.976 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 0.375524 | 0.425 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 0.263391 | 0.579 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 0.601865 | 0.221 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 0.092391 | 1.034 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to p16INK4A Defects | R-HSA-9632693 | 0.304636 | 0.516 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to p16INK4A Defects | R-HSA-9630750 | 0.304636 | 0.516 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH2 | R-HSA-5632928 | 0.304636 | 0.516 | 0 | 0 |
| CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde | R-HSA-442729 | 0.150277 | 0.823 | 1 | 1 |
| Zinc influx into cells by the SLC39 gene family | R-HSA-442380 | 0.179437 | 0.746 | 0 | 0 |
| Release of apoptotic factors from the mitochondria | R-HSA-111457 | 0.252749 | 0.597 | 0 | 0 |
| Interleukin-33 signaling | R-HSA-9014843 | 0.383959 | 0.416 | 0 | 0 |
| Localization of the PINCH-ILK-PARVIN complex to focal adhesions | R-HSA-446343 | 0.383959 | 0.416 | 0 | 0 |
| Neurophilin interactions with VEGF and VEGFR | R-HSA-194306 | 0.383959 | 0.416 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to lipogenesis | R-HSA-9029558 | 0.153514 | 0.814 | 0 | 0 |
| Signaling by AXIN mutants | R-HSA-4839735 | 0.273760 | 0.563 | 0 | 0 |
| MET interacts with TNS proteins | R-HSA-8875513 | 0.454237 | 0.343 | 0 | 0 |
| Activation of BIM and translocation to mitochondria | R-HSA-111446 | 0.454237 | 0.343 | 0 | 0 |
| Negative regulation of activity of TFAP2 (AP-2) family transcription factors | R-HSA-8866904 | 0.384529 | 0.415 | 0 | 0 |
| Phase 0 - rapid depolarisation | R-HSA-5576892 | 0.233302 | 0.632 | 1 | 1 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | R-HSA-9659787 | 0.339195 | 0.470 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 0.113739 | 0.944 | 0 | 0 |
| Signaling by FLT3 ITD and TKD mutants | R-HSA-9703648 | 0.299791 | 0.523 | 0 | 0 |
| Drug-mediated inhibition of CDK4/CDK6 activity | R-HSA-9754119 | 0.516502 | 0.287 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 0.273752 | 0.563 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 0.101105 | 0.995 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 0.170859 | 0.767 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 0.315160 | 0.501 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 0.294962 | 0.530 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | R-HSA-9701190 | 0.377875 | 0.423 | 0 | 0 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | R-HSA-141430 | 0.467260 | 0.330 | 0 | 0 |
| Bicarbonate transporters | R-HSA-425381 | 0.505399 | 0.296 | 0 | 0 |
| FGFRL1 modulation of FGFR1 signaling | R-HSA-5658623 | 0.505399 | 0.296 | 0 | 0 |
| Reelin signalling pathway | R-HSA-8866376 | 0.571666 | 0.243 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 0.441506 | 0.355 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 0.457066 | 0.340 | 0 | 0 |
| Serotonin Neurotransmitter Release Cycle | R-HSA-181429 | 0.527144 | 0.278 | 0 | 0 |
| PKA activation in glucagon signalling | R-HSA-164378 | 0.527144 | 0.278 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 0.437912 | 0.359 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 0.473131 | 0.325 | 0 | 0 |
| Phosphorylation of Emi1 | R-HSA-176417 | 0.620539 | 0.207 | 0 | 0 |
| Loss of Function of SMAD2/3 in Cancer | R-HSA-3304349 | 0.620539 | 0.207 | 0 | 0 |
| Synthesis of PS | R-HSA-1483101 | 0.620539 | 0.207 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 0.513559 | 0.289 | 0 | 0 |
| Platelet Adhesion to exposed collagen | R-HSA-75892 | 0.609776 | 0.215 | 0 | 0 |
| Membrane binding and targetting of GAG proteins | R-HSA-174490 | 0.609776 | 0.215 | 0 | 0 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | R-HSA-917729 | 0.611904 | 0.213 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 0.615390 | 0.211 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 0.375175 | 0.426 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 0.225428 | 0.647 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 0.445102 | 0.352 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 0.089056 | 1.050 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 0.604892 | 0.218 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 0.291593 | 0.535 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 0.216142 | 0.665 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 0.268522 | 0.571 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 0.441087 | 0.355 | 0 | 0 |
| Signaling by FGFR3 in disease | R-HSA-5655332 | 0.370410 | 0.431 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 0.466485 | 0.331 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 0.437488 | 0.359 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 0.102234 | 0.990 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 0.243036 | 0.614 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 0.243036 | 0.614 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 0.264882 | 0.577 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 0.177518 | 0.751 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 0.231772 | 0.635 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 0.327536 | 0.485 | 0 | 0 |
| Regulation of NF-kappa B signaling | R-HSA-9758274 | 0.436073 | 0.360 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 0.359642 | 0.444 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 0.359642 | 0.444 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 0.315102 | 0.502 | 1 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 0.252596 | 0.598 | 0 | 0 |
| Response of EIF2AK1 (HRI) to heme deficiency | R-HSA-9648895 | 0.276696 | 0.558 | 0 | 0 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 0.131691 | 0.880 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | R-HSA-5358606 | 0.497653 | 0.303 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 0.169467 | 0.771 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 0.326289 | 0.486 | 0 | 0 |
| MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 0.417670 | 0.379 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 0.115342 | 0.938 | 0 | 0 |
| HuR (ELAVL1) binds and stabilizes mRNA | R-HSA-450520 | 0.179437 | 0.746 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex in Cancer | R-HSA-3304351 | 0.297265 | 0.527 | 0 | 0 |
| Regulation of CDH11 gene transcription | R-HSA-9762293 | 0.426429 | 0.370 | 0 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 0.335455 | 0.474 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 0.466784 | 0.331 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 0.230381 | 0.638 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 0.343852 | 0.464 | 0 | 0 |
| STAT5 activation downstream of FLT3 ITD mutants | R-HSA-9702518 | 0.467260 | 0.330 | 0 | 0 |
| TRP channels | R-HSA-3295583 | 0.541922 | 0.266 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 0.555647 | 0.255 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 0.582430 | 0.235 | 0 | 0 |
| PKA-mediated phosphorylation of CREB | R-HSA-111931 | 0.609438 | 0.215 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 0.611904 | 0.213 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 0.501954 | 0.299 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 0.121309 | 0.916 | 0 | 0 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | R-HSA-6803205 | 0.128105 | 0.892 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 0.286495 | 0.543 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 0.189231 | 0.723 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 0.454882 | 0.342 | 0 | 0 |
| Pyroptosis | R-HSA-5620971 | 0.589318 | 0.230 | 0 | 0 |
| Intrinsic Pathway of Fibrin Clot Formation | R-HSA-140837 | 0.609438 | 0.215 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 0.314440 | 0.502 | 0 | 0 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | R-HSA-446388 | 0.252749 | 0.597 | 0 | 0 |
| Signal regulatory protein family interactions | R-HSA-391160 | 0.176585 | 0.753 | 0 | 0 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | R-HSA-170822 | 0.117314 | 0.931 | 0 | 0 |
| Activation of PUMA and translocation to mitochondria | R-HSA-139915 | 0.341352 | 0.467 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 0.306411 | 0.514 | 0 | 0 |
| Mitochondrial calcium ion transport | R-HSA-8949215 | 0.231772 | 0.635 | 0 | 0 |
| Uptake and function of anthrax toxins | R-HSA-5210891 | 0.277959 | 0.556 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 0.198286 | 0.703 | 0 | 0 |
| Interleukin-1 processing | R-HSA-448706 | 0.426429 | 0.370 | 0 | 0 |
| Homologous DNA Pairing and Strand Exchange | R-HSA-5693579 | 0.462479 | 0.335 | 0 | 0 |
| Defects of platelet adhesion to exposed collagen | R-HSA-9823587 | 0.620539 | 0.207 | 0 | 0 |
| Release of Hh-Np from the secreting cell | R-HSA-5362798 | 0.620539 | 0.207 | 0 | 0 |
| Vasopressin regulates renal water homeostasis via Aquaporins | R-HSA-432040 | 0.619282 | 0.208 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 0.523967 | 0.281 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 0.253988 | 0.595 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 0.554064 | 0.256 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 0.202864 | 0.693 | 0 | 0 |
| Signaling by KIT in disease | R-HSA-9669938 | 0.439677 | 0.357 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 0.102417 | 0.990 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 0.580561 | 0.236 | 0 | 0 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | R-HSA-1362300 | 0.436073 | 0.360 | 0 | 0 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | R-HSA-9619665 | 0.356623 | 0.448 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 0.412982 | 0.384 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 0.483245 | 0.316 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 0.527144 | 0.278 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 0.209962 | 0.678 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 0.347778 | 0.459 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 0.579617 | 0.237 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 0.185314 | 0.732 | 1 | 0 |
| Ion transport by P-type ATPases | R-HSA-936837 | 0.375524 | 0.425 | 1 | 1 |
| Cellular responses to stimuli | R-HSA-8953897 | 0.259307 | 0.586 | 1 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 0.297309 | 0.527 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 0.214107 | 0.669 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 0.582430 | 0.235 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 0.108700 | 0.964 | 0 | 0 |
| Breakdown of the nuclear lamina | R-HSA-352238 | 0.304636 | 0.516 | 0 | 0 |
| Diseases of cellular response to stress | R-HSA-9675132 | 0.383959 | 0.416 | 0 | 0 |
| Diseases of Cellular Senescence | R-HSA-9630747 | 0.383959 | 0.416 | 0 | 0 |
| Integration of viral DNA into host genomic DNA | R-HSA-175567 | 0.297265 | 0.527 | 0 | 0 |
| Synthesis of PI | R-HSA-1483226 | 0.241511 | 0.617 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 0.225793 | 0.646 | 0 | 0 |
| Diseases of Mismatch Repair (MMR) | R-HSA-5423599 | 0.454237 | 0.343 | 0 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 0.111408 | 0.953 | 0 | 0 |
| Early Phase of HIV Life Cycle | R-HSA-162594 | 0.210152 | 0.677 | 0 | 0 |
| NFE2L2 regulating tumorigenic genes | R-HSA-9818030 | 0.339195 | 0.470 | 0 | 0 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | R-HSA-442720 | 0.339195 | 0.470 | 0 | 0 |
| Cellular response to mitochondrial stress | R-HSA-9840373 | 0.426429 | 0.370 | 0 | 0 |
| NADE modulates death signalling | R-HSA-205025 | 0.516502 | 0.287 | 0 | 0 |
| Synthesis of IP3 and IP4 in the cytosol | R-HSA-1855204 | 0.335455 | 0.474 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 0.370410 | 0.431 | 0 | 0 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | R-HSA-141405 | 0.467260 | 0.330 | 0 | 0 |
| CD163 mediating an anti-inflammatory response | R-HSA-9662834 | 0.505399 | 0.296 | 0 | 0 |
| RHOBTB3 ATPase cycle | R-HSA-9706019 | 0.505399 | 0.296 | 0 | 0 |
| Interleukin-36 pathway | R-HSA-9014826 | 0.571666 | 0.243 | 0 | 0 |
| Biosynthesis of DPAn-3-derived 13-series resolvins | R-HSA-9026403 | 0.571666 | 0.243 | 0 | 0 |
| APOBEC3G mediated resistance to HIV-1 infection | R-HSA-180689 | 0.542147 | 0.266 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 0.509747 | 0.293 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 0.502653 | 0.299 | 0 | 0 |
| Signalling to p38 via RIT and RIN | R-HSA-187706 | 0.620539 | 0.207 | 0 | 0 |
| Acetylcholine Neurotransmitter Release Cycle | R-HSA-264642 | 0.609438 | 0.215 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 0.589424 | 0.230 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 0.606567 | 0.217 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 0.179437 | 0.746 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 0.113321 | 0.946 | 0 | 0 |
| Formation of Fibrin Clot (Clotting Cascade) | R-HSA-140877 | 0.420377 | 0.376 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 0.112314 | 0.950 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 0.129466 | 0.888 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 0.318139 | 0.497 | 0 | 0 |
| Presynaptic phase of homologous DNA pairing and strand exchange | R-HSA-5693616 | 0.399147 | 0.399 | 0 | 0 |
| Suppression of apoptosis | R-HSA-9635465 | 0.505399 | 0.296 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | R-HSA-6803204 | 0.565977 | 0.247 | 0 | 0 |
| Synthesis of PIPs at the Golgi membrane | R-HSA-1660514 | 0.541922 | 0.266 | 0 | 0 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | R-HSA-164938 | 0.497653 | 0.303 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 0.157826 | 0.802 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 0.216684 | 0.664 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 0.509747 | 0.293 | 0 | 0 |
| Sodium-coupled phosphate cotransporters | R-HSA-427652 | 0.252749 | 0.597 | 0 | 0 |
| tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis | R-HSA-9708296 | 0.383959 | 0.416 | 0 | 0 |
| Signaling by LTK in cancer | R-HSA-9842640 | 0.297265 | 0.527 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 0.200734 | 0.697 | 0 | 0 |
| Interleukin-18 signaling | R-HSA-9012546 | 0.384529 | 0.415 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 0.214500 | 0.669 | 0 | 0 |
| Transport of Ribonucleoproteins into the Host Nucleus | R-HSA-168271 | 0.230409 | 0.638 | 0 | 0 |
| NFE2L2 regulating MDR associated enzymes | R-HSA-9818032 | 0.426429 | 0.370 | 0 | 0 |
| AKT phosphorylates targets in the nucleus | R-HSA-198693 | 0.426429 | 0.370 | 0 | 0 |
| FLT3 signaling through SRC family kinases | R-HSA-9706374 | 0.516502 | 0.287 | 0 | 0 |
| Dopamine receptors | R-HSA-390651 | 0.516502 | 0.287 | 0 | 0 |
| Assembly and release of respiratory syncytial virus (RSV) virions | R-HSA-9820962 | 0.466784 | 0.331 | 0 | 0 |
| NrCAM interactions | R-HSA-447038 | 0.571666 | 0.243 | 0 | 0 |
| Co-inhibition by BTLA | R-HSA-9927353 | 0.571666 | 0.243 | 0 | 0 |
| NFE2L2 regulates pentose phosphate pathway genes | R-HSA-9818028 | 0.542147 | 0.266 | 0 | 0 |
| CLEC7A/inflammasome pathway | R-HSA-5660668 | 0.620539 | 0.207 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 0.308749 | 0.510 | 0 | 0 |
| Common Pathway of Fibrin Clot Formation | R-HSA-140875 | 0.583095 | 0.234 | 0 | 0 |
| Nephron development | R-HSA-9831926 | 0.304736 | 0.516 | 0 | 0 |
| Zinc transporters | R-HSA-435354 | 0.371870 | 0.430 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 0.483801 | 0.315 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 0.483245 | 0.316 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 0.615390 | 0.211 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 0.536370 | 0.271 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 0.479775 | 0.319 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 0.252749 | 0.597 | 0 | 0 |
| Formation of the canonical BAF (cBAF) complex | R-HSA-9933937 | 0.176585 | 0.753 | 0 | 0 |
| Uptake and function of diphtheria toxin | R-HSA-5336415 | 0.341352 | 0.467 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence | R-HSA-9825895 | 0.384529 | 0.415 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 0.184035 | 0.735 | 0 | 0 |
| Regulation of TP53 Activity through Association with Co-factors | R-HSA-6804759 | 0.339195 | 0.470 | 0 | 0 |
| Respiratory syncytial virus genome replication | R-HSA-9834752 | 0.426429 | 0.370 | 0 | 0 |
| Regulated proteolysis of p75NTR | R-HSA-193692 | 0.426429 | 0.370 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 0.332863 | 0.478 | 0 | 0 |
| DEx/H-box helicases activate type I IFN and inflammatory cytokines production | R-HSA-3134963 | 0.571666 | 0.243 | 0 | 0 |
| Epithelial-Mesenchymal Transition (EMT) during gastrulation | R-HSA-9758919 | 0.620539 | 0.207 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 0.589424 | 0.230 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 0.607458 | 0.216 | 0 | 0 |
| Apoptotic factor-mediated response | R-HSA-111471 | 0.527144 | 0.278 | 0 | 0 |
| Other interleukin signaling | R-HSA-449836 | 0.555647 | 0.255 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 0.367347 | 0.435 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 0.439677 | 0.357 | 0 | 0 |
| Tie2 Signaling | R-HSA-210993 | 0.527144 | 0.278 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 0.450476 | 0.346 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 0.147831 | 0.830 | 0 | 0 |
| Extrinsic Pathway of Fibrin Clot Formation | R-HSA-140834 | 0.516502 | 0.287 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 0.252596 | 0.598 | 0 | 0 |
| Nectin/Necl trans heterodimerization | R-HSA-420597 | 0.571666 | 0.243 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 0.503756 | 0.298 | 0 | 0 |
| Zygotic genome activation (ZGA) | R-HSA-9819196 | 0.609438 | 0.215 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 0.466784 | 0.331 | 0 | 0 |
| SMAC, XIAP-regulated apoptotic response | R-HSA-111469 | 0.620539 | 0.207 | 0 | 0 |
| Reversal of alkylation damage by DNA dioxygenases | R-HSA-73943 | 0.576951 | 0.239 | 0 | 0 |
| Interleukin-37 signaling | R-HSA-9008059 | 0.273143 | 0.564 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 0.279168 | 0.554 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 0.621591 | 0.206 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 0.621591 | 0.206 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 0.622472 | 0.206 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 0.626195 | 0.203 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 0.626195 | 0.203 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 0.630628 | 0.200 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 0.631437 | 0.200 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 0.631437 | 0.200 | 0 | 0 |
| NOTCH3 Intracellular Domain Regulates Transcription | R-HSA-9013508 | 0.633705 | 0.198 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 0.633705 | 0.198 | 0 | 0 |
| Activation of BH3-only proteins | R-HSA-114452 | 0.633705 | 0.198 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | R-HSA-76066 | 0.634644 | 0.197 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | R-HSA-5696397 | 0.634644 | 0.197 | 0 | 0 |
| SLC-mediated transport of inorganic anions | R-HSA-9958790 | 0.634847 | 0.197 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 0.634905 | 0.197 | 0 | 0 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | R-HSA-5684264 | 0.640621 | 0.193 | 0 | 0 |
| ERBB2 Activates PTK6 Signaling | R-HSA-8847993 | 0.640621 | 0.193 | 0 | 0 |
| Regulation of CDH1 mRNA translation by microRNAs | R-HSA-9764562 | 0.640621 | 0.193 | 0 | 0 |
| CLEC7A (Dectin-1) induces NFAT activation | R-HSA-5607763 | 0.640621 | 0.193 | 0 | 0 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | R-HSA-174495 | 0.640621 | 0.193 | 0 | 0 |
| TP53 Regulates Transcription of Death Receptors and Ligands | R-HSA-6803211 | 0.640621 | 0.193 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 0.643146 | 0.192 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 0.643146 | 0.192 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 0.648095 | 0.188 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 0.648435 | 0.188 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 0.653688 | 0.185 | 0 | 0 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | R-HSA-9725554 | 0.653688 | 0.185 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 0.655614 | 0.183 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 0.655614 | 0.183 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 0.658650 | 0.181 | 0 | 0 |
| FRS-mediated FGFR4 signaling | R-HSA-5654712 | 0.658692 | 0.181 | 0 | 0 |
| PI-3K cascade:FGFR1 | R-HSA-5654689 | 0.658692 | 0.181 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | R-HSA-76071 | 0.658692 | 0.181 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 0.658692 | 0.181 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | R-HSA-76061 | 0.658692 | 0.181 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 0.661835 | 0.179 | 0 | 0 |
| PTK6 promotes HIF1A stabilization | R-HSA-8857538 | 0.663839 | 0.178 | 0 | 0 |
| VLDL assembly | R-HSA-8866423 | 0.663839 | 0.178 | 0 | 0 |
| Chylomicron clearance | R-HSA-8964026 | 0.663839 | 0.178 | 0 | 0 |
| STAT5 Activation | R-HSA-9645135 | 0.663839 | 0.178 | 0 | 0 |
| Erythropoietin activates STAT5 | R-HSA-9027283 | 0.663839 | 0.178 | 0 | 0 |
| Branched-chain ketoacid dehydrogenase kinase deficiency | R-HSA-9912481 | 0.663839 | 0.178 | 0 | 0 |
| Defective CYP11A1 causes AICSR | R-HSA-5579026 | 0.663839 | 0.178 | 0 | 0 |
| Loss-of-function mutations in BCKDHA or BCKDHB cause MSUD | R-HSA-9865125 | 0.663839 | 0.178 | 0 | 0 |
| H139Hfs13* PPM1K causes a mild variant of MSUD | R-HSA-9912529 | 0.663839 | 0.178 | 0 | 0 |
| Toxicity of botulinum toxin type F (botF) | R-HSA-5250981 | 0.663839 | 0.178 | 0 | 0 |
| Toxicity of botulinum toxin type D (botD) | R-HSA-5250955 | 0.663839 | 0.178 | 0 | 0 |
| Agmatine biosynthesis | R-HSA-351143 | 0.663839 | 0.178 | 0 | 0 |
| Neurofascin interactions | R-HSA-447043 | 0.663839 | 0.178 | 0 | 0 |
| Nef and signal transduction | R-HSA-164944 | 0.663839 | 0.178 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 0.664826 | 0.177 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 0.667490 | 0.176 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 0.667595 | 0.175 | 0 | 0 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | R-HSA-8948700 | 0.669510 | 0.174 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 0.669510 | 0.174 | 0 | 0 |
| Processive synthesis on the lagging strand | R-HSA-69183 | 0.669510 | 0.174 | 0 | 0 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | R-HSA-450385 | 0.669510 | 0.174 | 0 | 0 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 0.669510 | 0.174 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR4 | R-HSA-5654228 | 0.669510 | 0.174 | 0 | 0 |
| ERBB2 Regulates Cell Motility | R-HSA-6785631 | 0.669510 | 0.174 | 0 | 0 |
| p38MAPK events | R-HSA-171007 | 0.669510 | 0.174 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 0.669510 | 0.174 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 0.669510 | 0.174 | 0 | 0 |
| Protein methylation | R-HSA-8876725 | 0.669510 | 0.174 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 0.669510 | 0.174 | 0 | 0 |
| DNA Damage Reversal | R-HSA-73942 | 0.669510 | 0.174 | 0 | 0 |
| Metal ion SLC transporters | R-HSA-425410 | 0.670920 | 0.173 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 0.671895 | 0.173 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 0.671895 | 0.173 | 0 | 0 |
| TP53 Regulates Transcription of Cell Death Genes | R-HSA-5633008 | 0.673476 | 0.172 | 0 | 0 |
| DNA strand elongation | R-HSA-69190 | 0.674867 | 0.171 | 0 | 0 |
| Signaling by WNT in cancer | R-HSA-4791275 | 0.674867 | 0.171 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 0.681528 | 0.167 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 0.681575 | 0.166 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 0.681575 | 0.166 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 0.681575 | 0.166 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 0.681575 | 0.166 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 0.681575 | 0.166 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 0.687101 | 0.163 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 0.687101 | 0.163 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 0.687897 | 0.162 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 0.689272 | 0.162 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 0.689459 | 0.161 | 0 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 0.689459 | 0.161 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 0.689459 | 0.161 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 0.690869 | 0.161 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 0.692628 | 0.160 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 0.694204 | 0.159 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 0.694204 | 0.159 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 0.696471 | 0.157 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 0.696489 | 0.157 | 0 | 0 |
| Killing mechanisms | R-HSA-9664420 | 0.696489 | 0.157 | 0 | 0 |
| WNT5:FZD7-mediated leishmania damping | R-HSA-9673324 | 0.696489 | 0.157 | 0 | 0 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | R-HSA-210744 | 0.696489 | 0.157 | 0 | 0 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | R-HSA-6803207 | 0.696489 | 0.157 | 0 | 0 |
| KSRP (KHSRP) binds and destabilizes mRNA | R-HSA-450604 | 0.696489 | 0.157 | 0 | 0 |
| Caspase activation via Death Receptors in the presence of ligand | R-HSA-140534 | 0.696489 | 0.157 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 0.698499 | 0.156 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 0.702182 | 0.154 | 0 | 0 |
| NOSTRIN mediated eNOS trafficking | R-HSA-203641 | 0.702199 | 0.154 | 0 | 0 |
| IFNG signaling activates MAPKs | R-HSA-9732724 | 0.702199 | 0.154 | 0 | 0 |
| Recycling of eIF2:GDP | R-HSA-72731 | 0.702199 | 0.154 | 0 | 0 |
| SLBP independent Processing of Histone Pre-mRNAs | R-HSA-111367 | 0.702199 | 0.154 | 0 | 0 |
| PP2A-mediated dephosphorylation of key metabolic factors | R-HSA-163767 | 0.702199 | 0.154 | 0 | 0 |
| LDL remodeling | R-HSA-8964041 | 0.702199 | 0.154 | 0 | 0 |
| PTK6 Expression | R-HSA-8849473 | 0.702199 | 0.154 | 0 | 0 |
| RUNX3 regulates WNT signaling | R-HSA-8951430 | 0.702199 | 0.154 | 0 | 0 |
| Electron transport from NADPH to Ferredoxin | R-HSA-2395516 | 0.702199 | 0.154 | 0 | 0 |
| Microbial modulation of RIPK1-mediated regulated necrosis | R-HSA-9686347 | 0.702199 | 0.154 | 0 | 0 |
| Cation-coupled Chloride cotransporters | R-HSA-426117 | 0.702199 | 0.154 | 0 | 0 |
| Binding of TCF/LEF:CTNNB1 to target gene promoters | R-HSA-4411364 | 0.702199 | 0.154 | 0 | 0 |
| Glycoprotein hormones | R-HSA-209822 | 0.702199 | 0.154 | 0 | 0 |
| Phase 3 - rapid repolarisation | R-HSA-5576890 | 0.702199 | 0.154 | 0 | 0 |
| Nef Mediated CD4 Down-regulation | R-HSA-167590 | 0.702199 | 0.154 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation | R-HSA-2892245 | 0.702199 | 0.154 | 0 | 0 |
| Displacement of DNA glycosylase by APEX1 | R-HSA-110357 | 0.702199 | 0.154 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 0.703005 | 0.153 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 0.703295 | 0.153 | 0 | 0 |
| Complex III assembly | R-HSA-9865881 | 0.703295 | 0.153 | 0 | 0 |
| Norepinephrine Neurotransmitter Release Cycle | R-HSA-181430 | 0.703295 | 0.153 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 0.703495 | 0.153 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 0.713304 | 0.147 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 0.716021 | 0.145 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 0.717835 | 0.144 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 0.719305 | 0.143 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 0.719305 | 0.143 | 0 | 0 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 0.721616 | 0.142 | 0 | 0 |
| Passive transport by Aquaporins | R-HSA-432047 | 0.721616 | 0.142 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 0.722628 | 0.141 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 0.723858 | 0.140 | 0 | 0 |
| PI-3K cascade:FGFR2 | R-HSA-5654695 | 0.723864 | 0.140 | 0 | 0 |
| Acyl chain remodelling of PS | R-HSA-1482801 | 0.723864 | 0.140 | 0 | 0 |
| MicroRNA (miRNA) biogenesis | R-HSA-203927 | 0.723864 | 0.140 | 0 | 0 |
| Glycogen breakdown (glycogenolysis) | R-HSA-70221 | 0.723864 | 0.140 | 0 | 0 |
| Synthesis of PIPs at the early endosome membrane | R-HSA-1660516 | 0.723864 | 0.140 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 0.725810 | 0.139 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 0.726263 | 0.139 | 0 | 0 |
| Dual Incision in GG-NER | R-HSA-5696400 | 0.730371 | 0.136 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 0.730371 | 0.136 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 0.730371 | 0.136 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 0.731674 | 0.136 | 1 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 0.732434 | 0.135 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 0.734565 | 0.134 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 0.734814 | 0.134 | 0 | 0 |
| phospho-PLA2 pathway | R-HSA-111995 | 0.736184 | 0.133 | 0 | 0 |
| SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | R-HSA-77588 | 0.736184 | 0.133 | 0 | 0 |
| Myoclonic epilepsy of Lafora | R-HSA-3785653 | 0.736184 | 0.133 | 0 | 0 |
| MET receptor recycling | R-HSA-8875656 | 0.736184 | 0.133 | 0 | 0 |
| Axonal growth inhibition (RHOA activation) | R-HSA-193634 | 0.736184 | 0.133 | 0 | 0 |
| Activation of RAS in B cells | R-HSA-1169092 | 0.736184 | 0.133 | 0 | 0 |
| BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members | R-HSA-111453 | 0.736184 | 0.133 | 0 | 0 |
| Downregulation of ERBB4 signaling | R-HSA-1253288 | 0.736184 | 0.133 | 0 | 0 |
| Formyl peptide receptors bind formyl peptides and many other ligands | R-HSA-444473 | 0.736184 | 0.133 | 0 | 0 |
| Activated NTRK2 signals through FYN | R-HSA-9032500 | 0.736184 | 0.133 | 0 | 0 |
| PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | R-HSA-8849469 | 0.736184 | 0.133 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 0.736780 | 0.133 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 0.736780 | 0.133 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 0.736780 | 0.133 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 0.738335 | 0.132 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 0.738821 | 0.131 | 0 | 0 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | R-HSA-110373 | 0.743302 | 0.129 | 0 | 0 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 0.743302 | 0.129 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 0.743302 | 0.129 | 0 | 0 |
| Glutamate Neurotransmitter Release Cycle | R-HSA-210500 | 0.743302 | 0.129 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 0.744564 | 0.128 | 0 | 0 |
| Elevation of cytosolic Ca2+ levels | R-HSA-139853 | 0.744962 | 0.128 | 0 | 0 |
| Regulation of NPAS4 gene expression | R-HSA-9768759 | 0.744962 | 0.128 | 0 | 0 |
| Specification of primordial germ cells | R-HSA-9827857 | 0.744962 | 0.128 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 0.746465 | 0.127 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 0.746465 | 0.127 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 0.747210 | 0.127 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 0.750976 | 0.124 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 0.751672 | 0.124 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 0.753178 | 0.123 | 0 | 0 |
| RMTs methylate histone arginines | R-HSA-3214858 | 0.753178 | 0.123 | 0 | 0 |
| Amine ligand-binding receptors | R-HSA-375280 | 0.753178 | 0.123 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 0.759956 | 0.119 | 0 | 0 |
| Processive synthesis on the C-strand of the telomere | R-HSA-174414 | 0.761633 | 0.118 | 0 | 0 |
| RNA Polymerase I Transcription Termination | R-HSA-73863 | 0.761633 | 0.118 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 0.761633 | 0.118 | 0 | 0 |
| Insulin processing | R-HSA-264876 | 0.761633 | 0.118 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 0.762729 | 0.118 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 0.763232 | 0.117 | 0 | 0 |
| Lysosome Vesicle Biogenesis | R-HSA-432720 | 0.763232 | 0.117 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 0.765769 | 0.116 | 1 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 0.765936 | 0.116 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 0.765936 | 0.116 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 0.765936 | 0.116 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex | R-HSA-937042 | 0.766293 | 0.116 | 0 | 0 |
| WNT mediated activation of DVL | R-HSA-201688 | 0.766293 | 0.116 | 0 | 0 |
| MASTL Facilitates Mitotic Progression | R-HSA-2465910 | 0.766293 | 0.116 | 0 | 0 |
| Toxicity of botulinum toxin type A (botA) | R-HSA-5250968 | 0.766293 | 0.116 | 0 | 0 |
| APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway | R-HSA-5649702 | 0.766293 | 0.116 | 0 | 0 |
| Activation of the TFAP2 (AP-2) family of transcription factors | R-HSA-8866907 | 0.766293 | 0.116 | 0 | 0 |
| Regulation of commissural axon pathfinding by SLIT and ROBO | R-HSA-428542 | 0.766293 | 0.116 | 0 | 0 |
| p75NTR regulates axonogenesis | R-HSA-193697 | 0.766293 | 0.116 | 0 | 0 |
| PCNA-Dependent Long Patch Base Excision Repair | R-HSA-5651801 | 0.766608 | 0.115 | 0 | 0 |
| Regulation of TP53 Activity through Methylation | R-HSA-6804760 | 0.766608 | 0.115 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 0.767480 | 0.115 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 0.767480 | 0.115 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 0.767870 | 0.115 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 0.772010 | 0.112 | 1 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 0.772787 | 0.112 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 0.772911 | 0.112 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 0.778886 | 0.109 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 0.778886 | 0.109 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 0.779288 | 0.108 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 0.779288 | 0.108 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 0.782644 | 0.106 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 0.783214 | 0.106 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 0.785030 | 0.105 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 0.785336 | 0.105 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 0.785336 | 0.105 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 0.785336 | 0.105 | 0 | 0 |
| Pre-NOTCH Processing in Golgi | R-HSA-1912420 | 0.786637 | 0.104 | 0 | 0 |
| Specification of the neural plate border | R-HSA-9834899 | 0.786637 | 0.104 | 0 | 0 |
| Signaling by FGFR2 IIIa TM | R-HSA-8851708 | 0.786637 | 0.104 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 0.786637 | 0.104 | 0 | 0 |
| E2F mediated regulation of DNA replication | R-HSA-113510 | 0.786637 | 0.104 | 0 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 0.786637 | 0.104 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 0.787985 | 0.103 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 0.792886 | 0.101 | 0 | 0 |
| Apoptosis induced DNA fragmentation | R-HSA-140342 | 0.792967 | 0.101 | 0 | 0 |
| Defective RIPK1-mediated regulated necrosis | R-HSA-9693928 | 0.792967 | 0.101 | 0 | 0 |
| Cross-presentation of particulate exogenous antigens (phagosomes) | R-HSA-1236973 | 0.792967 | 0.101 | 0 | 0 |
| Defective factor IX causes hemophilia B | R-HSA-9668250 | 0.792967 | 0.101 | 0 | 0 |
| Peptide hormone biosynthesis | R-HSA-209952 | 0.792967 | 0.101 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 0.794426 | 0.100 | 0 | 0 |
| mRNA Capping | R-HSA-72086 | 0.795098 | 0.100 | 0 | 0 |
| Termination of translesion DNA synthesis | R-HSA-5656169 | 0.795098 | 0.100 | 0 | 0 |
| Platelet calcium homeostasis | R-HSA-418360 | 0.795098 | 0.100 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 0.798777 | 0.098 | 0 | 0 |
| Regulation of PD-L1(CD274) translation | R-HSA-9909620 | 0.805136 | 0.094 | 0 | 0 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 0.805136 | 0.094 | 0 | 0 |
| BBSome-mediated cargo-targeting to cilium | R-HSA-5620922 | 0.805136 | 0.094 | 0 | 0 |
| Glycogen synthesis | R-HSA-3322077 | 0.805136 | 0.094 | 0 | 0 |
| Mitochondrial iron-sulfur cluster biogenesis | R-HSA-1362409 | 0.805136 | 0.094 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 0.805747 | 0.094 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 0.806595 | 0.093 | 0 | 0 |
| NGF-stimulated transcription | R-HSA-9031628 | 0.806595 | 0.093 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 0.808622 | 0.092 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 0.809962 | 0.092 | 0 | 0 |
| Activation of the pre-replicative complex | R-HSA-68962 | 0.810304 | 0.091 | 0 | 0 |
| Energy dependent regulation of mTOR by LKB1-AMPK | R-HSA-380972 | 0.810304 | 0.091 | 0 | 0 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | R-HSA-1474151 | 0.810304 | 0.091 | 0 | 0 |
| GABA synthesis, release, reuptake and degradation | R-HSA-888590 | 0.810304 | 0.091 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 0.811969 | 0.090 | 0 | 0 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | R-HSA-933543 | 0.816598 | 0.088 | 0 | 0 |
| Chylomicron assembly | R-HSA-8963888 | 0.816598 | 0.088 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 0.816598 | 0.088 | 0 | 0 |
| Alpha-protein kinase 1 signaling pathway | R-HSA-9645460 | 0.816598 | 0.088 | 0 | 0 |
| vRNP Assembly | R-HSA-192905 | 0.816598 | 0.088 | 0 | 0 |
| vRNA Synthesis | R-HSA-192814 | 0.816598 | 0.088 | 0 | 0 |
| Activated NTRK3 signals through RAS | R-HSA-9034864 | 0.816598 | 0.088 | 0 | 0 |
| Synthesis of PIPs at the ER membrane | R-HSA-1483248 | 0.816598 | 0.088 | 0 | 0 |
| Biosynthesis of DPAn-3-derived maresins | R-HSA-9026290 | 0.816598 | 0.088 | 0 | 0 |
| Transport of RCbl within the body | R-HSA-9758890 | 0.816598 | 0.088 | 0 | 0 |
| Interleukin-2 signaling | R-HSA-9020558 | 0.816598 | 0.088 | 0 | 0 |
| Dissolution of Fibrin Clot | R-HSA-75205 | 0.816598 | 0.088 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 0.818410 | 0.087 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 0.819479 | 0.086 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 0.819479 | 0.086 | 0 | 0 |
| Formation of Incision Complex in GG-NER | R-HSA-5696395 | 0.819479 | 0.086 | 0 | 0 |
| Glycogen metabolism | R-HSA-8982491 | 0.819479 | 0.086 | 0 | 0 |
| Lagging Strand Synthesis | R-HSA-69186 | 0.822193 | 0.085 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in apoptosis | R-HSA-9824594 | 0.822193 | 0.085 | 0 | 0 |
| Basigin interactions | R-HSA-210991 | 0.822193 | 0.085 | 0 | 0 |
| PD-L1(CD274) glycosylation and translocation to plasma membrane | R-HSA-9931295 | 0.822193 | 0.085 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 0.824545 | 0.084 | 0 | 0 |
| Respiratory syncytial virus (RSV) attachment and entry | R-HSA-9820960 | 0.824545 | 0.084 | 0 | 0 |
| Cargo concentration in the ER | R-HSA-5694530 | 0.824545 | 0.084 | 0 | 0 |
| Budding and maturation of HIV virion | R-HSA-162588 | 0.824545 | 0.084 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 0.829885 | 0.081 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 0.829885 | 0.081 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 0.829885 | 0.081 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 0.829885 | 0.081 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 0.829885 | 0.081 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 0.829997 | 0.081 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 0.831491 | 0.080 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 0.831491 | 0.080 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 0.831491 | 0.080 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 0.836880 | 0.077 | 0 | 0 |
| Scavenging by Class H Receptors | R-HSA-3000497 | 0.837533 | 0.077 | 0 | 0 |
| PI3K events in ERBB4 signaling | R-HSA-1250342 | 0.837533 | 0.077 | 0 | 0 |
| ERKs are inactivated | R-HSA-202670 | 0.837533 | 0.077 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis | R-HSA-9623433 | 0.837533 | 0.077 | 0 | 0 |
| Reduction of cytosolic Ca++ levels | R-HSA-418359 | 0.837533 | 0.077 | 0 | 0 |
| Activated NTRK2 signals through RAS | R-HSA-9026519 | 0.837533 | 0.077 | 0 | 0 |
| Sodium/Calcium exchangers | R-HSA-425561 | 0.837533 | 0.077 | 0 | 0 |
| SHC-mediated cascade:FGFR4 | R-HSA-5654719 | 0.837897 | 0.077 | 0 | 0 |
| FRS-mediated FGFR3 signaling | R-HSA-5654706 | 0.837897 | 0.077 | 0 | 0 |
| Assembly Of The HIV Virion | R-HSA-175474 | 0.837897 | 0.077 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 0.839324 | 0.076 | 0 | 0 |
| Aquaporin-mediated transport | R-HSA-445717 | 0.839786 | 0.076 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 0.840158 | 0.076 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 0.840727 | 0.075 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 0.840727 | 0.075 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 0.840727 | 0.075 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 0.843191 | 0.074 | 0 | 0 |
| HIV Transcription Initiation | R-HSA-167161 | 0.843191 | 0.074 | 0 | 0 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 0.843191 | 0.074 | 0 | 0 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | R-HSA-9615017 | 0.843191 | 0.074 | 0 | 0 |
| Intra-Golgi traffic | R-HSA-6811438 | 0.843191 | 0.074 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 0.843668 | 0.074 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 0.844174 | 0.074 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 0.845022 | 0.073 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 0.847264 | 0.072 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 0.848169 | 0.072 | 1 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 0.849215 | 0.071 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 0.849215 | 0.071 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 0.850009 | 0.071 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 0.850295 | 0.070 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 0.852120 | 0.069 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 0.852120 | 0.069 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 0.852120 | 0.069 | 0 | 0 |
| Regulation of IFNA/IFNB signaling | R-HSA-912694 | 0.852333 | 0.069 | 0 | 0 |
| LDL clearance | R-HSA-8964038 | 0.852333 | 0.069 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 0.852333 | 0.069 | 0 | 0 |
| Cytosolic tRNA aminoacylation | R-HSA-379716 | 0.854029 | 0.069 | 0 | 0 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | R-HSA-381676 | 0.854029 | 0.069 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 0.855213 | 0.068 | 0 | 0 |
| Signaling by NOTCH1 HD Domain Mutants in Cancer | R-HSA-2691230 | 0.856079 | 0.067 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD Domain Mutants | R-HSA-2691232 | 0.856079 | 0.067 | 0 | 0 |
| IRAK1 recruits IKK complex | R-HSA-937039 | 0.856079 | 0.067 | 0 | 0 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | R-HSA-975144 | 0.856079 | 0.067 | 0 | 0 |
| Maple Syrup Urine Disease | R-HSA-9865114 | 0.856079 | 0.067 | 0 | 0 |
| Phosphorylation and nuclear translocation of the CRY:PER:kinase complex | R-HSA-9931530 | 0.856079 | 0.067 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 0.856079 | 0.067 | 0 | 0 |
| Serotonin clearance from the synaptic cleft | R-HSA-380615 | 0.856079 | 0.067 | 0 | 0 |
| Biosynthesis of DPAn-3-derived protectins and resolvins | R-HSA-9026286 | 0.856079 | 0.067 | 0 | 0 |
| MET activates RAS signaling | R-HSA-8851805 | 0.856079 | 0.067 | 0 | 0 |
| Advanced glycosylation endproduct receptor signaling | R-HSA-879415 | 0.856079 | 0.067 | 0 | 0 |
| Polymerase switching | R-HSA-69091 | 0.856079 | 0.067 | 0 | 0 |
| Leading Strand Synthesis | R-HSA-69109 | 0.856079 | 0.067 | 0 | 0 |
| Regulation of IFNG signaling | R-HSA-877312 | 0.856079 | 0.067 | 0 | 0 |
| Estrogen biosynthesis | R-HSA-193144 | 0.856079 | 0.067 | 0 | 0 |
| Interleukin-15 signaling | R-HSA-8983432 | 0.856079 | 0.067 | 0 | 0 |
| OAS antiviral response | R-HSA-8983711 | 0.856079 | 0.067 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 0.858805 | 0.066 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 0.859805 | 0.066 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 0.859959 | 0.066 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 0.859959 | 0.066 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 0.861889 | 0.065 | 0 | 0 |
| Effects of PIP2 hydrolysis | R-HSA-114508 | 0.861889 | 0.065 | 0 | 0 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | R-HSA-9818027 | 0.861889 | 0.065 | 0 | 0 |
| Glucagon signaling in metabolic regulation | R-HSA-163359 | 0.861889 | 0.065 | 0 | 0 |
| Miscellaneous transport and binding events | R-HSA-5223345 | 0.861889 | 0.065 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 0.862298 | 0.064 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 0.863714 | 0.064 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 0.863714 | 0.064 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 0.863714 | 0.064 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 0.864224 | 0.063 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | R-HSA-167160 | 0.865587 | 0.063 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE | R-HSA-77075 | 0.865587 | 0.063 | 0 | 0 |
| G beta:gamma signalling through PI3Kgamma | R-HSA-392451 | 0.865587 | 0.063 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 0.866021 | 0.062 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 0.869006 | 0.061 | 0 | 0 |
| FGFR4 ligand binding and activation | R-HSA-190322 | 0.872509 | 0.059 | 0 | 0 |
| Chylomicron remodeling | R-HSA-8963901 | 0.872509 | 0.059 | 0 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 0.872509 | 0.059 | 0 | 0 |
| Formation of axial mesoderm | R-HSA-9796292 | 0.872509 | 0.059 | 0 | 0 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | R-HSA-75035 | 0.872509 | 0.059 | 0 | 0 |
| rRNA modification in the mitochondrion | R-HSA-6793080 | 0.872509 | 0.059 | 0 | 0 |
| IL-6-type cytokine receptor ligand interactions | R-HSA-6788467 | 0.872509 | 0.059 | 0 | 0 |
| eNOS activation | R-HSA-203615 | 0.872686 | 0.059 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 0.872686 | 0.059 | 0 | 0 |
| Regulation of TLR by endogenous ligand | R-HSA-5686938 | 0.872686 | 0.059 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 0.872905 | 0.059 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 0.873683 | 0.059 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 0.875634 | 0.058 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 0.877554 | 0.057 | 0 | 0 |
| Translocation of ZAP-70 to Immunological synapse | R-HSA-202430 | 0.877741 | 0.057 | 0 | 0 |
| Formation of tubulin folding intermediates by CCT/TriC | R-HSA-389960 | 0.877741 | 0.057 | 0 | 0 |
| TNFs bind their physiological receptors | R-HSA-5669034 | 0.877741 | 0.057 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 0.879177 | 0.056 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 0.879177 | 0.056 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 0.880978 | 0.055 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 0.882487 | 0.054 | 0 | 0 |
| PERK regulates gene expression | R-HSA-381042 | 0.882730 | 0.054 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 0.882791 | 0.054 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 0.882791 | 0.054 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 0.882791 | 0.054 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 0.883504 | 0.054 | 0 | 0 |
| Removal of the Flap Intermediate | R-HSA-69166 | 0.887064 | 0.052 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR3 | R-HSA-5654227 | 0.887064 | 0.052 | 0 | 0 |
| BCKDH synthesizes BCAA-CoA from KIC, KMVA, KIV | R-HSA-9859138 | 0.887064 | 0.052 | 0 | 0 |
| NRIF signals cell death from the nucleus | R-HSA-205043 | 0.887064 | 0.052 | 0 | 0 |
| Hydrolysis of LPC | R-HSA-1483115 | 0.887064 | 0.052 | 0 | 0 |
| Biosynthesis of E-series 18(R)-resolvins | R-HSA-9023661 | 0.887064 | 0.052 | 0 | 0 |
| cGMP effects | R-HSA-418457 | 0.887064 | 0.052 | 0 | 0 |
| Physiological factors | R-HSA-5578768 | 0.887064 | 0.052 | 0 | 0 |
| Respiratory syncytial virus genome transcription | R-HSA-9828642 | 0.887064 | 0.052 | 0 | 0 |
| Acyl chain remodeling of CL | R-HSA-1482798 | 0.887064 | 0.052 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 0.888201 | 0.051 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 0.888697 | 0.051 | 0 | 0 |
| FRS-mediated FGFR1 signaling | R-HSA-5654693 | 0.888873 | 0.051 | 0 | 0 |
| PIWI-interacting RNA (piRNA) biogenesis | R-HSA-5601884 | 0.888873 | 0.051 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 0.890340 | 0.050 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 0.890792 | 0.050 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 0.891146 | 0.050 | 1 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 0.891217 | 0.050 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 0.891217 | 0.050 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 0.891217 | 0.050 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 0.891217 | 0.050 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 0.893701 | 0.049 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 0.894516 | 0.048 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 0.895598 | 0.048 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 0.895598 | 0.048 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 0.896657 | 0.047 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 0.896657 | 0.047 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 0.897554 | 0.047 | 0 | 0 |
| Activated NOTCH1 Transmits Signal to the Nucleus | R-HSA-2122948 | 0.899057 | 0.046 | 0 | 0 |
| Myogenesis | R-HSA-525793 | 0.899057 | 0.046 | 0 | 0 |
| Sphingolipid catabolism | R-HSA-9845614 | 0.899057 | 0.046 | 0 | 0 |
| Caspase activation via extrinsic apoptotic signalling pathway | R-HSA-5357769 | 0.899057 | 0.046 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 0.899107 | 0.046 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 0.899107 | 0.046 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 0.899107 | 0.046 | 0 | 0 |
| Retrograde transport at the Trans-Golgi-Network | R-HSA-6811440 | 0.899107 | 0.046 | 0 | 0 |
| Activation of BAD and translocation to mitochondria | R-HSA-111447 | 0.899959 | 0.046 | 0 | 0 |
| RNA Polymerase III Chain Elongation | R-HSA-73780 | 0.899959 | 0.046 | 0 | 0 |
| Translesion synthesis by REV1 | R-HSA-110312 | 0.899959 | 0.046 | 0 | 0 |
| SARS-CoV-2 targets host intracellular signalling and regulatory pathways | R-HSA-9755779 | 0.899959 | 0.046 | 0 | 0 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | R-HSA-450513 | 0.899959 | 0.046 | 0 | 0 |
| Protein lipoylation | R-HSA-9857492 | 0.899959 | 0.046 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 0.900396 | 0.046 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 0.904431 | 0.044 | 0 | 0 |
| Amino acid transport across the plasma membrane | R-HSA-352230 | 0.907141 | 0.042 | 0 | 0 |
| Phosphorylation of CD3 and TCR zeta chains | R-HSA-202427 | 0.908365 | 0.042 | 0 | 0 |
| Cristae formation | R-HSA-8949613 | 0.908365 | 0.042 | 0 | 0 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | R-HSA-8866652 | 0.908365 | 0.042 | 0 | 0 |
| Metabolism of nitric oxide: NOS3 activation and regulation | R-HSA-202131 | 0.908746 | 0.042 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 0.909338 | 0.041 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 0.909466 | 0.041 | 0 | 0 |
| Translesion synthesis by POLI | R-HSA-5656121 | 0.911381 | 0.040 | 0 | 0 |
| Class I peroxisomal membrane protein import | R-HSA-9603798 | 0.911381 | 0.040 | 0 | 0 |
| Phase 4 - resting membrane potential | R-HSA-5576886 | 0.911381 | 0.040 | 0 | 0 |
| Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion | R-HSA-434316 | 0.911381 | 0.040 | 0 | 0 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | R-HSA-9634600 | 0.911381 | 0.040 | 0 | 0 |
| Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells) | R-HSA-9942503 | 0.911381 | 0.040 | 0 | 0 |
| Differentiation of T cells | R-HSA-9945266 | 0.911381 | 0.040 | 0 | 0 |
| Synthesis of wybutosine at G37 of tRNA(Phe) | R-HSA-6782861 | 0.911381 | 0.040 | 0 | 0 |
| Activation of SMO | R-HSA-5635838 | 0.911381 | 0.040 | 0 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 0.911381 | 0.040 | 0 | 0 |
| Atorvastatin ADME | R-HSA-9754706 | 0.911381 | 0.040 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 0.913386 | 0.039 | 0 | 0 |
| Kinesins | R-HSA-983189 | 0.913483 | 0.039 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 0.915157 | 0.039 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 0.916180 | 0.038 | 0 | 0 |
| GSK3B-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929356 | 0.916180 | 0.038 | 0 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 0.916180 | 0.038 | 0 | 0 |
| FRS-mediated FGFR2 signaling | R-HSA-5654700 | 0.916864 | 0.038 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 0.916864 | 0.038 | 0 | 0 |
| ATF4 activates genes in response to endoplasmic reticulum stress | R-HSA-380994 | 0.916864 | 0.038 | 0 | 0 |
| G beta:gamma signalling through CDC42 | R-HSA-8964616 | 0.921501 | 0.036 | 0 | 0 |
| Translesion synthesis by POLK | R-HSA-5655862 | 0.921501 | 0.036 | 0 | 0 |
| Antigen processing: Ub, ATP-independent proteasomal degradation | R-HSA-9912633 | 0.921501 | 0.036 | 0 | 0 |
| Scavenging by Class B Receptors | R-HSA-3000471 | 0.921501 | 0.036 | 0 | 0 |
| TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling | R-HSA-975110 | 0.921501 | 0.036 | 0 | 0 |
| TRAF3-dependent IRF activation pathway | R-HSA-918233 | 0.921501 | 0.036 | 0 | 0 |
| Phase 2 - plateau phase | R-HSA-5576893 | 0.921501 | 0.036 | 0 | 0 |
| SHC1 events in ERBB4 signaling | R-HSA-1250347 | 0.921501 | 0.036 | 0 | 0 |
| Regulation of innate immune responses to cytosolic DNA | R-HSA-3134975 | 0.921501 | 0.036 | 0 | 0 |
| Galactose catabolism | R-HSA-70370 | 0.921501 | 0.036 | 0 | 0 |
| Coenzyme A biosynthesis | R-HSA-196783 | 0.921501 | 0.036 | 0 | 0 |
| Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) | R-HSA-9651496 | 0.921501 | 0.036 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 0.921861 | 0.035 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 0.923057 | 0.035 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 0.923057 | 0.035 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 0.923057 | 0.035 | 0 | 0 |
| Nitric oxide stimulates guanylate cyclase | R-HSA-392154 | 0.924618 | 0.034 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 0.925034 | 0.034 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 0.925034 | 0.034 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 0.925834 | 0.033 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 0.926691 | 0.033 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 0.928349 | 0.032 | 1 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 0.928540 | 0.032 | 0 | 0 |
| Maturation of spike protein | R-HSA-9694548 | 0.929414 | 0.032 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 0.929836 | 0.032 | 0 | 0 |
| Removal of the Flap Intermediate from the C-strand | R-HSA-174437 | 0.930465 | 0.031 | 0 | 0 |
| Phospholipase C-mediated cascade: FGFR1 | R-HSA-5654219 | 0.930465 | 0.031 | 0 | 0 |
| Glycogen storage diseases | R-HSA-3229121 | 0.930465 | 0.031 | 0 | 0 |
| Biosynthesis of aspirin-triggered D-series resolvins | R-HSA-9020265 | 0.930465 | 0.031 | 0 | 0 |
| Choline catabolism | R-HSA-6798163 | 0.930465 | 0.031 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 0.930704 | 0.031 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 0.931433 | 0.031 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 0.931433 | 0.031 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 0.933144 | 0.030 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 0.935195 | 0.029 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 0.935285 | 0.029 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 0.935285 | 0.029 | 0 | 0 |
| Telomere C-strand (Lagging Strand) Synthesis | R-HSA-174417 | 0.935285 | 0.029 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 0.936354 | 0.029 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 0.937600 | 0.028 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 0.937818 | 0.028 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 0.937818 | 0.028 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 0.938123 | 0.028 | 0 | 0 |
| Molecules associated with elastic fibres | R-HSA-2129379 | 0.938123 | 0.028 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 0.938123 | 0.028 | 0 | 0 |
| G beta:gamma signalling through PLC beta | R-HSA-418217 | 0.938406 | 0.028 | 0 | 0 |
| Presynaptic function of Kainate receptors | R-HSA-500657 | 0.938406 | 0.028 | 0 | 0 |
| Biosynthesis of Lipoxins (LX) | R-HSA-2142700 | 0.938406 | 0.028 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9679504 | 0.938406 | 0.028 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 0.939617 | 0.027 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 0.939617 | 0.027 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 0.940702 | 0.027 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 0.941498 | 0.026 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 0.944197 | 0.025 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 0.945324 | 0.024 | 0 | 0 |
| Translesion Synthesis by POLH | R-HSA-110320 | 0.945440 | 0.024 | 0 | 0 |
| Synthesis of 5-eicosatetraenoic acids | R-HSA-2142688 | 0.945440 | 0.024 | 0 | 0 |
| Diseases of hemostasis | R-HSA-9671793 | 0.945440 | 0.024 | 0 | 0 |
| Mechanical load activates signaling by PIEZO1 and integrins in osteocytes | R-HSA-9856532 | 0.945440 | 0.024 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9694631 | 0.945440 | 0.024 | 0 | 0 |
| Paracetamol ADME | R-HSA-9753281 | 0.946007 | 0.024 | 0 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 0.946007 | 0.024 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 0.947493 | 0.023 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 0.947493 | 0.023 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 0.947493 | 0.023 | 0 | 0 |
| Interleukin-10 signaling | R-HSA-6783783 | 0.947493 | 0.023 | 0 | 0 |
| SLC-mediated transport of amino acids | R-HSA-9958863 | 0.948127 | 0.023 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 0.949309 | 0.023 | 0 | 0 |
| Cardiogenesis | R-HSA-9733709 | 0.949309 | 0.023 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 0.949735 | 0.022 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 0.950296 | 0.022 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 0.950296 | 0.022 | 0 | 0 |
| Proteasome assembly | R-HSA-9907900 | 0.950296 | 0.022 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 0.950296 | 0.022 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 0.950296 | 0.022 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR2 | R-HSA-5654221 | 0.951672 | 0.022 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 0.951672 | 0.022 | 0 | 0 |
| Pregnenolone biosynthesis | R-HSA-196108 | 0.951672 | 0.022 | 0 | 0 |
| Acyl chain remodelling of PI | R-HSA-1482922 | 0.951672 | 0.022 | 0 | 0 |
| Creatine metabolism | R-HSA-71288 | 0.951672 | 0.022 | 0 | 0 |
| Protein hydroxylation | R-HSA-9629569 | 0.951672 | 0.022 | 0 | 0 |
| Signaling by NODAL | R-HSA-1181150 | 0.951672 | 0.022 | 0 | 0 |
| Regulation of insulin secretion | R-HSA-422356 | 0.951869 | 0.021 | 0 | 0 |
| Acyl chain remodelling of PC | R-HSA-1482788 | 0.954151 | 0.020 | 0 | 0 |
| Vitamin B5 (pantothenate) metabolism | R-HSA-199220 | 0.954151 | 0.020 | 0 | 0 |
| Heme degradation | R-HSA-189483 | 0.954151 | 0.020 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 0.954531 | 0.020 | 0 | 0 |
| ADORA2B mediated anti-inflammatory cytokines production | R-HSA-9660821 | 0.954531 | 0.020 | 0 | 0 |
| MyD88 deficiency (TLR2/4) | R-HSA-5602498 | 0.957192 | 0.019 | 0 | 0 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | R-HSA-2979096 | 0.957192 | 0.019 | 0 | 0 |
| G-protein activation | R-HSA-202040 | 0.957192 | 0.019 | 0 | 0 |
| Matriglycan biosynthesis on DAG1 | R-HSA-9939291 | 0.957192 | 0.019 | 0 | 0 |
| SHC-mediated cascade:FGFR3 | R-HSA-5654704 | 0.957192 | 0.019 | 0 | 0 |
| Biosynthesis of E-series 18(S)-resolvins | R-HSA-9018896 | 0.957192 | 0.019 | 0 | 0 |
| Acyl chain remodelling of PG | R-HSA-1482925 | 0.957192 | 0.019 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 0.957693 | 0.019 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 0.958426 | 0.018 | 0 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 0.958426 | 0.018 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 0.958426 | 0.018 | 0 | 0 |
| Signaling by NOTCH2 | R-HSA-1980145 | 0.958548 | 0.018 | 0 | 0 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | R-HSA-6814122 | 0.958548 | 0.018 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 0.958548 | 0.018 | 0 | 0 |
| Developmental Lineage of Mammary Gland Alveolar Cells | R-HSA-9927426 | 0.958548 | 0.018 | 0 | 0 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | R-HSA-983170 | 0.958548 | 0.018 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 0.958548 | 0.018 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 0.958675 | 0.018 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 0.960381 | 0.018 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 0.960440 | 0.018 | 0 | 0 |
| Extension of Telomeres | R-HSA-180786 | 0.961037 | 0.017 | 0 | 0 |
| IRAK4 deficiency (TLR2/4) | R-HSA-5603041 | 0.962082 | 0.017 | 0 | 0 |
| activated TAK1 mediates p38 MAPK activation | R-HSA-450302 | 0.962082 | 0.017 | 0 | 0 |
| Attachment and Entry | R-HSA-9694614 | 0.962082 | 0.017 | 0 | 0 |
| Glutathione synthesis and recycling | R-HSA-174403 | 0.962082 | 0.017 | 0 | 0 |
| Acyl chain remodelling of PE | R-HSA-1482839 | 0.962540 | 0.017 | 0 | 0 |
| Protein folding | R-HSA-391251 | 0.962818 | 0.016 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 0.963916 | 0.016 | 0 | 0 |
| tRNA Aminoacylation | R-HSA-379724 | 0.964134 | 0.016 | 0 | 0 |
| Sphingolipid de novo biosynthesis | R-HSA-1660661 | 0.964134 | 0.016 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 0.965295 | 0.015 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 0.965307 | 0.015 | 0 | 0 |
| G1/S-Specific Transcription | R-HSA-69205 | 0.966161 | 0.015 | 0 | 0 |
| FGFR2 mutant receptor activation | R-HSA-1839126 | 0.966161 | 0.015 | 0 | 0 |
| Biosynthesis of D-series resolvins | R-HSA-9018676 | 0.966413 | 0.015 | 0 | 0 |
| Neurotoxicity of clostridium toxins | R-HSA-168799 | 0.966413 | 0.015 | 0 | 0 |
| WNT ligand biogenesis and trafficking | R-HSA-3238698 | 0.966413 | 0.015 | 0 | 0 |
| RAF-independent MAPK1/3 activation | R-HSA-112409 | 0.966413 | 0.015 | 0 | 0 |
| Ethanol oxidation | R-HSA-71384 | 0.966413 | 0.015 | 0 | 0 |
| Cholesterol biosynthesis via lathosterol | R-HSA-6807062 | 0.966413 | 0.015 | 0 | 0 |
| Cellular hexose transport | R-HSA-189200 | 0.966413 | 0.015 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9694676 | 0.966413 | 0.015 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 0.967001 | 0.015 | 0 | 0 |
| Ca2+ pathway | R-HSA-4086398 | 0.967224 | 0.014 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 0.967642 | 0.014 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 0.969353 | 0.014 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 0.969443 | 0.013 | 0 | 0 |
| TRAF6 mediated IRF7 activation | R-HSA-933541 | 0.969443 | 0.013 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 0.969620 | 0.013 | 0 | 0 |
| Free fatty acids regulate insulin secretion | R-HSA-400451 | 0.970250 | 0.013 | 0 | 0 |
| Carnitine shuttle | R-HSA-200425 | 0.970250 | 0.013 | 0 | 0 |
| Biosynthesis of maresins | R-HSA-9018682 | 0.970250 | 0.013 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 0.971346 | 0.013 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 0.971664 | 0.012 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 0.971664 | 0.012 | 0 | 0 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 0.972418 | 0.012 | 0 | 0 |
| Elastic fibre formation | R-HSA-1566948 | 0.972418 | 0.012 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 0.972492 | 0.012 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 0.973345 | 0.012 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 0.973623 | 0.012 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 0.973623 | 0.012 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 0.973623 | 0.012 | 0 | 0 |
| Plasma lipoprotein assembly | R-HSA-8963898 | 0.973649 | 0.012 | 0 | 0 |
| Recognition of DNA damage by PCNA-containing replication complex | R-HSA-110314 | 0.973649 | 0.012 | 0 | 0 |
| SHC-mediated cascade:FGFR1 | R-HSA-5654688 | 0.973649 | 0.012 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 1 | R-HSA-418592 | 0.973649 | 0.012 | 0 | 0 |
| Synthesis of dolichyl-phosphate | R-HSA-446199 | 0.973649 | 0.012 | 0 | 0 |
| Interleukin-6 family signaling | R-HSA-6783589 | 0.973649 | 0.012 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 0.973715 | 0.012 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 0.973815 | 0.012 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 0.974370 | 0.011 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 0.975112 | 0.011 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 0.975949 | 0.011 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 0.975949 | 0.011 | 0 | 0 |
| Polymerase switching on the C-strand of the telomere | R-HSA-174411 | 0.976660 | 0.010 | 0 | 0 |
| Biosynthesis of electrophilic ω-3 PUFA oxo-derivatives | R-HSA-9027604 | 0.976660 | 0.010 | 0 | 0 |
| Laminin interactions | R-HSA-3000157 | 0.976660 | 0.010 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 0.977149 | 0.010 | 0 | 0 |
| rRNA processing in the mitochondrion | R-HSA-8868766 | 0.977550 | 0.010 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 0.977550 | 0.010 | 0 | 0 |
| Amino acids regulate mTORC1 | R-HSA-9639288 | 0.978080 | 0.010 | 0 | 0 |
| tRNA modification in the nucleus and cytosol | R-HSA-6782315 | 0.978393 | 0.009 | 0 | 0 |
| MET activates PTK2 signaling | R-HSA-8874081 | 0.979327 | 0.009 | 0 | 0 |
| Diseases of branched-chain amino acid catabolism | R-HSA-9865118 | 0.979327 | 0.009 | 0 | 0 |
| Metalloprotease DUBs | R-HSA-5689901 | 0.979327 | 0.009 | 0 | 0 |
| Synthesis of IP2, IP, and Ins in the cytosol | R-HSA-1855183 | 0.979327 | 0.009 | 0 | 0 |
| Urea cycle | R-HSA-70635 | 0.979327 | 0.009 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 0.979425 | 0.009 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 0.979786 | 0.009 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 0.980173 | 0.009 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 0.980367 | 0.009 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 0.980813 | 0.008 | 0 | 0 |
| Biosynthesis of DPAn-3 SPMs | R-HSA-9025094 | 0.981689 | 0.008 | 0 | 0 |
| SHC-mediated cascade:FGFR2 | R-HSA-5654699 | 0.981689 | 0.008 | 0 | 0 |
| ER Quality Control Compartment (ERQC) | R-HSA-901032 | 0.981689 | 0.008 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 0.981752 | 0.008 | 0 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 0.981752 | 0.008 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 0.982114 | 0.008 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 0.983444 | 0.007 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 0.983541 | 0.007 | 0 | 0 |
| Telomere Extension By Telomerase | R-HSA-171319 | 0.983781 | 0.007 | 0 | 0 |
| Insulin receptor recycling | R-HSA-77387 | 0.983781 | 0.007 | 0 | 0 |
| Activation of kainate receptors upon glutamate binding | R-HSA-451326 | 0.983781 | 0.007 | 0 | 0 |
| Iron assimilation using enterobactin | R-HSA-9638334 | 0.983781 | 0.007 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 0.984751 | 0.007 | 0 | 0 |
| Defective pyroptosis | R-HSA-9710421 | 0.985186 | 0.006 | 0 | 0 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 0.985186 | 0.006 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 0.985186 | 0.006 | 0 | 0 |
| DNA methylation | R-HSA-5334118 | 0.985635 | 0.006 | 0 | 0 |
| Biosynthesis of EPA-derived SPMs | R-HSA-9018679 | 0.985635 | 0.006 | 0 | 0 |
| Signaling by CSF3 (G-CSF) | R-HSA-9674555 | 0.985635 | 0.006 | 0 | 0 |
| Synthesis of Leukotrienes (LT) and Eoxins (EX) | R-HSA-2142691 | 0.986659 | 0.006 | 0 | 0 |
| Thrombin signalling through proteinase activated receptors (PARs) | R-HSA-456926 | 0.987277 | 0.006 | 0 | 0 |
| Neurotransmitter clearance | R-HSA-112311 | 0.987277 | 0.006 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 0.987297 | 0.006 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 0.987538 | 0.005 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 0.987988 | 0.005 | 0 | 0 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | R-HSA-211733 | 0.988731 | 0.005 | 0 | 0 |
| Biosynthesis of DPA-derived SPMs | R-HSA-9018683 | 0.988731 | 0.005 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 0.989152 | 0.005 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 0.989188 | 0.005 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 0.990009 | 0.004 | 1 | 1 |
| Developmental Lineage of Multipotent Pancreatic Progenitor Cells | R-HSA-9937080 | 0.990019 | 0.004 | 0 | 0 |
| Regulation of ornithine decarboxylase (ODC) | R-HSA-350562 | 0.990019 | 0.004 | 0 | 0 |
| DAG1 glycosylations | R-HSA-8931838 | 0.990019 | 0.004 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 0.990649 | 0.004 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 0.990692 | 0.004 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 0.991010 | 0.004 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 0.991160 | 0.004 | 0 | 0 |
| Defective B3GALTL causes PpS | R-HSA-5083635 | 0.991160 | 0.004 | 0 | 0 |
| Assembly of the ORC complex at the origin of replication | R-HSA-68616 | 0.991160 | 0.004 | 0 | 0 |
| Diseases associated with glycosylation precursor biosynthesis | R-HSA-5609975 | 0.991160 | 0.004 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 0.991218 | 0.004 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9694635 | 0.991786 | 0.004 | 0 | 0 |
| Chemokine receptors bind chemokines | R-HSA-380108 | 0.992128 | 0.003 | 0 | 0 |
| Vpu mediated degradation of CD4 | R-HSA-180534 | 0.992170 | 0.003 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 0.992469 | 0.003 | 0 | 0 |
| Cholesterol biosynthesis | R-HSA-191273 | 0.992494 | 0.003 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 0.993004 | 0.003 | 0 | 0 |
| Ubiquitin-dependent degradation of Cyclin D | R-HSA-75815 | 0.993065 | 0.003 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 0.993065 | 0.003 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 0.993065 | 0.003 | 0 | 0 |
| RA biosynthesis pathway | R-HSA-5365859 | 0.993065 | 0.003 | 0 | 0 |
| Calnexin/calreticulin cycle | R-HSA-901042 | 0.993065 | 0.003 | 0 | 0 |
| Signal amplification | R-HSA-392518 | 0.993065 | 0.003 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 0.993179 | 0.003 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 0.993505 | 0.003 | 0 | 0 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | R-HSA-8854050 | 0.993858 | 0.003 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 0.993858 | 0.003 | 0 | 0 |
| Regulation of Apoptosis | R-HSA-169911 | 0.993858 | 0.003 | 0 | 0 |
| Transferrin endocytosis and recycling | R-HSA-917977 | 0.993858 | 0.003 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 0.994283 | 0.002 | 0 | 0 |
| PRC2 methylates histones and DNA | R-HSA-212300 | 0.994561 | 0.002 | 0 | 0 |
| Vif-mediated degradation of APOBEC3G | R-HSA-180585 | 0.994561 | 0.002 | 0 | 0 |
| Glycosphingolipid transport | R-HSA-9845576 | 0.994561 | 0.002 | 0 | 0 |
| HS-GAG biosynthesis | R-HSA-2022928 | 0.994561 | 0.002 | 0 | 0 |
| Triglyceride catabolism | R-HSA-163560 | 0.994561 | 0.002 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 0.994575 | 0.002 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 0.994575 | 0.002 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 0.994758 | 0.002 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 0.994758 | 0.002 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 0.995077 | 0.002 | 0 | 0 |
| O-glycosylation of TSR domain-containing proteins | R-HSA-5173214 | 0.995182 | 0.002 | 0 | 0 |
| Voltage gated Potassium channels | R-HSA-1296072 | 0.995182 | 0.002 | 0 | 0 |
| SIRT1 negatively regulates rRNA expression | R-HSA-427359 | 0.995182 | 0.002 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 0.995182 | 0.002 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 0.995182 | 0.002 | 0 | 0 |
| SLC-mediated transport of organic cations | R-HSA-549127 | 0.995182 | 0.002 | 0 | 0 |
| Lysine catabolism | R-HSA-71064 | 0.995182 | 0.002 | 0 | 0 |
| Collagen chain trimerization | R-HSA-8948216 | 0.995182 | 0.002 | 0 | 0 |
| Metabolism of folate and pterines | R-HSA-196757 | 0.995182 | 0.002 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 0.995657 | 0.002 | 0 | 0 |
| Fatty acyl-CoA biosynthesis | R-HSA-75105 | 0.995711 | 0.002 | 0 | 0 |
| tRNA processing in the mitochondrion | R-HSA-6785470 | 0.995733 | 0.002 | 0 | 0 |
| Transcriptional regulation of pluripotent stem cells | R-HSA-452723 | 0.995733 | 0.002 | 0 | 0 |
| Diseases associated with O-glycosylation of proteins | R-HSA-3906995 | 0.996115 | 0.002 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 0.996115 | 0.002 | 0 | 0 |
| RAS processing | R-HSA-9648002 | 0.996221 | 0.002 | 0 | 0 |
| Cross-presentation of soluble exogenous antigens (endosomes) | R-HSA-1236978 | 0.996221 | 0.002 | 0 | 0 |
| Pentose phosphate pathway | R-HSA-71336 | 0.996221 | 0.002 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 0.996542 | 0.002 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 0.996653 | 0.001 | 0 | 0 |
| Maturation of TCA enzymes and regulation of TCA cycle | R-HSA-9854311 | 0.996653 | 0.001 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 0.996653 | 0.001 | 0 | 0 |
| Tryptophan catabolism | R-HSA-71240 | 0.996653 | 0.001 | 0 | 0 |
| Mitochondrial tRNA aminoacylation | R-HSA-379726 | 0.996653 | 0.001 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 0.996777 | 0.001 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 0.996826 | 0.001 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 0.996826 | 0.001 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 0.996999 | 0.001 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 0.997003 | 0.001 | 0 | 0 |
| Chromatin modifications during the maternal to zygotic transition (MZT) | R-HSA-9821002 | 0.997036 | 0.001 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 0.997036 | 0.001 | 0 | 0 |
| Hh mutants are degraded by ERAD | R-HSA-5362768 | 0.997036 | 0.001 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 0.997036 | 0.001 | 0 | 0 |
| Purine ribonucleoside monophosphate biosynthesis | R-HSA-73817 | 0.997036 | 0.001 | 0 | 0 |
| Aflatoxin activation and detoxification | R-HSA-5423646 | 0.997036 | 0.001 | 0 | 0 |
| ROS and RNS production in phagocytes | R-HSA-1222556 | 0.997115 | 0.001 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 0.997181 | 0.001 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 0.997206 | 0.001 | 0 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 0.997306 | 0.001 | 0 | 0 |
| Scavenging by Class A Receptors | R-HSA-3000480 | 0.997375 | 0.001 | 0 | 0 |
| SLC-mediated transport of neurotransmitters | R-HSA-442660 | 0.997375 | 0.001 | 0 | 0 |
| Citric acid cycle (TCA cycle) | R-HSA-71403 | 0.997389 | 0.001 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 0.997429 | 0.001 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 0.997514 | 0.001 | 0 | 0 |
| Metabolism of polyamines | R-HSA-351202 | 0.997583 | 0.001 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 0.997675 | 0.001 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 0.997675 | 0.001 | 0 | 0 |
| Collagen degradation | R-HSA-1442490 | 0.997832 | 0.001 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 0.998067 | 0.001 | 0 | 0 |
| Cobalamin (Cbl, vitamin B12) transport and metabolism | R-HSA-196741 | 0.998177 | 0.001 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 0.998245 | 0.001 | 0 | 0 |
| Late SARS-CoV-2 Infection Events | R-HSA-9772573 | 0.998295 | 0.001 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 0.998385 | 0.001 | 0 | 0 |
| Inactivation, recovery and regulation of the phototransduction cascade | R-HSA-2514859 | 0.998570 | 0.001 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 0.998590 | 0.001 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 0.998619 | 0.001 | 0 | 0 |
| Carboxyterminal post-translational modifications of tubulin | R-HSA-8955332 | 0.998734 | 0.001 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 0.998818 | 0.001 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 0.998834 | 0.001 | 0 | 0 |
| Metabolism of steroid hormones | R-HSA-196071 | 0.998873 | 0.000 | 0 | 0 |
| Plasma lipoprotein remodeling | R-HSA-8963899 | 0.998879 | 0.000 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 0.998879 | 0.000 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 0.998883 | 0.000 | 0 | 0 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | R-HSA-532668 | 0.999007 | 0.000 | 0 | 0 |
| Azathioprine ADME | R-HSA-9748787 | 0.999121 | 0.000 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 0.999180 | 0.000 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 0.999205 | 0.000 | 0 | 0 |
| Branched-chain amino acid catabolism | R-HSA-70895 | 0.999221 | 0.000 | 0 | 0 |
| Complex IV assembly | R-HSA-9864848 | 0.999221 | 0.000 | 0 | 0 |
| The phototransduction cascade | R-HSA-2514856 | 0.999221 | 0.000 | 0 | 0 |
| Retinoid metabolism and transport | R-HSA-975634 | 0.999274 | 0.000 | 0 | 0 |
| Metabolism of porphyrins | R-HSA-189445 | 0.999274 | 0.000 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 0.999286 | 0.000 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 0.999361 | 0.000 | 0 | 0 |
| Nucleotide biosynthesis | R-HSA-8956320 | 0.999389 | 0.000 | 0 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 0.999459 | 0.000 | 0 | 0 |
| Dectin-2 family | R-HSA-5621480 | 0.999624 | 0.000 | 0 | 0 |
| Synthesis of PA | R-HSA-1483166 | 0.999624 | 0.000 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 0.999652 | 0.000 | 0 | 0 |
| Heparan sulfate/heparin (HS-GAG) metabolism | R-HSA-1638091 | 0.999706 | 0.000 | 0 | 0 |
| Triglyceride metabolism | R-HSA-8979227 | 0.999706 | 0.000 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 0.999714 | 0.000 | 0 | 0 |
| RAB geranylgeranylation | R-HSA-8873719 | 0.999739 | 0.000 | 0 | 0 |
| Glutathione conjugation | R-HSA-156590 | 0.999739 | 0.000 | 0 | 0 |
| Signaling by Retinoic Acid | R-HSA-5362517 | 0.999739 | 0.000 | 0 | 0 |
| Metabolism of fat-soluble vitamins | R-HSA-6806667 | 0.999760 | 0.000 | 0 | 0 |
| Endogenous sterols | R-HSA-211976 | 0.999769 | 0.000 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 0.999778 | 0.000 | 0 | 0 |
| Translation | R-HSA-72766 | 0.999819 | 0.000 | 0 | 0 |
| Complex I biogenesis | R-HSA-6799198 | 0.999819 | 0.000 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 0.999833 | 0.000 | 0 | 0 |
| Synthesis of bile acids and bile salts | R-HSA-192105 | 0.999837 | 0.000 | 0 | 0 |
| CD22 mediated BCR regulation | R-HSA-5690714 | 0.999840 | 0.000 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 0.999865 | 0.000 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 0.999878 | 0.000 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 0.999878 | 0.000 | 0 | 0 |
| Nicotinate metabolism | R-HSA-196807 | 0.999889 | 0.000 | 0 | 0 |
| Peptide hormone metabolism | R-HSA-2980736 | 0.999900 | 0.000 | 0 | 0 |
| Collagen biosynthesis and modifying enzymes | R-HSA-1650814 | 0.999901 | 0.000 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 0.999909 | 0.000 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 0.999925 | 0.000 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 0.999932 | 0.000 | 0 | 0 |
| Metal ion assimilation from the host | R-HSA-9638482 | 0.999932 | 0.000 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 0.999944 | 0.000 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 0.999944 | 0.000 | 1 | 0 |
| Diseases of carbohydrate metabolism | R-HSA-5663084 | 0.999946 | 0.000 | 0 | 0 |
| Aspirin ADME | R-HSA-9749641 | 0.999946 | 0.000 | 0 | 0 |
| Bile acid and bile salt metabolism | R-HSA-194068 | 0.999954 | 0.000 | 0 | 0 |
| Iron uptake and transport | R-HSA-917937 | 0.999958 | 0.000 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 0.999966 | 0.000 | 0 | 0 |
| Metabolic disorders of biological oxidation enzymes | R-HSA-5579029 | 0.999974 | 0.000 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 0.999974 | 0.000 | 0 | 0 |
| Mitochondrial translation initiation | R-HSA-5368286 | 0.999975 | 0.000 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 0.999977 | 0.000 | 1 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 0.999979 | 0.000 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 0.999979 | 0.000 | 0 | 0 |
| Biosynthesis of DHA-derived SPMs | R-HSA-9018677 | 0.999980 | 0.000 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 0.999982 | 0.000 | 0 | 0 |
| Mitochondrial ribosome-associated quality control | R-HSA-9937383 | 0.999986 | 0.000 | 0 | 0 |
| Peroxisomal lipid metabolism | R-HSA-390918 | 0.999986 | 0.000 | 0 | 0 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | R-HSA-163841 | 0.999990 | 0.000 | 0 | 0 |
| Immune System | R-HSA-168256 | 0.999997 | 0.000 | 1 | 0 |
| Post-translational protein modification | R-HSA-597592 | 0.999998 | 0.000 | 0 | 0 |
| Mitochondrial translation elongation | R-HSA-5389840 | 0.999998 | 0.000 | 0 | 0 |
| Potassium Channels | R-HSA-1296071 | 0.999998 | 0.000 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 0.999998 | 0.000 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 0.999999 | 0.000 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 0.999999 | 0.000 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 0.999999 | 0.000 | 1 | 0 |
| Mitochondrial translation | R-HSA-5368287 | 0.999999 | 0.000 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 0.999999 | 0.000 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 0.999999 | 0.000 | 0 | 0 |
| Post-translational modification: synthesis of GPI-anchored proteins | R-HSA-163125 | 0.999999 | 0.000 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 0.999999 | 0.000 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 1.000000 | 0.000 | 0 | 0 |
| Mitochondrial translation termination | R-HSA-5419276 | 1.000000 | 0.000 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 1.000000 | 0.000 | 0 | 0 |
| Antimicrobial peptides | R-HSA-6803157 | 1.000000 | 0.000 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 1.000000 | 0.000 | 0 | 0 |
| Arachidonate metabolism | R-HSA-2142753 | 1.000000 | 0.000 | 0 | 0 |
| O-linked glycosylation | R-HSA-5173105 | 1.000000 | 0.000 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 1.000000 | 0.000 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 1.000000 | 0.000 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 1.000000 | 0.000 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 1.000000 | 0.000 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 1.000000 | 0.000 | 0 | 0 |
| Synthesis of substrates in N-glycan biosythesis | R-HSA-446219 | 1.000000 | 0.000 | 0 | 0 |
| Biosynthesis of specialized proresolving mediators (SPMs) | R-HSA-9018678 | 1.000000 | 0.000 | 0 | 0 |
| Metabolism of water-soluble vitamins and cofactors | R-HSA-196849 | 1.000000 | 0.000 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 1.000000 | 0.000 | 1 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 1.000000 | 0.000 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 1.000000 | 0.000 | 0 | 0 |
| Disease | R-HSA-1643685 | 1.000000 | 0.000 | 1 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 1.000000 | 0.000 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 1.000000 | 0.000 | 0 | 0 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | R-HSA-446193 | 1.000000 | 0.000 | 0 | 0 |
| Cytochrome P450 - arranged by substrate type | R-HSA-211897 | 1.000000 | 0.000 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 1.000000 | 0.000 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 1.000000 | 0.000 | 0 | 0 |
| Glycosaminoglycan metabolism | R-HSA-1630316 | 1.000000 | 0.000 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 1.000000 | 0.000 | 0 | 0 |
| Infection with Enterobacteria | R-HSA-9640148 | 1.000000 | 0.000 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 1.000000 | 0.000 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 1.000000 | 0.000 | 0 | 0 |
| Phase II - Conjugation of compounds | R-HSA-156580 | 1.000000 | 0.000 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 1.000000 | 0.000 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 1.000000 | 0.000 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 1.000000 | 0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 1.000000 | -0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000 | -0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 1.000000 | -0.000 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 1.000000 | -0.000 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 1.000000 | -0.000 | 0 | 0 |
Top15 pathways (red highlights are reference pathways)
Compared with reference pathways
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Cell Cycle | R-HSA-1640170 | 4.440892e-16 | 15.353 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 1.154632e-14 | 13.938 | 0 | 0 |
| M Phase | R-HSA-68886 | 6.050715e-14 | 13.218 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 1.236788e-13 | 12.908 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 9.710011e-13 | 12.013 | 1 | 0 |
| Mitotic Prophase | R-HSA-68875 | 1.102640e-11 | 10.958 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 4.203671e-11 | 10.376 | 1 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 4.660305e-11 | 10.332 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 6.155945e-10 | 9.211 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 6.155945e-10 | 9.211 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 5.180584e-10 | 9.286 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 6.025452e-10 | 9.220 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 1.489648e-09 | 8.827 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 1.769301e-09 | 8.752 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 2.615220e-09 | 8.582 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 2.947905e-09 | 8.530 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 3.471110e-09 | 8.460 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 3.731095e-09 | 8.428 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 4.287404e-09 | 8.368 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 4.836320e-09 | 8.315 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 5.860317e-09 | 8.232 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 6.636061e-09 | 8.178 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 6.591605e-09 | 8.181 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 6.430304e-09 | 8.192 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 7.299778e-09 | 8.137 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 9.686984e-09 | 8.014 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 1.655982e-08 | 7.781 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 1.655982e-08 | 7.781 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 1.792206e-08 | 7.747 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 1.864434e-08 | 7.729 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 2.071777e-08 | 7.684 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 2.857804e-08 | 7.544 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 2.857804e-08 | 7.544 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 2.946844e-08 | 7.531 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 3.163785e-08 | 7.500 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 3.558097e-08 | 7.449 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 3.498045e-08 | 7.456 | 0 | 0 |
| PRC2 methylates histones and DNA | R-HSA-212300 | 3.836811e-08 | 7.416 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 4.716197e-08 | 7.326 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 4.599996e-08 | 7.337 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 4.501697e-08 | 7.347 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 5.768720e-08 | 7.239 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 7.558711e-08 | 7.122 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 1.184147e-07 | 6.927 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 1.403324e-07 | 6.853 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 1.581735e-07 | 6.801 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 1.581735e-07 | 6.801 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 1.728938e-07 | 6.762 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 2.072053e-07 | 6.684 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 2.353195e-07 | 6.628 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 2.776264e-07 | 6.557 | 0 | 0 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | R-HSA-2559584 | 2.885828e-07 | 6.540 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 2.919469e-07 | 6.535 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 3.067742e-07 | 6.513 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 3.289682e-07 | 6.483 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 3.281625e-07 | 6.484 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 3.671176e-07 | 6.435 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 3.864336e-07 | 6.413 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 3.864336e-07 | 6.413 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 4.153501e-07 | 6.382 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 4.334810e-07 | 6.363 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 4.919352e-07 | 6.308 | 0 | 0 |
| RNA Polymerase I Promoter Opening | R-HSA-73728 | 4.974090e-07 | 6.303 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 6.604919e-07 | 6.180 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 7.056800e-07 | 6.151 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 8.863524e-07 | 6.052 | 0 | 0 |
| Assembly of the ORC complex at the origin of replication | R-HSA-68616 | 9.352489e-07 | 6.029 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 9.612366e-07 | 6.017 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 1.025575e-06 | 5.989 | 0 | 0 |
| DNA methylation | R-HSA-5334118 | 1.057710e-06 | 5.976 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 1.113322e-06 | 5.953 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 1.085876e-06 | 5.964 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 1.520862e-06 | 5.818 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 1.667543e-06 | 5.778 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 1.705366e-06 | 5.768 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 2.088545e-06 | 5.680 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 1.997985e-06 | 5.699 | 0 | 0 |
| Defective pyroptosis | R-HSA-9710421 | 2.163787e-06 | 5.665 | 0 | 0 |
| Packaging Of Telomere Ends | R-HSA-171306 | 2.429398e-06 | 5.615 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 2.423524e-06 | 5.616 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 2.378632e-06 | 5.624 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 2.681021e-06 | 5.572 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 2.688115e-06 | 5.571 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 2.891442e-06 | 5.539 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected purine | R-HSA-110330 | 2.979362e-06 | 5.526 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 3.570292e-06 | 5.447 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 3.590210e-06 | 5.445 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 3.625264e-06 | 5.441 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 4.081163e-06 | 5.389 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 4.093118e-06 | 5.388 | 1 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 4.449328e-06 | 5.352 | 0 | 0 |
| SIRT1 negatively regulates rRNA expression | R-HSA-427359 | 4.551658e-06 | 5.342 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 4.609213e-06 | 5.336 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 4.734567e-06 | 5.325 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 5.102266e-06 | 5.292 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 4.857355e-06 | 5.314 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 5.310873e-06 | 5.275 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 5.988194e-06 | 5.223 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 6.034618e-06 | 5.219 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 6.197166e-06 | 5.208 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 7.415054e-06 | 5.130 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 7.034803e-06 | 5.153 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 7.596126e-06 | 5.119 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 7.739273e-06 | 5.111 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 8.249727e-06 | 5.084 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 9.039155e-06 | 5.044 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 9.039155e-06 | 5.044 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 1.006057e-05 | 4.997 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 1.055159e-05 | 4.977 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 1.256884e-05 | 4.901 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 1.275881e-05 | 4.894 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 1.708720e-05 | 4.767 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 1.625886e-05 | 4.789 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 1.757406e-05 | 4.755 | 1 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 1.767098e-05 | 4.753 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 1.777698e-05 | 4.750 | 1 | 1 |
| Cleavage of the damaged purine | R-HSA-110331 | 1.777955e-05 | 4.750 | 0 | 0 |
| Regulation of localization of FOXO transcription factors | R-HSA-9614399 | 1.795867e-05 | 4.746 | 0 | 0 |
| Replacement of protamines by nucleosomes in the male pronucleus | R-HSA-9821993 | 1.823569e-05 | 4.739 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 1.838359e-05 | 4.736 | 0 | 0 |
| Depurination | R-HSA-73927 | 2.320908e-05 | 4.634 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 2.773455e-05 | 4.557 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 2.810711e-05 | 4.551 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 2.877568e-05 | 4.541 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 2.901456e-05 | 4.537 | 0 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 2.968741e-05 | 4.527 | 1 | 1 |
| HCMV Infection | R-HSA-9609646 | 2.981374e-05 | 4.526 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 3.075013e-05 | 4.512 | 1 | 1 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 3.103447e-05 | 4.508 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 3.148837e-05 | 4.502 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 3.375081e-05 | 4.472 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 4.660787e-05 | 4.332 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 4.688781e-05 | 4.329 | 1 | 0 |
| Base Excision Repair | R-HSA-73884 | 4.713802e-05 | 4.327 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 4.772439e-05 | 4.321 | 0 | 0 |
| Chromatin modifications during the maternal to zygotic transition (MZT) | R-HSA-9821002 | 4.931415e-05 | 4.307 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 5.193593e-05 | 4.285 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 5.378912e-05 | 4.269 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 5.378912e-05 | 4.269 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 5.391759e-05 | 4.268 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 5.551551e-05 | 4.256 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 6.250376e-05 | 4.204 | 1 | 1 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 7.101176e-05 | 4.149 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 7.681740e-05 | 4.115 | 1 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 7.856101e-05 | 4.105 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 7.869842e-05 | 4.104 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 7.869842e-05 | 4.104 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 7.941464e-05 | 4.100 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 8.544833e-05 | 4.068 | 0 | 0 |
| Cohesin Loading onto Chromatin | R-HSA-2470946 | 9.019475e-05 | 4.045 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 9.682718e-05 | 4.014 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 1.065229e-04 | 3.973 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 1.203407e-04 | 3.920 | 0 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 1.334782e-04 | 3.875 | 1 | 1 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 1.493817e-04 | 3.826 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 1.494166e-04 | 3.826 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 1.709860e-04 | 3.767 | 0 | 0 |
| Activation of BAD and translocation to mitochondria | R-HSA-111447 | 1.794167e-04 | 3.746 | 0 | 0 |
| SARS-CoV-2 targets host intracellular signalling and regulatory pathways | R-HSA-9755779 | 1.794167e-04 | 3.746 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 1.860625e-04 | 3.730 | 1 | 1 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 1.860625e-04 | 3.730 | 1 | 1 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 1.860625e-04 | 3.730 | 1 | 1 |
| Signaling by RAS mutants | R-HSA-6802949 | 1.860625e-04 | 3.730 | 1 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 1.964543e-04 | 3.707 | 1 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 2.259059e-04 | 3.646 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 2.274795e-04 | 3.643 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 2.384430e-04 | 3.623 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 2.409126e-04 | 3.618 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 2.418350e-04 | 3.616 | 1 | 1 |
| Interferon Signaling | R-HSA-913531 | 2.713978e-04 | 3.566 | 1 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 2.894645e-04 | 3.538 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 3.049869e-04 | 3.516 | 0 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 3.067215e-04 | 3.513 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 3.226935e-04 | 3.491 | 0 | 0 |
| Formation of tubulin folding intermediates by CCT/TriC | R-HSA-389960 | 3.242208e-04 | 3.489 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 3.428732e-04 | 3.465 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 3.432909e-04 | 3.464 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 3.515651e-04 | 3.454 | 0 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 3.515651e-04 | 3.454 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 3.916914e-04 | 3.407 | 0 | 0 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | R-HSA-75035 | 4.219669e-04 | 3.375 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 4.248697e-04 | 3.372 | 1 | 1 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 4.334273e-04 | 3.363 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 4.395766e-04 | 3.357 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 4.595189e-04 | 3.338 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 5.233845e-04 | 3.281 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 5.520595e-04 | 3.258 | 1 | 1 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 5.617029e-04 | 3.250 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 6.105502e-04 | 3.214 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 6.719579e-04 | 3.173 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 7.017849e-04 | 3.154 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 7.017849e-04 | 3.154 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 7.179695e-04 | 3.144 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 7.265782e-04 | 3.139 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 7.265782e-04 | 3.139 | 0 | 0 |
| Vpr-mediated nuclear import of PICs | R-HSA-180910 | 7.349874e-04 | 3.134 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 7.435080e-04 | 3.129 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 7.612538e-04 | 3.118 | 1 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 7.749689e-04 | 3.111 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 7.752298e-04 | 3.111 | 1 | 0 |
| G2/M Transition | R-HSA-69275 | 7.798292e-04 | 3.108 | 0 | 0 |
| Transport of the SLBP independent Mature mRNA | R-HSA-159227 | 8.210959e-04 | 3.086 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 9.432581e-04 | 3.025 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 8.679581e-04 | 3.062 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 8.679581e-04 | 3.062 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 9.512800e-04 | 3.022 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 9.420318e-04 | 3.026 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 9.562632e-04 | 3.019 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 9.372685e-04 | 3.028 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 9.232676e-04 | 3.035 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 8.619446e-04 | 3.065 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 9.788838e-04 | 3.009 | 0 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 9.986977e-04 | 3.001 | 0 | 0 |
| Transport of the SLBP Dependant Mature mRNA | R-HSA-159230 | 1.016244e-03 | 2.993 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 1.245041e-03 | 2.905 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 1.248470e-03 | 2.904 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 1.248470e-03 | 2.904 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 1.260153e-03 | 2.900 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 1.260153e-03 | 2.900 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 1.308534e-03 | 2.883 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 1.318429e-03 | 2.880 | 0 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 1.318429e-03 | 2.880 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 1.348786e-03 | 2.870 | 0 | 0 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | R-HSA-5619107 | 1.402841e-03 | 2.853 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 1.522971e-03 | 2.817 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 1.537235e-03 | 2.813 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 1.537235e-03 | 2.813 | 0 | 0 |
| IP3 and IP4 transport between cytosol and nucleus | R-HSA-1855196 | 1.733384e-03 | 2.761 | 0 | 0 |
| IP6 and IP7 transport between cytosol and nucleus | R-HSA-1855229 | 1.733384e-03 | 2.761 | 0 | 0 |
| snRNP Assembly | R-HSA-191859 | 1.767896e-03 | 2.753 | 0 | 0 |
| Metabolism of non-coding RNA | R-HSA-194441 | 1.767896e-03 | 2.753 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 1.808481e-03 | 2.743 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 1.839081e-03 | 2.735 | 0 | 0 |
| CaM pathway | R-HSA-111997 | 1.845377e-03 | 2.734 | 1 | 0 |
| Calmodulin induced events | R-HSA-111933 | 1.845377e-03 | 2.734 | 1 | 0 |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | R-HSA-190840 | 2.142383e-03 | 2.669 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 2.221747e-03 | 2.653 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 2.163272e-03 | 2.665 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 2.244232e-03 | 2.649 | 1 | 0 |
| G-protein mediated events | R-HSA-112040 | 2.212067e-03 | 2.655 | 1 | 0 |
| S Phase | R-HSA-69242 | 2.269818e-03 | 2.644 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 2.086775e-03 | 2.681 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 1.978798e-03 | 2.704 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 2.275160e-03 | 2.643 | 0 | 0 |
| Protein folding | R-HSA-391251 | 2.287916e-03 | 2.641 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 2.355232e-03 | 2.628 | 1 | 0 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 2.383179e-03 | 2.623 | 0 | 0 |
| CaMK IV-mediated phosphorylation of CREB | R-HSA-111932 | 2.383179e-03 | 2.623 | 1 | 1 |
| Apoptosis induced DNA fragmentation | R-HSA-140342 | 2.383179e-03 | 2.623 | 0 | 0 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | R-HSA-428359 | 2.383179e-03 | 2.623 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 2.403868e-03 | 2.619 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 2.403868e-03 | 2.619 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 2.444054e-03 | 2.612 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 2.453177e-03 | 2.610 | 0 | 0 |
| TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation | R-HSA-8869496 | 2.484712e-03 | 2.605 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 2.514271e-03 | 2.600 | 0 | 0 |
| IPs transport between nucleus and cytosol | R-HSA-1855170 | 2.585207e-03 | 2.588 | 0 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 2.585207e-03 | 2.588 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 2.600844e-03 | 2.585 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 2.658568e-03 | 2.575 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 2.704888e-03 | 2.568 | 0 | 0 |
| Transport of connexons to the plasma membrane | R-HSA-190872 | 2.802048e-03 | 2.553 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 2.823737e-03 | 2.549 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 2.868633e-03 | 2.542 | 0 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 3.096509e-03 | 2.509 | 0 | 0 |
| RMTs methylate histone arginines | R-HSA-3214858 | 3.117307e-03 | 2.506 | 0 | 0 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | R-HSA-170822 | 3.122910e-03 | 2.505 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 3.162738e-03 | 2.500 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 3.475965e-03 | 2.459 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 3.494512e-03 | 2.457 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 3.647640e-03 | 2.438 | 1 | 0 |
| Aggrephagy | R-HSA-9646399 | 3.741556e-03 | 2.427 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 4.307024e-03 | 2.366 | 1 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 4.501583e-03 | 2.347 | 1 | 0 |
| Post-chaperonin tubulin folding pathway | R-HSA-389977 | 4.588026e-03 | 2.338 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 4.713064e-03 | 2.327 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 4.805152e-03 | 2.318 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperone genes | R-HSA-381183 | 4.751764e-03 | 2.323 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 5.567741e-03 | 2.254 | 0 | 0 |
| Kinesins | R-HSA-983189 | 4.947221e-03 | 2.306 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 5.211775e-03 | 2.283 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 5.607766e-03 | 2.251 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 5.764925e-03 | 2.239 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 5.844388e-03 | 2.233 | 1 | 0 |
| Centrosome maturation | R-HSA-380287 | 5.938621e-03 | 2.226 | 0 | 0 |
| LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | R-HSA-3134973 | 6.036292e-03 | 2.219 | 0 | 0 |
| Loss of phosphorylation of MECP2 at T308 | R-HSA-9022535 | 6.036292e-03 | 2.219 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 6.233826e-03 | 2.205 | 0 | 0 |
| DNA strand elongation | R-HSA-69190 | 6.324531e-03 | 2.199 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 7.140245e-03 | 2.146 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 7.337579e-03 | 2.134 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 7.506982e-03 | 2.125 | 0 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 7.506982e-03 | 2.125 | 1 | 0 |
| Translation | R-HSA-72766 | 7.797835e-03 | 2.108 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 7.956153e-03 | 2.099 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 7.994858e-03 | 2.097 | 0 | 0 |
| Unwinding of DNA | R-HSA-176974 | 8.186833e-03 | 2.087 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 8.353683e-03 | 2.078 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperones | R-HSA-381033 | 8.514317e-03 | 2.070 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 8.760115e-03 | 2.057 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 8.981967e-03 | 2.047 | 0 | 0 |
| Activation of kainate receptors upon glutamate binding | R-HSA-451326 | 8.981967e-03 | 2.047 | 0 | 0 |
| Phase 0 - rapid depolarisation | R-HSA-5576892 | 8.981967e-03 | 2.047 | 1 | 1 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 9.297324e-03 | 2.032 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 9.297324e-03 | 2.032 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 9.437629e-03 | 2.025 | 0 | 0 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | R-HSA-446388 | 9.517134e-03 | 2.021 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 9.731933e-03 | 2.012 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 9.835233e-03 | 2.007 | 1 | 0 |
| Cilium Assembly | R-HSA-5617833 | 1.010528e-02 | 1.995 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 1.063986e-02 | 1.973 | 0 | 0 |
| Folding of actin by CCT/TriC | R-HSA-390450 | 1.125947e-02 | 1.948 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 1.137625e-02 | 1.944 | 0 | 0 |
| Transport of Ribonucleoproteins into the Host Nucleus | R-HSA-168271 | 1.137625e-02 | 1.944 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 1.147859e-02 | 1.940 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 1.169915e-02 | 1.932 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 1.182653e-02 | 1.927 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 1.204676e-02 | 1.919 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 1.204676e-02 | 1.919 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 1.239842e-02 | 1.907 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 1.245413e-02 | 1.905 | 0 | 0 |
| Activation of the pre-replicative complex | R-HSA-68962 | 1.261862e-02 | 1.899 | 0 | 0 |
| Activation of BH3-only proteins | R-HSA-114452 | 1.261862e-02 | 1.899 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 1.268415e-02 | 1.897 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 1.306196e-02 | 1.884 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 1.361731e-02 | 1.866 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 1.392419e-02 | 1.856 | 0 | 0 |
| Formation of the embryonic stem cell BAF (esBAF) complex | R-HSA-9933946 | 1.404353e-02 | 1.853 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 1.404353e-02 | 1.853 | 0 | 0 |
| Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | R-HSA-9934037 | 1.515934e-02 | 1.819 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 1.493048e-02 | 1.826 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 1.480148e-02 | 1.830 | 1 | 1 |
| Formation of the dystrophin-glycoprotein complex (DGC) | R-HSA-9913351 | 1.480148e-02 | 1.830 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 1.728290e-02 | 1.762 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 1.754732e-02 | 1.756 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 1.745039e-02 | 1.758 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 1.572909e-02 | 1.803 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 1.741865e-02 | 1.759 | 0 | 0 |
| Diseases of Telomere Maintenance | R-HSA-9673013 | 1.799972e-02 | 1.745 | 0 | 0 |
| Alternative Lengthening of Telomeres (ALT) | R-HSA-9006821 | 1.799972e-02 | 1.745 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere | R-HSA-9670621 | 1.799972e-02 | 1.745 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations | R-HSA-9670615 | 1.799972e-02 | 1.745 | 0 | 0 |
| Loss of MECP2 binding ability to 5hmC-DNA | R-HSA-9022534 | 1.799972e-02 | 1.745 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations | R-HSA-9670613 | 1.799972e-02 | 1.745 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 1.890259e-02 | 1.723 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 1.944886e-02 | 1.711 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 1.962173e-02 | 1.707 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 1.971217e-02 | 1.705 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 1.998247e-02 | 1.699 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 1.998247e-02 | 1.699 | 0 | 0 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 1.998247e-02 | 1.699 | 1 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 2.018061e-02 | 1.695 | 1 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 2.099376e-02 | 1.678 | 0 | 0 |
| G beta:gamma signalling through CDC42 | R-HSA-8964616 | 2.168352e-02 | 1.664 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 2.174608e-02 | 1.663 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 2.177612e-02 | 1.662 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 2.193408e-02 | 1.659 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 2.193408e-02 | 1.659 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 2.193792e-02 | 1.659 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 2.248160e-02 | 1.648 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 2.343764e-02 | 1.630 | 0 | 0 |
| TLR3-mediated TICAM1-dependent programmed cell death | R-HSA-9013957 | 2.397048e-02 | 1.620 | 0 | 0 |
| AKT-mediated inactivation of FOXO1A | R-HSA-211163 | 2.397048e-02 | 1.620 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 2.419592e-02 | 1.616 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 2.445811e-02 | 1.612 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 2.501141e-02 | 1.602 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 2.527729e-02 | 1.597 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 2.528223e-02 | 1.597 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 2.635980e-02 | 1.579 | 1 | 1 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 2.675824e-02 | 1.573 | 0 | 0 |
| CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde | R-HSA-442729 | 2.690517e-02 | 1.570 | 1 | 1 |
| Type I hemidesmosome assembly | R-HSA-446107 | 2.690517e-02 | 1.570 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence | R-HSA-9825895 | 2.690517e-02 | 1.570 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 2.690517e-02 | 1.570 | 0 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 2.717526e-02 | 1.566 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 2.761294e-02 | 1.559 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 2.833108e-02 | 1.548 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 2.849025e-02 | 1.545 | 0 | 0 |
| Late endosomal microautophagy | R-HSA-9615710 | 2.862417e-02 | 1.543 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 2.892347e-02 | 1.539 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 2.994849e-02 | 1.524 | 1 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 3.019814e-02 | 1.520 | 0 | 0 |
| NFE2L2 regulating tumorigenic genes | R-HSA-9818030 | 3.115349e-02 | 1.506 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 3.115349e-02 | 1.506 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 3.137829e-02 | 1.503 | 0 | 0 |
| G beta:gamma signalling through PLC beta | R-HSA-418217 | 3.172582e-02 | 1.499 | 0 | 0 |
| Presynaptic function of Kainate receptors | R-HSA-500657 | 3.172582e-02 | 1.499 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 3.235574e-02 | 1.490 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 3.235574e-02 | 1.490 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 3.235574e-02 | 1.490 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 3.247068e-02 | 1.489 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 3.287923e-02 | 1.483 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 3.339454e-02 | 1.476 | 1 | 1 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 3.339454e-02 | 1.476 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 3.405433e-02 | 1.468 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 3.405433e-02 | 1.468 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 3.499255e-02 | 1.456 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 3.515964e-02 | 1.454 | 1 | 0 |
| NFE2L2 regulating MDR associated enzymes | R-HSA-9818032 | 3.526213e-02 | 1.453 | 0 | 0 |
| AKT phosphorylates targets in the nucleus | R-HSA-198693 | 3.526213e-02 | 1.453 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 3.526213e-02 | 1.453 | 0 | 0 |
| HuR (ELAVL1) binds and stabilizes mRNA | R-HSA-450520 | 3.526213e-02 | 1.453 | 0 | 0 |
| Signaling by membrane-tethered fusions of PDGFRA or PDGFRB | R-HSA-9673768 | 3.537222e-02 | 1.451 | 0 | 0 |
| NrCAM interactions | R-HSA-447038 | 3.537222e-02 | 1.451 | 0 | 0 |
| Recognition of DNA damage by PCNA-containing replication complex | R-HSA-110314 | 3.563862e-02 | 1.448 | 0 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 3.563862e-02 | 1.448 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 3.568892e-02 | 1.447 | 0 | 0 |
| Manipulation of host energy metabolism | R-HSA-9636667 | 3.790808e-02 | 1.421 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 4.908727e-02 | 1.309 | 0 | 0 |
| 2-LTR circle formation | R-HSA-164843 | 4.495923e-02 | 1.347 | 0 | 0 |
| Formation of the canonical BAF (cBAF) complex | R-HSA-9933937 | 3.826242e-02 | 1.417 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 4.628524e-02 | 1.335 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 4.736796e-02 | 1.325 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 4.177832e-02 | 1.379 | 1 | 1 |
| Ca2+ pathway | R-HSA-4086398 | 4.072053e-02 | 1.390 | 0 | 0 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | R-HSA-110373 | 4.736796e-02 | 1.325 | 0 | 0 |
| Vasopressin regulates renal water homeostasis via Aquaporins | R-HSA-432040 | 4.740821e-02 | 1.324 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 4.829063e-02 | 1.316 | 0 | 0 |
| Breakdown of the nuclear lamina | R-HSA-352238 | 3.790808e-02 | 1.421 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 4.273119e-02 | 1.369 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 4.439174e-02 | 1.353 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 4.795137e-02 | 1.319 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 4.299563e-02 | 1.367 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 5.027729e-02 | 1.299 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 4.842502e-02 | 1.315 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 4.273119e-02 | 1.369 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 4.423219e-02 | 1.354 | 0 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 3.772008e-02 | 1.423 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 4.122583e-02 | 1.385 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 4.908727e-02 | 1.309 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 5.094842e-02 | 1.293 | 0 | 0 |
| Early Phase of HIV Life Cycle | R-HSA-162594 | 5.175572e-02 | 1.286 | 0 | 0 |
| NOTCH4 Intracellular Domain Regulates Transcription | R-HSA-9013695 | 5.175572e-02 | 1.286 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 5.225862e-02 | 1.282 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 5.281201e-02 | 1.277 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 5.303200e-02 | 1.275 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 5.379612e-02 | 1.269 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 5.448909e-02 | 1.264 | 0 | 0 |
| Glucagon signaling in metabolic regulation | R-HSA-163359 | 5.448909e-02 | 1.264 | 0 | 0 |
| PECAM1 interactions | R-HSA-210990 | 5.599704e-02 | 1.252 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 5.685199e-02 | 1.245 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 5.773524e-02 | 1.239 | 0 | 0 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 5.969489e-02 | 1.224 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | R-HSA-5696397 | 5.982154e-02 | 1.223 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 6.039934e-02 | 1.219 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 6.065578e-02 | 1.217 | 0 | 0 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | R-HSA-6814122 | 6.101739e-02 | 1.215 | 0 | 0 |
| Gap junction assembly | R-HSA-190861 | 6.101739e-02 | 1.215 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 6.311740e-02 | 1.200 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 6.311740e-02 | 1.200 | 0 | 0 |
| Localization of the PINCH-ILK-PARVIN complex to focal adhesions | R-HSA-446343 | 6.311740e-02 | 1.200 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 6.311740e-02 | 1.200 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 6.311740e-02 | 1.200 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 6.311740e-02 | 1.200 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 6.311740e-02 | 1.200 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 6.311740e-02 | 1.200 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 6.311740e-02 | 1.200 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 6.311740e-02 | 1.200 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 6.311740e-02 | 1.200 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 6.311740e-02 | 1.200 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 6.345826e-02 | 1.198 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 6.345826e-02 | 1.198 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 6.499193e-02 | 1.187 | 0 | 0 |
| Regulation of NFE2L2 gene expression | R-HSA-9818749 | 6.500478e-02 | 1.187 | 0 | 0 |
| Acetylcholine regulates insulin secretion | R-HSA-399997 | 6.511150e-02 | 1.186 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 6.517020e-02 | 1.186 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 6.549713e-02 | 1.184 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 6.612745e-02 | 1.180 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 6.712531e-02 | 1.173 | 0 | 0 |
| Integration of provirus | R-HSA-162592 | 6.835547e-02 | 1.165 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 6.949998e-02 | 1.158 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 6.953324e-02 | 1.158 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 7.269342e-02 | 1.139 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 7.269342e-02 | 1.139 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 7.442074e-02 | 1.128 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 7.548672e-02 | 1.122 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | R-HSA-5358565 | 7.591028e-02 | 1.120 | 0 | 0 |
| Uptake and function of anthrax toxins | R-HSA-5210891 | 7.591028e-02 | 1.120 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 7.750292e-02 | 1.111 | 0 | 0 |
| G beta:gamma signalling through PI3Kgamma | R-HSA-392451 | 7.807011e-02 | 1.108 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 7.807011e-02 | 1.108 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 7.910347e-02 | 1.102 | 0 | 0 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 8.199618e-02 | 1.086 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 8.199618e-02 | 1.086 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 8.199618e-02 | 1.086 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 8.199618e-02 | 1.086 | 0 | 0 |
| Regulation of FOXO transcriptional activity by acetylation | R-HSA-9617629 | 8.199618e-02 | 1.086 | 0 | 0 |
| TRIF-mediated programmed cell death | R-HSA-2562578 | 8.297127e-02 | 1.081 | 0 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 8.297127e-02 | 1.081 | 0 | 0 |
| CHL1 interactions | R-HSA-447041 | 8.297127e-02 | 1.081 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 8.561418e-02 | 1.067 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 8.724133e-02 | 1.059 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 8.761460e-02 | 1.057 | 0 | 0 |
| PCNA-Dependent Long Patch Base Excision Repair | R-HSA-5651801 | 8.761460e-02 | 1.057 | 0 | 0 |
| Mismatch Repair | R-HSA-5358508 | 8.761460e-02 | 1.057 | 0 | 0 |
| PKA activation | R-HSA-163615 | 8.761460e-02 | 1.057 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 8.761460e-02 | 1.057 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 8.824548e-02 | 1.054 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 8.824548e-02 | 1.054 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 8.971581e-02 | 1.047 | 0 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 8.974642e-02 | 1.047 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 9.113462e-02 | 1.040 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 9.175323e-02 | 1.037 | 0 | 0 |
| Loss of MECP2 binding ability to 5mC-DNA | R-HSA-9022538 | 9.242048e-02 | 1.034 | 0 | 0 |
| Signaling by cytosolic PDGFRA and PDGFRB fusion proteins | R-HSA-9673766 | 9.242048e-02 | 1.034 | 0 | 0 |
| MET activates PTPN11 | R-HSA-8865999 | 9.242048e-02 | 1.034 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 9.371777e-02 | 1.028 | 0 | 0 |
| ADORA2B mediated anti-inflammatory cytokines production | R-HSA-9660821 | 9.523138e-02 | 1.021 | 0 | 0 |
| Defective translocation of RB1 mutants to the nucleus | R-HSA-9661070 | 9.649617e-02 | 1.015 | 0 | 0 |
| APC truncation mutants are not K63 polyubiquitinated | R-HSA-5467333 | 9.649617e-02 | 1.015 | 0 | 0 |
| HDR through MMEJ (alt-NHEJ) | R-HSA-5685939 | 9.686509e-02 | 1.014 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 9.739223e-02 | 1.011 | 0 | 0 |
| HDMs demethylate histones | R-HSA-3214842 | 9.910834e-02 | 1.004 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 9.910834e-02 | 1.004 | 0 | 0 |
| Mechanical load activates signaling by PIEZO1 and integrins in osteocytes | R-HSA-9856532 | 1.002005e-01 | 0.999 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 1.006920e-01 | 0.997 | 0 | 0 |
| Formation of annular gap junctions | R-HSA-196025 | 1.028039e-01 | 0.988 | 0 | 0 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 1.028039e-01 | 0.988 | 0 | 0 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 1.028039e-01 | 0.988 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of myeloid cells | R-HSA-8939246 | 1.028039e-01 | 0.988 | 0 | 0 |
| ROBO receptors bind AKAP5 | R-HSA-9010642 | 1.028039e-01 | 0.988 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 1.053482e-01 | 0.977 | 0 | 0 |
| Synthesis of IP3 and IP4 in the cytosol | R-HSA-1855204 | 1.060300e-01 | 0.975 | 0 | 0 |
| SARS-CoV-1-mediated effects on programmed cell death | R-HSA-9692913 | 1.247935e-01 | 0.904 | 0 | 0 |
| MECP2 regulates transcription of genes involved in GABA signaling | R-HSA-9022927 | 1.247935e-01 | 0.904 | 0 | 0 |
| NFE2L2 regulating ER-stress associated genes | R-HSA-9818035 | 1.247935e-01 | 0.904 | 0 | 0 |
| IRS activation | R-HSA-74713 | 1.593720e-01 | 0.798 | 0 | 0 |
| NFE2L2 regulating inflammation associated genes | R-HSA-9818026 | 1.593720e-01 | 0.798 | 0 | 0 |
| Loss of Function of TGFBR1 in Cancer | R-HSA-3656534 | 1.593720e-01 | 0.798 | 0 | 0 |
| Activation of RAC1 downstream of NMDARs | R-HSA-9619229 | 1.243013e-01 | 0.906 | 0 | 0 |
| Gap junction degradation | R-HSA-190873 | 1.243013e-01 | 0.906 | 0 | 0 |
| Activation of Ca-permeable Kainate Receptor | R-HSA-451308 | 1.472521e-01 | 0.832 | 0 | 0 |
| Processive synthesis on the lagging strand | R-HSA-69183 | 1.300075e-01 | 0.886 | 0 | 0 |
| G beta:gamma signalling through BTK | R-HSA-8964315 | 1.300075e-01 | 0.886 | 0 | 0 |
| Transcription of E2F targets under negative control by DREAM complex | R-HSA-1362277 | 1.136365e-01 | 0.944 | 0 | 0 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 1.136365e-01 | 0.944 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 1.481163e-01 | 0.829 | 0 | 0 |
| Lagging Strand Synthesis | R-HSA-69186 | 1.278847e-01 | 0.893 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 1.586381e-01 | 0.800 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 1.166389e-01 | 0.933 | 0 | 0 |
| Dual Incision in GG-NER | R-HSA-5696400 | 1.277774e-01 | 0.894 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 1.496492e-01 | 0.825 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 1.515753e-01 | 0.819 | 0 | 0 |
| Adrenaline,noradrenaline inhibits insulin secretion | R-HSA-400042 | 1.106429e-01 | 0.956 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 1.394292e-01 | 0.856 | 0 | 0 |
| Muscarinic acetylcholine receptors | R-HSA-390648 | 1.593720e-01 | 0.798 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 1.472521e-01 | 0.832 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 1.472521e-01 | 0.832 | 0 | 0 |
| Formation of Incision Complex in GG-NER | R-HSA-5696395 | 1.100914e-01 | 0.958 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 1.358984e-01 | 0.867 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 12 | R-HSA-392170 | 1.278847e-01 | 0.893 | 0 | 0 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | R-HSA-381676 | 1.408477e-01 | 0.851 | 0 | 0 |
| PKA-mediated phosphorylation of CREB | R-HSA-111931 | 1.278847e-01 | 0.893 | 0 | 0 |
| Myogenesis | R-HSA-525793 | 1.106429e-01 | 0.956 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 1.106429e-01 | 0.956 | 0 | 0 |
| NADE modulates death signalling | R-HSA-205025 | 1.247935e-01 | 0.904 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 1.243013e-01 | 0.906 | 0 | 0 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | R-HSA-450385 | 1.300075e-01 | 0.886 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 1.490562e-01 | 0.827 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 1.519610e-01 | 0.818 | 0 | 0 |
| Regulation of insulin secretion | R-HSA-422356 | 1.496492e-01 | 0.825 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 1.308938e-01 | 0.883 | 0 | 0 |
| Caspase activation via extrinsic apoptotic signalling pathway | R-HSA-5357769 | 1.106429e-01 | 0.956 | 0 | 0 |
| PTK6 Regulates Proteins Involved in RNA Processing | R-HSA-8849468 | 1.593720e-01 | 0.798 | 0 | 0 |
| Zinc influx into cells by the SLC39 gene family | R-HSA-442380 | 1.243013e-01 | 0.906 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 1.349358e-01 | 0.870 | 1 | 1 |
| RNA Polymerase II Transcription | R-HSA-73857 | 1.082626e-01 | 0.966 | 1 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 1.270053e-01 | 0.896 | 1 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 1.200696e-01 | 0.921 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 1.228291e-01 | 0.911 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 1.312272e-01 | 0.882 | 0 | 0 |
| Basigin interactions | R-HSA-210991 | 1.278847e-01 | 0.893 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 1.510753e-01 | 0.821 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 1.125690e-01 | 0.949 | 0 | 0 |
| Maturation of spike protein | R-HSA-9683686 | 1.472521e-01 | 0.832 | 0 | 0 |
| Zinc transporters | R-HSA-435354 | 1.128949e-01 | 0.947 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 1.472521e-01 | 0.832 | 0 | 0 |
| CASP4 inflammasome assembly | R-HSA-9948001 | 1.472521e-01 | 0.832 | 0 | 0 |
| Butyrophilin (BTN) family interactions | R-HSA-8851680 | 1.243013e-01 | 0.906 | 0 | 0 |
| Metal ion SLC transporters | R-HSA-425410 | 1.213909e-01 | 0.916 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 1.066545e-01 | 0.972 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 1.472521e-01 | 0.832 | 0 | 0 |
| Caspase activation via Dependence Receptors in the absence of ligand | R-HSA-418889 | 1.243013e-01 | 0.906 | 0 | 0 |
| Assembly of Viral Components at the Budding Site | R-HSA-168316 | 1.593720e-01 | 0.798 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 1.630387e-01 | 0.788 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 1.630387e-01 | 0.788 | 0 | 0 |
| NOTCH3 Intracellular Domain Regulates Transcription | R-HSA-9013508 | 1.630387e-01 | 0.788 | 0 | 0 |
| Proteasome assembly | R-HSA-9907900 | 1.634812e-01 | 0.787 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 1.634812e-01 | 0.787 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 1.655313e-01 | 0.781 | 0 | 0 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | R-HSA-936964 | 1.671286e-01 | 0.777 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 1.671286e-01 | 0.777 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 1.681909e-01 | 0.774 | 0 | 0 |
| Aquaporin-mediated transport | R-HSA-445717 | 1.692258e-01 | 0.772 | 0 | 0 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | R-HSA-933543 | 1.714420e-01 | 0.766 | 0 | 0 |
| Ionotropic activity of kainate receptors | R-HSA-451306 | 1.714420e-01 | 0.766 | 0 | 0 |
| Suppression of apoptosis | R-HSA-9635465 | 1.714420e-01 | 0.766 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 1.750421e-01 | 0.757 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 1.753917e-01 | 0.756 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 1.821579e-01 | 0.740 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH6 | R-HSA-5632968 | 1.836860e-01 | 0.736 | 0 | 0 |
| RPIA deficiency: failed conversion of R5P to RU5P | R-HSA-5659996 | 1.836860e-01 | 0.736 | 0 | 0 |
| Defective SLC2A1 causes GLUT1 deficiency syndrome 1 (GLUT1DS1) | R-HSA-5619043 | 1.836860e-01 | 0.736 | 0 | 0 |
| RPIA deficiency: failed conversion of RU5P to R5P | R-HSA-6791461 | 1.836860e-01 | 0.736 | 0 | 0 |
| TICAM1 deficiency - HSE | R-HSA-5602566 | 1.836860e-01 | 0.736 | 0 | 0 |
| Formation of editosomes by ADAR proteins | R-HSA-77042 | 1.836860e-01 | 0.736 | 0 | 0 |
| Inhibition of PKR | R-HSA-169131 | 1.836860e-01 | 0.736 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 1.869471e-01 | 0.728 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | R-HSA-5358606 | 1.869471e-01 | 0.728 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 1 | R-HSA-418592 | 1.920577e-01 | 0.717 | 0 | 0 |
| Noncanonical activation of NOTCH3 | R-HSA-9017802 | 1.954295e-01 | 0.709 | 0 | 0 |
| CDC6 association with the ORC:origin complex | R-HSA-68689 | 1.954295e-01 | 0.709 | 0 | 0 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | R-HSA-9022537 | 1.954295e-01 | 0.709 | 0 | 0 |
| Negative feedback regulation of MAPK pathway | R-HSA-5674499 | 1.954295e-01 | 0.709 | 0 | 0 |
| PKA-mediated phosphorylation of key metabolic factors | R-HSA-163358 | 1.954295e-01 | 0.709 | 0 | 0 |
| Aryl hydrocarbon receptor signalling | R-HSA-8937144 | 1.954295e-01 | 0.709 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 1.954766e-01 | 0.709 | 0 | 0 |
| TICAM1-dependent activation of IRF3/IRF7 | R-HSA-9013973 | 1.966586e-01 | 0.706 | 0 | 0 |
| Signaling by GSK3beta mutants | R-HSA-5339716 | 1.966586e-01 | 0.706 | 0 | 0 |
| Sensing of DNA Double Strand Breaks | R-HSA-5693548 | 1.966586e-01 | 0.706 | 0 | 0 |
| POLB-Dependent Long Patch Base Excision Repair | R-HSA-110362 | 1.966586e-01 | 0.706 | 0 | 0 |
| Regulation of gene expression by Hypoxia-inducible Factor | R-HSA-1234158 | 1.966586e-01 | 0.706 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 1.970398e-01 | 0.705 | 1 | 1 |
| Generic Transcription Pathway | R-HSA-212436 | 2.040246e-01 | 0.690 | 1 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 2.046529e-01 | 0.689 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 2.059276e-01 | 0.686 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 2.073813e-01 | 0.683 | 0 | 0 |
| ARL13B-mediated ciliary trafficking of INPP5E | R-HSA-5624958 | 2.624664e-01 | 0.581 | 0 | 0 |
| IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR) | R-HSA-5603027 | 2.624664e-01 | 0.581 | 0 | 0 |
| TRAF3 deficiency - HSE | R-HSA-5602571 | 2.624664e-01 | 0.581 | 0 | 0 |
| Signaling by TCF7L2 mutants | R-HSA-5339700 | 2.624664e-01 | 0.581 | 0 | 0 |
| Defective GFPT1 causes CMSTA1 | R-HSA-4085023 | 2.624664e-01 | 0.581 | 0 | 0 |
| IKBKB deficiency causes SCID | R-HSA-5602636 | 2.624664e-01 | 0.581 | 0 | 0 |
| Defective SLC20A2 causes idiopathic basal ganglia calcification 1 (IBGC1) | R-HSA-5619111 | 2.624664e-01 | 0.581 | 0 | 0 |
| Defective SLC4A4 causes renal tubular acidosis, proximal, with ocular abnormalities and mental retardation (pRTA-OA) | R-HSA-5619054 | 2.624664e-01 | 0.581 | 0 | 0 |
| Defective SLC6A2 causes orthostatic intolerance (OI) | R-HSA-5619109 | 2.624664e-01 | 0.581 | 0 | 0 |
| Defective POMGNT1 causes MDDGA3, MDDGB3 and MDDGC3 | R-HSA-5083628 | 2.624664e-01 | 0.581 | 0 | 0 |
| Defective POMT1 causes MDDGA1, MDDGB1 and MDDGC1 | R-HSA-5083633 | 3.336482e-01 | 0.477 | 0 | 0 |
| Defective POMT2 causes MDDGA2, MDDGB2 and MDDGC2 | R-HSA-5083629 | 3.336482e-01 | 0.477 | 0 | 0 |
| TGFBR1 LBD Mutants in Cancer | R-HSA-3656535 | 3.336482e-01 | 0.477 | 0 | 0 |
| Defective SLC6A5 causes hyperekplexia 3 (HKPX3) | R-HSA-5619089 | 3.336482e-01 | 0.477 | 0 | 0 |
| Signaling by LTK in cancer | R-HSA-9842640 | 2.323590e-01 | 0.634 | 0 | 0 |
| RUNX3 regulates YAP1-mediated transcription | R-HSA-8951671 | 2.323590e-01 | 0.634 | 0 | 0 |
| Erythropoietin activates STAT5 | R-HSA-9027283 | 2.323590e-01 | 0.634 | 0 | 0 |
| Autointegration results in viral DNA circles | R-HSA-177539 | 2.323590e-01 | 0.634 | 0 | 0 |
| E2F-enabled inhibition of pre-replication complex formation | R-HSA-113507 | 2.323590e-01 | 0.634 | 0 | 0 |
| MECP2 regulates transcription factors | R-HSA-9022707 | 2.696570e-01 | 0.569 | 0 | 0 |
| RUNX3 regulates WNT signaling | R-HSA-8951430 | 2.696570e-01 | 0.569 | 0 | 0 |
| Binding of TCF/LEF:CTNNB1 to target gene promoters | R-HSA-4411364 | 2.696570e-01 | 0.569 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 2.696570e-01 | 0.569 | 0 | 0 |
| Disinhibition of SNARE formation | R-HSA-114516 | 2.696570e-01 | 0.569 | 0 | 0 |
| Axonal growth stimulation | R-HSA-209563 | 3.979638e-01 | 0.400 | 0 | 0 |
| Defective SLC7A7 causes lysinuric protein intolerance (LPI) | R-HSA-5660862 | 3.979638e-01 | 0.400 | 0 | 0 |
| NOTCH2 intracellular domain regulates transcription | R-HSA-2197563 | 2.226959e-01 | 0.652 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 2.226959e-01 | 0.652 | 0 | 0 |
| Polymerase switching | R-HSA-69091 | 2.226959e-01 | 0.652 | 0 | 0 |
| Leading Strand Synthesis | R-HSA-69109 | 2.226959e-01 | 0.652 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 2.226959e-01 | 0.652 | 0 | 0 |
| Signaling by CTNNB1 phospho-site mutants | R-HSA-4839743 | 2.226959e-01 | 0.652 | 0 | 0 |
| CTNNB1 S45 mutants aren't phosphorylated | R-HSA-5358751 | 2.226959e-01 | 0.652 | 0 | 0 |
| CTNNB1 S33 mutants aren't phosphorylated | R-HSA-5358747 | 2.226959e-01 | 0.652 | 0 | 0 |
| CTNNB1 T41 mutants aren't phosphorylated | R-HSA-5358752 | 2.226959e-01 | 0.652 | 0 | 0 |
| CTNNB1 S37 mutants aren't phosphorylated | R-HSA-5358749 | 2.226959e-01 | 0.652 | 0 | 0 |
| Regulation by c-FLIP | R-HSA-3371378 | 3.069086e-01 | 0.513 | 0 | 0 |
| Formyl peptide receptors bind formyl peptides and many other ligands | R-HSA-444473 | 3.069086e-01 | 0.513 | 0 | 0 |
| Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation | R-HSA-9828211 | 3.069086e-01 | 0.513 | 0 | 0 |
| Dimerization of procaspase-8 | R-HSA-69416 | 3.069086e-01 | 0.513 | 0 | 0 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | R-HSA-442720 | 2.493572e-01 | 0.603 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 2.074721e-01 | 0.683 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 2.074721e-01 | 0.683 | 0 | 0 |
| RNA Polymerase III Transcription Termination | R-HSA-73980 | 2.074721e-01 | 0.683 | 0 | 0 |
| PKA activation in glucagon signalling | R-HSA-164378 | 2.074721e-01 | 0.683 | 0 | 0 |
| Removal of the Flap Intermediate | R-HSA-69166 | 2.764569e-01 | 0.558 | 0 | 0 |
| Lipophagy | R-HSA-9613354 | 3.437757e-01 | 0.464 | 0 | 0 |
| Calcineurin activates NFAT | R-HSA-2025928 | 3.437757e-01 | 0.464 | 0 | 0 |
| CASP8 activity is inhibited | R-HSA-5218900 | 3.437757e-01 | 0.464 | 0 | 0 |
| Adenylate cyclase inhibitory pathway | R-HSA-170670 | 3.038225e-01 | 0.517 | 0 | 0 |
| Beta-catenin phosphorylation cascade | R-HSA-196299 | 3.038225e-01 | 0.517 | 0 | 0 |
| TICAM1, RIP1-mediated IKK complex recruitment | R-HSA-168927 | 3.038225e-01 | 0.517 | 0 | 0 |
| MECP2 regulates transcription of neuronal ligands | R-HSA-9022702 | 3.799858e-01 | 0.420 | 0 | 0 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | R-HSA-9014325 | 3.799858e-01 | 0.420 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 3.799858e-01 | 0.420 | 0 | 0 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | R-HSA-9027277 | 3.799858e-01 | 0.420 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 2.461827e-01 | 0.609 | 0 | 0 |
| Caspase activation via Death Receptors in the presence of ligand | R-HSA-140534 | 3.312953e-01 | 0.480 | 0 | 0 |
| Translesion synthesis by POLI | R-HSA-5656121 | 3.312953e-01 | 0.480 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 3.312953e-01 | 0.480 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | R-HSA-76066 | 2.946388e-01 | 0.531 | 0 | 0 |
| Developmental Lineage of Mammary Gland Alveolar Cells | R-HSA-9927426 | 2.402317e-01 | 0.619 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 2.842227e-01 | 0.546 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 3.172127e-01 | 0.499 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 3.172127e-01 | 0.499 | 0 | 0 |
| Translesion synthesis by POLK | R-HSA-5655862 | 3.587304e-01 | 0.445 | 0 | 0 |
| Antigen processing: Ub, ATP-independent proteasomal degradation | R-HSA-9912633 | 3.587304e-01 | 0.445 | 0 | 0 |
| Activation of GABAB receptors | R-HSA-991365 | 2.484402e-01 | 0.605 | 0 | 0 |
| RNA Polymerase III Abortive And Retractive Initiation | R-HSA-749476 | 2.737666e-01 | 0.563 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 2.909366e-01 | 0.536 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 3.859975e-01 | 0.413 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 3.859975e-01 | 0.413 | 0 | 0 |
| Removal of the Flap Intermediate from the C-strand | R-HSA-174437 | 3.859975e-01 | 0.413 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 2.680269e-01 | 0.572 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 3.626684e-01 | 0.440 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 3.626684e-01 | 0.440 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 2.947523e-01 | 0.531 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 3.430076e-01 | 0.465 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 2.823171e-01 | 0.549 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 2.823171e-01 | 0.549 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 2.823171e-01 | 0.549 | 0 | 0 |
| FOXO-mediated transcription of cell death genes | R-HSA-9614657 | 4.129804e-01 | 0.384 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 3.106050e-01 | 0.508 | 0 | 0 |
| Activation of G protein gated Potassium channels | R-HSA-1296041 | 3.853880e-01 | 0.414 | 0 | 0 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | R-HSA-997272 | 3.853880e-01 | 0.414 | 0 | 0 |
| G protein gated Potassium channels | R-HSA-1296059 | 3.853880e-01 | 0.414 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 2.617345e-01 | 0.582 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 3.435513e-01 | 0.464 | 0 | 0 |
| Carboxyterminal post-translational modifications of tubulin | R-HSA-8955332 | 3.266128e-01 | 0.486 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 3.114512e-01 | 0.507 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 2.177845e-01 | 0.662 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 3.262458e-01 | 0.486 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 3.791393e-01 | 0.421 | 0 | 0 |
| HIV Transcription Initiation | R-HSA-167161 | 3.791393e-01 | 0.421 | 0 | 0 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 3.791393e-01 | 0.421 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 3.561669e-01 | 0.448 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 3.367479e-01 | 0.473 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 4.147744e-01 | 0.382 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 4.079045e-01 | 0.389 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 3.244835e-01 | 0.489 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 3.288233e-01 | 0.483 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 2.080517e-01 | 0.682 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 2.725382e-01 | 0.565 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 3.653866e-01 | 0.437 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 3.262458e-01 | 0.486 | 0 | 0 |
| GABA B receptor activation | R-HSA-977444 | 2.484402e-01 | 0.605 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 3.589694e-01 | 0.445 | 0 | 0 |
| RNA Polymerase III Transcription | R-HSA-74158 | 2.737666e-01 | 0.563 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 2.096264e-01 | 0.679 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 2.189171e-01 | 0.660 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 2.823171e-01 | 0.549 | 0 | 0 |
| G-protein activation | R-HSA-202040 | 2.722836e-01 | 0.565 | 0 | 0 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 3.799858e-01 | 0.420 | 0 | 0 |
| Hh mutants are degraded by ERAD | R-HSA-5362768 | 3.613206e-01 | 0.442 | 0 | 0 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 3.172127e-01 | 0.499 | 0 | 0 |
| Translesion synthesis by REV1 | R-HSA-110312 | 3.038225e-01 | 0.517 | 0 | 0 |
| Regulation of IFNA/IFNB signaling | R-HSA-912694 | 3.172127e-01 | 0.499 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | R-HSA-76061 | 3.172127e-01 | 0.499 | 0 | 0 |
| Nuclear RNA decay | R-HSA-9930044 | 3.628307e-01 | 0.440 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 3.435513e-01 | 0.464 | 0 | 0 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 2.461827e-01 | 0.609 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 2.850952e-01 | 0.545 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 2.850952e-01 | 0.545 | 0 | 0 |
| Regulation of IFNG signaling | R-HSA-877312 | 2.226959e-01 | 0.652 | 0 | 0 |
| Membrane binding and targetting of GAG proteins | R-HSA-174490 | 2.493572e-01 | 0.603 | 0 | 0 |
| Microbial factors inhibit CASP4 activity | R-HSA-9956593 | 2.493572e-01 | 0.603 | 0 | 0 |
| RIP-mediated NFkB activation via ZBP1 | R-HSA-1810476 | 3.038225e-01 | 0.517 | 0 | 0 |
| The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex | R-HSA-9931521 | 3.587304e-01 | 0.445 | 0 | 0 |
| Thromboxane signalling through TP receptor | R-HSA-428930 | 3.626684e-01 | 0.440 | 0 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 3.859975e-01 | 0.413 | 0 | 0 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 4.147744e-01 | 0.382 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 3.265956e-01 | 0.486 | 0 | 0 |
| Signal amplification | R-HSA-392518 | 2.402317e-01 | 0.619 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 3.720975e-01 | 0.429 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 3.826771e-01 | 0.417 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 2.074721e-01 | 0.683 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 2.226959e-01 | 0.652 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 2.226959e-01 | 0.652 | 0 | 0 |
| Thrombin signalling through proteinase activated receptors (PARs) | R-HSA-456926 | 3.036469e-01 | 0.518 | 0 | 0 |
| FasL/ CD95L signaling | R-HSA-75157 | 3.979638e-01 | 0.400 | 0 | 0 |
| Prostacyclin signalling through prostacyclin receptor | R-HSA-392851 | 2.286031e-01 | 0.641 | 0 | 0 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | R-HSA-174495 | 2.764569e-01 | 0.558 | 0 | 0 |
| KSRP (KHSRP) binds and destabilizes mRNA | R-HSA-450604 | 3.312953e-01 | 0.480 | 0 | 0 |
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 2.568508e-01 | 0.590 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 2.539539e-01 | 0.595 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 2.725382e-01 | 0.565 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 2.080517e-01 | 0.682 | 0 | 0 |
| Neurofascin interactions | R-HSA-447043 | 2.323590e-01 | 0.634 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 3.791393e-01 | 0.421 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 2.132774e-01 | 0.671 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 3.628307e-01 | 0.440 | 0 | 0 |
| Platelet sensitization by LDL | R-HSA-432142 | 2.074721e-01 | 0.683 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | R-HSA-6804114 | 3.587304e-01 | 0.445 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 3.258705e-01 | 0.487 | 0 | 0 |
| eNOS activation | R-HSA-203615 | 4.024956e-01 | 0.395 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 3.430076e-01 | 0.465 | 0 | 0 |
| Transport of connexins along the secretory pathway | R-HSA-190827 | 2.624664e-01 | 0.581 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH2 | R-HSA-5632928 | 2.624664e-01 | 0.581 | 0 | 0 |
| mRNA Editing: A to I Conversion | R-HSA-75064 | 3.336482e-01 | 0.477 | 0 | 0 |
| C6 deamination of adenosine | R-HSA-75102 | 3.336482e-01 | 0.477 | 0 | 0 |
| MET interacts with TNS proteins | R-HSA-8875513 | 3.979638e-01 | 0.400 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 2.226959e-01 | 0.652 | 0 | 0 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | R-HSA-450513 | 3.038225e-01 | 0.517 | 0 | 0 |
| Defective RIPK1-mediated regulated necrosis | R-HSA-9693928 | 3.799858e-01 | 0.420 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 2.335229e-01 | 0.632 | 0 | 0 |
| STAT5 activation downstream of FLT3 ITD mutants | R-HSA-9702518 | 3.587304e-01 | 0.445 | 0 | 0 |
| Modulation of host responses by IFN-stimulated genes | R-HSA-9909505 | 3.859975e-01 | 0.413 | 0 | 0 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | R-HSA-211733 | 3.232611e-01 | 0.490 | 0 | 0 |
| Synaptic adhesion-like molecules | R-HSA-8849932 | 4.129804e-01 | 0.384 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 3.427445e-01 | 0.465 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 3.613206e-01 | 0.442 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 3.472841e-01 | 0.459 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 3.915785e-01 | 0.407 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 2.076746e-01 | 0.683 | 1 | 0 |
| Neuronal System | R-HSA-112316 | 3.851744e-01 | 0.414 | 1 | 0 |
| Interleukin-6 signaling | R-HSA-1059683 | 2.493572e-01 | 0.603 | 0 | 0 |
| Protein methylation | R-HSA-8876725 | 3.038225e-01 | 0.517 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 3.106050e-01 | 0.508 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 3.868148e-01 | 0.412 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex in Cancer | R-HSA-3304351 | 2.323590e-01 | 0.634 | 0 | 0 |
| Regulation of CDH11 gene transcription | R-HSA-9762293 | 3.437757e-01 | 0.464 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 3.799858e-01 | 0.420 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 3.853880e-01 | 0.414 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 3.375585e-01 | 0.472 | 0 | 0 |
| BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members | R-HSA-111453 | 3.069086e-01 | 0.513 | 0 | 0 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | R-HSA-9013700 | 3.437757e-01 | 0.464 | 0 | 0 |
| Protein hydroxylation | R-HSA-9629569 | 2.502398e-01 | 0.602 | 0 | 0 |
| Interleukin-27 signaling | R-HSA-9020956 | 3.799858e-01 | 0.420 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 2.335229e-01 | 0.632 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 2.335229e-01 | 0.632 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 2.680269e-01 | 0.572 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 4.120294e-01 | 0.385 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 2.708311e-01 | 0.567 | 0 | 0 |
| Immune System | R-HSA-168256 | 2.333331e-01 | 0.632 | 1 | 0 |
| Macroautophagy | R-HSA-1632852 | 2.595466e-01 | 0.586 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 2.737666e-01 | 0.563 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 2.947523e-01 | 0.531 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 2.947523e-01 | 0.531 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 3.273905e-01 | 0.485 | 1 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 2.142900e-01 | 0.669 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 2.529915e-01 | 0.597 | 0 | 0 |
| Ion transport by P-type ATPases | R-HSA-936837 | 3.113714e-01 | 0.507 | 1 | 1 |
| Signaling by KIT in disease | R-HSA-9669938 | 3.172127e-01 | 0.499 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 3.718640e-01 | 0.430 | 0 | 0 |
| Oligomerization of connexins into connexons | R-HSA-190704 | 2.624664e-01 | 0.581 | 0 | 0 |
| Integration of viral DNA into host genomic DNA | R-HSA-175567 | 2.323590e-01 | 0.634 | 0 | 0 |
| Diseases of Mismatch Repair (MMR) | R-HSA-5423599 | 3.979638e-01 | 0.400 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 3.437757e-01 | 0.464 | 0 | 0 |
| Metalloprotease DUBs | R-HSA-5689901 | 2.276884e-01 | 0.643 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 3.312953e-01 | 0.480 | 0 | 0 |
| Regulation of ornithine decarboxylase (ODC) | R-HSA-350562 | 3.430076e-01 | 0.465 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 3.435513e-01 | 0.464 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 2.666936e-01 | 0.574 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 2.636384e-01 | 0.579 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 3.541226e-01 | 0.451 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 3.760615e-01 | 0.425 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 2.502398e-01 | 0.602 | 0 | 0 |
| Calnexin/calreticulin cycle | R-HSA-901042 | 2.402317e-01 | 0.619 | 0 | 0 |
| Signal regulatory protein family interactions | R-HSA-391160 | 2.764569e-01 | 0.558 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 2.132774e-01 | 0.671 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 2.346561e-01 | 0.630 | 0 | 0 |
| Histamine receptors | R-HSA-390650 | 3.979638e-01 | 0.400 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 3.172127e-01 | 0.499 | 0 | 0 |
| Cross-presentation of soluble exogenous antigens (endosomes) | R-HSA-1236978 | 3.258705e-01 | 0.487 | 0 | 0 |
| GSK3B-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929356 | 3.258705e-01 | 0.487 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 2.445657e-01 | 0.612 | 0 | 0 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | R-HSA-9619665 | 3.826771e-01 | 0.417 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 3.613206e-01 | 0.442 | 0 | 0 |
| Activation, myristolyation of BID and translocation to mitochondria | R-HSA-75108 | 3.336482e-01 | 0.477 | 0 | 0 |
| Displacement of DNA glycosylase by APEX1 | R-HSA-110357 | 2.696570e-01 | 0.569 | 0 | 0 |
| Role of ABL in ROBO-SLIT signaling | R-HSA-428890 | 2.696570e-01 | 0.569 | 0 | 0 |
| The NLRP1 inflammasome | R-HSA-844455 | 3.979638e-01 | 0.400 | 0 | 0 |
| Interleukin-18 signaling | R-HSA-9012546 | 3.069086e-01 | 0.513 | 0 | 0 |
| Sodium/Proton exchangers | R-HSA-425986 | 3.069086e-01 | 0.513 | 0 | 0 |
| Assembly and release of respiratory syncytial virus (RSV) virions | R-HSA-9820962 | 3.799858e-01 | 0.420 | 0 | 0 |
| Glucagon-type ligand receptors | R-HSA-420092 | 2.842227e-01 | 0.546 | 0 | 0 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | R-HSA-9725554 | 3.258705e-01 | 0.487 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 2.096264e-01 | 0.679 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 2.823171e-01 | 0.549 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 4.111045e-01 | 0.386 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 3.435513e-01 | 0.464 | 0 | 0 |
| ATF6B (ATF6-beta) activates chaperones | R-HSA-8874177 | 3.336482e-01 | 0.477 | 0 | 0 |
| RUNX3 Regulates Immune Response and Cell Migration | R-HSA-8949275 | 2.696570e-01 | 0.569 | 0 | 0 |
| Uptake and function of diphtheria toxin | R-HSA-5336415 | 2.696570e-01 | 0.569 | 0 | 0 |
| Respiratory syncytial virus genome replication | R-HSA-9834752 | 3.437757e-01 | 0.464 | 0 | 0 |
| BBSome-mediated cargo-targeting to cilium | R-HSA-5620922 | 2.502398e-01 | 0.602 | 0 | 0 |
| Vpu mediated degradation of CD4 | R-HSA-180534 | 3.826771e-01 | 0.417 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 4.024956e-01 | 0.395 | 0 | 0 |
| Ubiquitin-dependent degradation of Cyclin D | R-HSA-75815 | 4.024956e-01 | 0.395 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 3.399171e-01 | 0.469 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 2.348619e-01 | 0.629 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 2.502398e-01 | 0.602 | 0 | 0 |
| Non-canonical inflammasome activation | R-HSA-9686114 | 2.764569e-01 | 0.558 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 3.129290e-01 | 0.505 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 4.153224e-01 | 0.382 | 0 | 0 |
| RHOBTB3 ATPase cycle | R-HSA-9706019 | 4.153224e-01 | 0.382 | 0 | 0 |
| Signaling by APC mutants | R-HSA-4839744 | 4.153224e-01 | 0.382 | 0 | 0 |
| APC truncation mutants have impaired AXIN binding | R-HSA-5467337 | 4.153224e-01 | 0.382 | 0 | 0 |
| Truncations of AMER1 destabilize the destruction complex | R-HSA-5467348 | 4.153224e-01 | 0.382 | 0 | 0 |
| AXIN missense mutants destabilize the destruction complex | R-HSA-5467340 | 4.153224e-01 | 0.382 | 0 | 0 |
| Bicarbonate transporters | R-HSA-425381 | 4.153224e-01 | 0.382 | 0 | 0 |
| CD163 mediating an anti-inflammatory response | R-HSA-9662834 | 4.153224e-01 | 0.382 | 0 | 0 |
| RUNX2 regulates genes involved in cell migration | R-HSA-8941332 | 4.153224e-01 | 0.382 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 4.168345e-01 | 0.380 | 0 | 0 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | R-HSA-8854050 | 4.222380e-01 | 0.374 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 4.222380e-01 | 0.374 | 0 | 0 |
| Regulation of Apoptosis | R-HSA-169911 | 4.222380e-01 | 0.374 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 4.239238e-01 | 0.373 | 0 | 0 |
| Processive synthesis on the C-strand of the telomere | R-HSA-174414 | 4.304449e-01 | 0.366 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 4.304449e-01 | 0.366 | 0 | 0 |
| RNA Polymerase I Transcription Termination | R-HSA-73863 | 4.304449e-01 | 0.366 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 4.317937e-01 | 0.365 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 4.325195e-01 | 0.364 | 0 | 0 |
| IKK complex recruitment mediated by RIP1 | R-HSA-937041 | 4.395764e-01 | 0.357 | 0 | 0 |
| Translesion Synthesis by POLH | R-HSA-110320 | 4.395764e-01 | 0.357 | 0 | 0 |
| E2F mediated regulation of DNA replication | R-HSA-113510 | 4.395764e-01 | 0.357 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 4.395764e-01 | 0.357 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9694631 | 4.395764e-01 | 0.357 | 0 | 0 |
| Vif-mediated degradation of APOBEC3G | R-HSA-180585 | 4.418588e-01 | 0.355 | 0 | 0 |
| NFE2L2 regulates pentose phosphate pathway genes | R-HSA-9818028 | 4.496170e-01 | 0.347 | 0 | 0 |
| Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 | R-HSA-9824878 | 4.496170e-01 | 0.347 | 0 | 0 |
| Phosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promoters | R-HSA-9931512 | 4.496170e-01 | 0.347 | 0 | 0 |
| Signaling by AXIN mutants | R-HSA-4839735 | 4.496170e-01 | 0.347 | 0 | 0 |
| Signaling by AMER1 mutants | R-HSA-4839748 | 4.496170e-01 | 0.347 | 0 | 0 |
| APOBEC3G mediated resistance to HIV-1 infection | R-HSA-180689 | 4.496170e-01 | 0.347 | 0 | 0 |
| Reduction of cytosolic Ca++ levels | R-HSA-418359 | 4.496170e-01 | 0.347 | 0 | 0 |
| Sodium/Calcium exchangers | R-HSA-425561 | 4.496170e-01 | 0.347 | 0 | 0 |
| Activation of RAC1 | R-HSA-428540 | 4.496170e-01 | 0.347 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 4.501713e-01 | 0.347 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 4.501713e-01 | 0.347 | 0 | 0 |
| Fanconi Anemia Pathway | R-HSA-6783310 | 4.501713e-01 | 0.347 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 4.501713e-01 | 0.347 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 4.501713e-01 | 0.347 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 4.526526e-01 | 0.344 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 4.560751e-01 | 0.341 | 0 | 0 |
| HCN channels | R-HSA-1296061 | 4.560751e-01 | 0.341 | 0 | 0 |
| PLCG1 events in ERBB2 signaling | R-HSA-1251932 | 4.560751e-01 | 0.341 | 0 | 0 |
| RUNX3 regulates BCL2L11 (BIM) transcription | R-HSA-8952158 | 4.560751e-01 | 0.341 | 0 | 0 |
| Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes | R-HSA-69200 | 4.560751e-01 | 0.341 | 0 | 0 |
| GRB7 events in ERBB2 signaling | R-HSA-1306955 | 4.560751e-01 | 0.341 | 0 | 0 |
| TGFBR1 KD Mutants in Cancer | R-HSA-3656532 | 4.560751e-01 | 0.341 | 0 | 0 |
| Defective LFNG causes SCDO3 | R-HSA-5083630 | 4.560751e-01 | 0.341 | 0 | 0 |
| p75NTR negatively regulates cell cycle via SC1 | R-HSA-193670 | 4.560751e-01 | 0.341 | 0 | 0 |
| Dopamine receptors | R-HSA-390651 | 4.560751e-01 | 0.341 | 0 | 0 |
| Regulation of HMOX1 expression and activity | R-HSA-9707587 | 4.560751e-01 | 0.341 | 0 | 0 |
| SARS-CoV-2 targets PDZ proteins in cell-cell junction | R-HSA-9705677 | 4.560751e-01 | 0.341 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 4.592419e-01 | 0.338 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 4.613155e-01 | 0.336 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 4.613155e-01 | 0.336 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 4.613155e-01 | 0.336 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 4.618997e-01 | 0.335 | 0 | 0 |
| VxPx cargo-targeting to cilium | R-HSA-5620916 | 4.656961e-01 | 0.332 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 4.656961e-01 | 0.332 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 4.676985e-01 | 0.330 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 4.676985e-01 | 0.330 | 0 | 0 |
| Inactivation, recovery and regulation of the phototransduction cascade | R-HSA-2514859 | 4.676985e-01 | 0.330 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 4.727168e-01 | 0.325 | 0 | 0 |
| Termination of translesion DNA synthesis | R-HSA-5656169 | 4.745694e-01 | 0.324 | 0 | 0 |
| DARPP-32 events | R-HSA-180024 | 4.745694e-01 | 0.324 | 0 | 0 |
| Regulation of gene expression in beta cells | R-HSA-210745 | 4.745694e-01 | 0.324 | 0 | 0 |
| Metabolism of nitric oxide: NOS3 activation and regulation | R-HSA-202131 | 4.805686e-01 | 0.318 | 0 | 0 |
| Repression of WNT target genes | R-HSA-4641265 | 4.827415e-01 | 0.316 | 0 | 0 |
| Scavenging by Class F Receptors | R-HSA-3000484 | 4.827415e-01 | 0.316 | 0 | 0 |
| RUNX3 regulates p14-ARF | R-HSA-8951936 | 4.827415e-01 | 0.316 | 0 | 0 |
| Serotonin clearance from the synaptic cleft | R-HSA-380615 | 4.827415e-01 | 0.316 | 0 | 0 |
| Interleukin-35 Signalling | R-HSA-8984722 | 4.827415e-01 | 0.316 | 0 | 0 |
| Advanced glycosylation endproduct receptor signaling | R-HSA-879415 | 4.827415e-01 | 0.316 | 0 | 0 |
| p75NTR recruits signalling complexes | R-HSA-209543 | 4.827415e-01 | 0.316 | 0 | 0 |
| OAS antiviral response | R-HSA-8983711 | 4.827415e-01 | 0.316 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 4.833584e-01 | 0.316 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 4.850714e-01 | 0.314 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 4.860332e-01 | 0.313 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 4.886717e-01 | 0.311 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 4.912623e-01 | 0.309 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 4.912623e-01 | 0.309 | 0 | 0 |
| APC-Cdc20 mediated degradation of Nek2A | R-HSA-179409 | 4.912623e-01 | 0.309 | 0 | 0 |
| TNFR1-induced proapoptotic signaling | R-HSA-5357786 | 4.912623e-01 | 0.309 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 4.916744e-01 | 0.308 | 0 | 0 |
| RNA Polymerase III Transcription Initiation | R-HSA-76046 | 4.961444e-01 | 0.304 | 0 | 0 |
| Interleukin-37 signaling | R-HSA-9008059 | 4.961444e-01 | 0.304 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 4.988966e-01 | 0.302 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 5.063911e-01 | 0.296 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 5.080782e-01 | 0.294 | 0 | 0 |
| NFE2L2 regulating TCA cycle genes | R-HSA-9818025 | 5.085804e-01 | 0.294 | 0 | 0 |
| SMAD2/3 Phosphorylation Motif Mutants in Cancer | R-HSA-3304356 | 5.085804e-01 | 0.294 | 0 | 0 |
| Resolution of AP sites via the single-nucleotide replacement pathway | R-HSA-110381 | 5.085804e-01 | 0.294 | 0 | 0 |
| IRF3 mediated activation of type 1 IFN | R-HSA-1606341 | 5.085804e-01 | 0.294 | 0 | 0 |
| Post-transcriptional silencing by small RNAs | R-HSA-426496 | 5.085804e-01 | 0.294 | 0 | 0 |
| Reelin signalling pathway | R-HSA-8866376 | 5.085804e-01 | 0.294 | 0 | 0 |
| Biosynthesis of DPAn-3-derived 13-series resolvins | R-HSA-9026403 | 5.085804e-01 | 0.294 | 0 | 0 |
| Nectin/Necl trans heterodimerization | R-HSA-420597 | 5.085804e-01 | 0.294 | 0 | 0 |
| RUNX2 regulates chondrocyte maturation | R-HSA-8941284 | 5.085804e-01 | 0.294 | 0 | 0 |
| Co-inhibition by BTLA | R-HSA-9927353 | 5.085804e-01 | 0.294 | 0 | 0 |
| Zinc efflux and compartmentalization by the SLC30 family | R-HSA-435368 | 5.085804e-01 | 0.294 | 0 | 0 |
| Adenylate cyclase activating pathway | R-HSA-170660 | 5.146023e-01 | 0.289 | 0 | 0 |
| Formation of axial mesoderm | R-HSA-9796292 | 5.146023e-01 | 0.289 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 5.146023e-01 | 0.289 | 0 | 0 |
| Platelet Adhesion to exposed collagen | R-HSA-75892 | 5.146023e-01 | 0.289 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9683610 | 5.146023e-01 | 0.289 | 0 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 5.146023e-01 | 0.289 | 0 | 0 |
| Regulation of TP53 Activity through Association with Co-factors | R-HSA-6804759 | 5.146023e-01 | 0.289 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 5.162097e-01 | 0.287 | 0 | 0 |
| Assembly Of The HIV Virion | R-HSA-175474 | 5.162097e-01 | 0.287 | 0 | 0 |
| Molecules associated with elastic fibres | R-HSA-2129379 | 5.173324e-01 | 0.286 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 5.173324e-01 | 0.286 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 5.183213e-01 | 0.285 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 5.183213e-01 | 0.285 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 5.192455e-01 | 0.285 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 5.192455e-01 | 0.285 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 5.192455e-01 | 0.285 | 0 | 0 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | R-HSA-532668 | 5.192455e-01 | 0.285 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 5.353633e-01 | 0.271 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 5.354369e-01 | 0.271 | 0 | 0 |
| GABA receptor activation | R-HSA-977443 | 5.355847e-01 | 0.271 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 5.357986e-01 | 0.271 | 0 | 0 |
| Purine ribonucleoside monophosphate biosynthesis | R-HSA-73817 | 5.367572e-01 | 0.270 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 5.367572e-01 | 0.270 | 0 | 0 |
| Signaling by WNT in cancer | R-HSA-4791275 | 5.380933e-01 | 0.269 | 0 | 0 |
| Inwardly rectifying K+ channels | R-HSA-1296065 | 5.380933e-01 | 0.269 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 5.404838e-01 | 0.267 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 5.404838e-01 | 0.267 | 0 | 0 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | R-HSA-2032785 | 5.451349e-01 | 0.263 | 0 | 0 |
| ERBB2 Activates PTK6 Signaling | R-HSA-8847993 | 5.451349e-01 | 0.263 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | R-HSA-975163 | 5.451349e-01 | 0.263 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 5.451349e-01 | 0.263 | 0 | 0 |
| NRIF signals cell death from the nucleus | R-HSA-205043 | 5.451349e-01 | 0.263 | 0 | 0 |
| HDL assembly | R-HSA-8963896 | 5.451349e-01 | 0.263 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 5.481770e-01 | 0.261 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 5.508407e-01 | 0.259 | 0 | 0 |
| The phototransduction cascade | R-HSA-2514856 | 5.524950e-01 | 0.258 | 0 | 0 |
| Telomere C-strand (Lagging Strand) Synthesis | R-HSA-174417 | 5.548620e-01 | 0.256 | 0 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 5.548620e-01 | 0.256 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9683701 | 5.548620e-01 | 0.256 | 0 | 0 |
| Signaling by Overexpressed Wild-Type EGFR in Cancer | R-HSA-5638302 | 5.560201e-01 | 0.255 | 0 | 0 |
| Inhibition of Signaling by Overexpressed EGFR | R-HSA-5638303 | 5.560201e-01 | 0.255 | 0 | 0 |
| Toxicity of botulinum toxin type E (botE) | R-HSA-5250992 | 5.560201e-01 | 0.255 | 0 | 0 |
| TRAIL signaling | R-HSA-75158 | 5.560201e-01 | 0.255 | 0 | 0 |
| Pentose phosphate pathway disease | R-HSA-6791465 | 5.560201e-01 | 0.255 | 0 | 0 |
| IkBA variant leads to EDA-ID | R-HSA-5603029 | 5.560201e-01 | 0.255 | 0 | 0 |
| Cam-PDE 1 activation | R-HSA-111957 | 5.560201e-01 | 0.255 | 0 | 0 |
| Loss of Function of SMAD2/3 in Cancer | R-HSA-3304349 | 5.560201e-01 | 0.255 | 0 | 0 |
| Signalling to p38 via RIT and RIN | R-HSA-187706 | 5.560201e-01 | 0.255 | 0 | 0 |
| Intestinal hexose absorption | R-HSA-8981373 | 5.560201e-01 | 0.255 | 0 | 0 |
| Acetylcholine inhibits contraction of outer hair cells | R-HSA-9667769 | 5.560201e-01 | 0.255 | 0 | 0 |
| Signaling by MST1 | R-HSA-8852405 | 5.560201e-01 | 0.255 | 0 | 0 |
| Sodium-coupled phosphate cotransporters | R-HSA-427652 | 5.560201e-01 | 0.255 | 0 | 0 |
| SLC15A4:TASL-dependent IRF5 activation | R-HSA-9860276 | 5.560201e-01 | 0.255 | 0 | 0 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | R-HSA-5693568 | 5.583923e-01 | 0.253 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 5.583923e-01 | 0.253 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 5.583923e-01 | 0.253 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 5.658768e-01 | 0.247 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 5.687195e-01 | 0.245 | 0 | 0 |
| Cytosolic tRNA aminoacylation | R-HSA-379716 | 5.726113e-01 | 0.242 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 5.726113e-01 | 0.242 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 5.742987e-01 | 0.241 | 0 | 0 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | R-HSA-937072 | 5.742987e-01 | 0.241 | 0 | 0 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 5.742987e-01 | 0.241 | 0 | 0 |
| RNA Polymerase III Chain Elongation | R-HSA-73780 | 5.742987e-01 | 0.241 | 0 | 0 |
| ERBB2 Regulates Cell Motility | R-HSA-6785631 | 5.742987e-01 | 0.241 | 0 | 0 |
| p75NTR signals via NF-kB | R-HSA-193639 | 5.742987e-01 | 0.241 | 0 | 0 |
| Signaling by PDGFRA extracellular domain mutants | R-HSA-9673770 | 5.742987e-01 | 0.241 | 0 | 0 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | R-HSA-9673767 | 5.742987e-01 | 0.241 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 5.742987e-01 | 0.241 | 0 | 0 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | R-HSA-9818027 | 5.781993e-01 | 0.238 | 0 | 0 |
| Resolution of D-Loop Structures | R-HSA-5693537 | 5.781993e-01 | 0.238 | 0 | 0 |
| Effects of PIP2 hydrolysis | R-HSA-114508 | 5.781993e-01 | 0.238 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 5.806779e-01 | 0.236 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 5.806779e-01 | 0.236 | 0 | 0 |
| Signaling by FLT3 ITD and TKD mutants | R-HSA-9703648 | 5.868438e-01 | 0.231 | 0 | 0 |
| Interleukin-6 family signaling | R-HSA-6783589 | 5.868438e-01 | 0.231 | 0 | 0 |
| Plasma lipoprotein assembly | R-HSA-8963898 | 5.868438e-01 | 0.231 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 5.899837e-01 | 0.229 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 5.912873e-01 | 0.228 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 5.952298e-01 | 0.225 | 0 | 0 |
| Signaling by NOTCH2 | R-HSA-1980145 | 5.974890e-01 | 0.224 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 5.974890e-01 | 0.224 | 0 | 0 |
| PTK6 promotes HIF1A stabilization | R-HSA-8857538 | 5.988827e-01 | 0.223 | 0 | 0 |
| Small interfering RNA (siRNA) biogenesis | R-HSA-426486 | 5.988827e-01 | 0.223 | 0 | 0 |
| Activation of NIMA Kinases NEK9, NEK6, NEK7 | R-HSA-2980767 | 5.988827e-01 | 0.223 | 0 | 0 |
| STAT5 Activation | R-HSA-9645135 | 5.988827e-01 | 0.223 | 0 | 0 |
| Toxicity of botulinum toxin type F (botF) | R-HSA-5250981 | 5.988827e-01 | 0.223 | 0 | 0 |
| Toxicity of botulinum toxin type D (botD) | R-HSA-5250955 | 5.988827e-01 | 0.223 | 0 | 0 |
| G2/M DNA replication checkpoint | R-HSA-69478 | 5.988827e-01 | 0.223 | 0 | 0 |
| Lactose synthesis | R-HSA-5653890 | 5.988827e-01 | 0.223 | 0 | 0 |
| VLDL assembly | R-HSA-8866423 | 5.988827e-01 | 0.223 | 0 | 0 |
| HDL clearance | R-HSA-8964011 | 5.988827e-01 | 0.223 | 0 | 0 |
| MET Receptor Activation | R-HSA-6806942 | 5.988827e-01 | 0.223 | 0 | 0 |
| Nef and signal transduction | R-HSA-164944 | 5.988827e-01 | 0.223 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 6.002773e-01 | 0.222 | 0 | 0 |
| Regulation of NF-kappa B signaling | R-HSA-9758274 | 6.020734e-01 | 0.220 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 6.020734e-01 | 0.220 | 0 | 0 |
| Regulation of BACH1 activity | R-HSA-9708530 | 6.020734e-01 | 0.220 | 0 | 0 |
| Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion | R-HSA-434316 | 6.020734e-01 | 0.220 | 0 | 0 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | R-HSA-9634600 | 6.020734e-01 | 0.220 | 0 | 0 |
| Activation of SMO | R-HSA-5635838 | 6.020734e-01 | 0.220 | 0 | 0 |
| WNT5A-dependent internalization of FZD4 | R-HSA-5099900 | 6.020734e-01 | 0.220 | 0 | 0 |
| Virus Assembly and Release | R-HSA-168268 | 6.020734e-01 | 0.220 | 0 | 0 |
| Amine ligand-binding receptors | R-HSA-375280 | 6.069603e-01 | 0.217 | 0 | 0 |
| Polymerase switching on the C-strand of the telomere | R-HSA-174411 | 6.088677e-01 | 0.215 | 0 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 6.162405e-01 | 0.210 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 6.179683e-01 | 0.209 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 6.235250e-01 | 0.205 | 0 | 0 |
| Disease | R-HSA-1643685 | 6.271006e-01 | 0.203 | 1 | 0 |
| Processing of Intronless Pre-mRNAs | R-HSA-77595 | 6.284556e-01 | 0.202 | 0 | 0 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | R-HSA-141430 | 6.284556e-01 | 0.202 | 0 | 0 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | R-HSA-141405 | 6.284556e-01 | 0.202 | 0 | 0 |
| mRNA decay by 5' to 3' exoribonuclease | R-HSA-430039 | 6.284556e-01 | 0.202 | 0 | 0 |
| TRAF3-dependent IRF activation pathway | R-HSA-918233 | 6.284556e-01 | 0.202 | 0 | 0 |
| Coenzyme A biosynthesis | R-HSA-196783 | 6.284556e-01 | 0.202 | 0 | 0 |
| Passive transport by Aquaporins | R-HSA-432047 | 6.284556e-01 | 0.202 | 0 | 0 |
| Synthesis of PG | R-HSA-1483148 | 6.284556e-01 | 0.202 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 6.284556e-01 | 0.202 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 6.300928e-01 | 0.201 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 6.300928e-01 | 0.201 | 0 | 0 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 6.300928e-01 | 0.201 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 6.305479e-01 | 0.200 | 0 | 0 |
| Lysosome Vesicle Biogenesis | R-HSA-432720 | 6.344370e-01 | 0.198 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 6.344370e-01 | 0.198 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 6.344370e-01 | 0.198 | 0 | 0 |
| MET activates PI3K/AKT signaling | R-HSA-8851907 | 6.376095e-01 | 0.195 | 0 | 0 |
| IFNG signaling activates MAPKs | R-HSA-9732724 | 6.376095e-01 | 0.195 | 0 | 0 |
| Pre-NOTCH Processing in the Endoplasmic Reticulum | R-HSA-1912399 | 6.376095e-01 | 0.195 | 0 | 0 |
| DAG1 core M1 glycosylations | R-HSA-8932506 | 6.376095e-01 | 0.195 | 0 | 0 |
| Recycling of eIF2:GDP | R-HSA-72731 | 6.376095e-01 | 0.195 | 0 | 0 |
| PTK6 Expression | R-HSA-8849473 | 6.376095e-01 | 0.195 | 0 | 0 |
| Activated NTRK2 signals through CDK5 | R-HSA-9032845 | 6.376095e-01 | 0.195 | 0 | 0 |
| Microbial modulation of RIPK1-mediated regulated necrosis | R-HSA-9686347 | 6.376095e-01 | 0.195 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 6.376095e-01 | 0.195 | 0 | 0 |
| VLDL clearance | R-HSA-8964046 | 6.376095e-01 | 0.195 | 0 | 0 |
| LDL remodeling | R-HSA-8964041 | 6.376095e-01 | 0.195 | 0 | 0 |
| Ca2+ activated K+ channels | R-HSA-1296052 | 6.376095e-01 | 0.195 | 0 | 0 |
| TGFBR3 regulates TGF-beta signaling | R-HSA-9839389 | 6.376095e-01 | 0.195 | 0 | 0 |
| Regulation of PTEN localization | R-HSA-8948747 | 6.376095e-01 | 0.195 | 0 | 0 |
| Netrin mediated repulsion signals | R-HSA-418886 | 6.376095e-01 | 0.195 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 6.436977e-01 | 0.191 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 6.505066e-01 | 0.187 | 0 | 0 |
| Cristae formation | R-HSA-8949613 | 6.505066e-01 | 0.187 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 6.505066e-01 | 0.187 | 0 | 0 |
| Phosphorylation of CD3 and TCR zeta chains | R-HSA-202427 | 6.505066e-01 | 0.187 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 6.505066e-01 | 0.187 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 6.505066e-01 | 0.187 | 0 | 0 |
| Insulin processing | R-HSA-264876 | 6.505066e-01 | 0.187 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 6.520653e-01 | 0.186 | 0 | 0 |
| Regulation of NPAS4 gene expression | R-HSA-9768759 | 6.534550e-01 | 0.185 | 0 | 0 |
| Choline catabolism | R-HSA-6798163 | 6.534550e-01 | 0.185 | 0 | 0 |
| Specification of primordial germ cells | R-HSA-9827857 | 6.534550e-01 | 0.185 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 6.553673e-01 | 0.184 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 6.567323e-01 | 0.183 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 6.691162e-01 | 0.174 | 0 | 0 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 6.691162e-01 | 0.174 | 0 | 0 |
| Elastic fibre formation | R-HSA-1566948 | 6.691162e-01 | 0.174 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 6.701028e-01 | 0.174 | 0 | 0 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 6.701028e-01 | 0.174 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 6.701028e-01 | 0.174 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 6.701028e-01 | 0.174 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 6.701028e-01 | 0.174 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 6.716695e-01 | 0.173 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 6.718381e-01 | 0.173 | 0 | 0 |
| phospho-PLA2 pathway | R-HSA-111995 | 6.725995e-01 | 0.172 | 0 | 0 |
| DAG1 core M2 glycosylations | R-HSA-8932504 | 6.725995e-01 | 0.172 | 0 | 0 |
| EGFR interacts with phospholipase C-gamma | R-HSA-212718 | 6.725995e-01 | 0.172 | 0 | 0 |
| MET receptor recycling | R-HSA-8875656 | 6.725995e-01 | 0.172 | 0 | 0 |
| Regulation of NPAS4 mRNA translation | R-HSA-9768778 | 6.725995e-01 | 0.172 | 0 | 0 |
| Activated NTRK2 signals through PI3K | R-HSA-9028335 | 6.725995e-01 | 0.172 | 0 | 0 |
| Nef mediated downregulation of MHC class I complex cell surface expression | R-HSA-164940 | 6.725995e-01 | 0.172 | 0 | 0 |
| Negative regulation of activity of TFAP2 (AP-2) family transcription factors | R-HSA-8866904 | 6.725995e-01 | 0.172 | 0 | 0 |
| Co-stimulation by ICOS | R-HSA-9927354 | 6.725995e-01 | 0.172 | 0 | 0 |
| Interleukin-9 signaling | R-HSA-8985947 | 6.725995e-01 | 0.172 | 0 | 0 |
| Adrenoceptors | R-HSA-390696 | 6.725995e-01 | 0.172 | 0 | 0 |
| Axonal growth inhibition (RHOA activation) | R-HSA-193634 | 6.725995e-01 | 0.172 | 0 | 0 |
| TGFBR3 PTM regulation | R-HSA-9839383 | 6.725995e-01 | 0.172 | 0 | 0 |
| SLC-mediated bile acid transport | R-HSA-9958517 | 6.725995e-01 | 0.172 | 0 | 0 |
| PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | R-HSA-8849469 | 6.725995e-01 | 0.172 | 0 | 0 |
| Intestinal absorption | R-HSA-8963676 | 6.725995e-01 | 0.172 | 0 | 0 |
| Interleukin-23 signaling | R-HSA-9020933 | 6.725995e-01 | 0.172 | 0 | 0 |
| Extension of Telomeres | R-HSA-180786 | 6.733414e-01 | 0.172 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 6.733414e-01 | 0.172 | 0 | 0 |
| Trafficking of GluR2-containing AMPA receptors | R-HSA-416993 | 6.770928e-01 | 0.169 | 0 | 0 |
| Polo-like kinase mediated events | R-HSA-156711 | 6.770928e-01 | 0.169 | 0 | 0 |
| Tie2 Signaling | R-HSA-210993 | 6.770928e-01 | 0.169 | 0 | 0 |
| Nephron development | R-HSA-9831926 | 6.770928e-01 | 0.169 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 6.855833e-01 | 0.164 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 6.855833e-01 | 0.164 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 6.868768e-01 | 0.163 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 6.868768e-01 | 0.163 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 6.868768e-01 | 0.163 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 6.868768e-01 | 0.163 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 6.868768e-01 | 0.163 | 0 | 0 |
| tRNA Aminoacylation | R-HSA-379724 | 6.868768e-01 | 0.163 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 6.881825e-01 | 0.162 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 6.888807e-01 | 0.162 | 0 | 0 |
| Signaling by CSF3 (G-CSF) | R-HSA-9674555 | 6.888807e-01 | 0.162 | 0 | 0 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | R-HSA-917729 | 6.888807e-01 | 0.162 | 0 | 0 |
| Impaired BRCA2 binding to RAD51 | R-HSA-9709570 | 6.888807e-01 | 0.162 | 0 | 0 |
| Platelet calcium homeostasis | R-HSA-418360 | 6.888807e-01 | 0.162 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 6.892121e-01 | 0.162 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 6.913459e-01 | 0.160 | 0 | 0 |
| PI-3K cascade:FGFR3 | R-HSA-5654710 | 6.993988e-01 | 0.155 | 0 | 0 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | R-HSA-167242 | 6.993988e-01 | 0.155 | 0 | 0 |
| Impaired BRCA2 binding to PALB2 | R-HSA-9709603 | 6.993988e-01 | 0.155 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 6.993988e-01 | 0.155 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 6.993988e-01 | 0.155 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 6.997787e-01 | 0.155 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 6.997787e-01 | 0.155 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 7.014637e-01 | 0.154 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 7.014637e-01 | 0.154 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 7.014637e-01 | 0.154 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 7.034821e-01 | 0.153 | 0 | 0 |
| ALK mutants bind TKIs | R-HSA-9700645 | 7.042129e-01 | 0.152 | 0 | 0 |
| Toxicity of botulinum toxin type A (botA) | R-HSA-5250968 | 7.042129e-01 | 0.152 | 0 | 0 |
| APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway | R-HSA-5649702 | 7.042129e-01 | 0.152 | 0 | 0 |
| p75NTR regulates axonogenesis | R-HSA-193697 | 7.042129e-01 | 0.152 | 0 | 0 |
| MASTL Facilitates Mitotic Progression | R-HSA-2465910 | 7.042129e-01 | 0.152 | 0 | 0 |
| Activation of the AP-1 family of transcription factors | R-HSA-450341 | 7.042129e-01 | 0.152 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex | R-HSA-937042 | 7.042129e-01 | 0.152 | 0 | 0 |
| Interleukin-21 signaling | R-HSA-9020958 | 7.042129e-01 | 0.152 | 0 | 0 |
| mRNA Editing | R-HSA-75072 | 7.042129e-01 | 0.152 | 0 | 0 |
| MAPK1 (ERK2) activation | R-HSA-112411 | 7.042129e-01 | 0.152 | 0 | 0 |
| Regulation of signaling by NODAL | R-HSA-1433617 | 7.042129e-01 | 0.152 | 0 | 0 |
| WNT mediated activation of DVL | R-HSA-201688 | 7.042129e-01 | 0.152 | 0 | 0 |
| AMPK inhibits chREBP transcriptional activation activity | R-HSA-163680 | 7.042129e-01 | 0.152 | 0 | 0 |
| Activation of the TFAP2 (AP-2) family of transcription factors | R-HSA-8866907 | 7.042129e-01 | 0.152 | 0 | 0 |
| Regulation of NPAS4 gene transcription | R-HSA-9768777 | 7.042129e-01 | 0.152 | 0 | 0 |
| Regulated proteolysis of p75NTR | R-HSA-193692 | 7.042129e-01 | 0.152 | 0 | 0 |
| Cellular response to mitochondrial stress | R-HSA-9840373 | 7.042129e-01 | 0.152 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 7.068439e-01 | 0.151 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 7.068439e-01 | 0.151 | 0 | 0 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | R-HSA-1474151 | 7.068439e-01 | 0.151 | 0 | 0 |
| RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | R-HSA-9933387 | 7.068439e-01 | 0.151 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 7.128234e-01 | 0.147 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 7.136677e-01 | 0.147 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 7.167568e-01 | 0.145 | 0 | 0 |
| Maturation of spike protein | R-HSA-9694548 | 7.167568e-01 | 0.145 | 0 | 0 |
| PI-3K cascade:FGFR4 | R-HSA-5654720 | 7.204098e-01 | 0.142 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | R-HSA-9701193 | 7.204098e-01 | 0.142 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | R-HSA-9704331 | 7.204098e-01 | 0.142 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | R-HSA-9704646 | 7.204098e-01 | 0.142 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | R-HSA-9701192 | 7.204098e-01 | 0.142 | 0 | 0 |
| Signaling by NODAL | R-HSA-1181150 | 7.204098e-01 | 0.142 | 0 | 0 |
| Creatine metabolism | R-HSA-71288 | 7.204098e-01 | 0.142 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 7.229416e-01 | 0.141 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 7.240005e-01 | 0.140 | 0 | 0 |
| Budding and maturation of HIV virion | R-HSA-162588 | 7.240005e-01 | 0.140 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 7.240005e-01 | 0.140 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 7.248714e-01 | 0.140 | 0 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 7.270960e-01 | 0.138 | 0 | 0 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | R-HSA-9615017 | 7.314647e-01 | 0.136 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 7.314647e-01 | 0.136 | 0 | 0 |
| Binding and entry of HIV virion | R-HSA-173107 | 7.327754e-01 | 0.135 | 0 | 0 |
| Metabolism of serotonin | R-HSA-380612 | 7.327754e-01 | 0.135 | 0 | 0 |
| Cross-presentation of particulate exogenous antigens (phagosomes) | R-HSA-1236973 | 7.327754e-01 | 0.135 | 0 | 0 |
| Pexophagy | R-HSA-9664873 | 7.327754e-01 | 0.135 | 0 | 0 |
| MAPK3 (ERK1) activation | R-HSA-110056 | 7.327754e-01 | 0.135 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 7.360568e-01 | 0.133 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 7.400464e-01 | 0.131 | 0 | 0 |
| Nucleotide biosynthesis | R-HSA-8956320 | 7.400642e-01 | 0.131 | 0 | 0 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | R-HSA-2979096 | 7.401678e-01 | 0.131 | 0 | 0 |
| Matriglycan biosynthesis on DAG1 | R-HSA-9939291 | 7.401678e-01 | 0.131 | 0 | 0 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | R-HSA-450321 | 7.401678e-01 | 0.131 | 0 | 0 |
| Zygotic genome activation (ZGA) | R-HSA-9819196 | 7.401678e-01 | 0.131 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 7.403620e-01 | 0.131 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 7.517366e-01 | 0.124 | 0 | 0 |
| HDR through Single Strand Annealing (SSA) | R-HSA-5685938 | 7.559430e-01 | 0.122 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 7.559925e-01 | 0.121 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9694635 | 7.576235e-01 | 0.121 | 0 | 0 |
| DAG1 core M3 glycosylations | R-HSA-8932505 | 7.585814e-01 | 0.120 | 0 | 0 |
| Regulation of CDH11 mRNA translation by microRNAs | R-HSA-9759811 | 7.585814e-01 | 0.120 | 0 | 0 |
| LGI-ADAM interactions | R-HSA-5682910 | 7.585814e-01 | 0.120 | 0 | 0 |
| vRNA Synthesis | R-HSA-192814 | 7.585814e-01 | 0.120 | 0 | 0 |
| vRNP Assembly | R-HSA-192905 | 7.585814e-01 | 0.120 | 0 | 0 |
| Chylomicron assembly | R-HSA-8963888 | 7.585814e-01 | 0.120 | 0 | 0 |
| Alpha-protein kinase 1 signaling pathway | R-HSA-9645460 | 7.585814e-01 | 0.120 | 0 | 0 |
| Biosynthesis of DPAn-3-derived maresins | R-HSA-9026290 | 7.585814e-01 | 0.120 | 0 | 0 |
| Inactivation of CSF3 (G-CSF) signaling | R-HSA-9705462 | 7.587188e-01 | 0.120 | 0 | 0 |
| FOXO-mediated transcription of cell cycle genes | R-HSA-9617828 | 7.587188e-01 | 0.120 | 0 | 0 |
| Mitochondrial calcium ion transport | R-HSA-8949215 | 7.587188e-01 | 0.120 | 0 | 0 |
| activated TAK1 mediates p38 MAPK activation | R-HSA-450302 | 7.587188e-01 | 0.120 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 7.587188e-01 | 0.120 | 0 | 0 |
| Ribavirin ADME | R-HSA-9755088 | 7.587188e-01 | 0.120 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 7.591439e-01 | 0.120 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 7.678935e-01 | 0.115 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 7.721295e-01 | 0.112 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 7.721295e-01 | 0.112 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 7.721295e-01 | 0.112 | 0 | 0 |
| PI-3K cascade:FGFR1 | R-HSA-5654689 | 7.761117e-01 | 0.110 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | R-HSA-76071 | 7.761117e-01 | 0.110 | 0 | 0 |
| Ethanol oxidation | R-HSA-71384 | 7.761117e-01 | 0.110 | 0 | 0 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | R-HSA-6803205 | 7.761117e-01 | 0.110 | 0 | 0 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | R-HSA-113501 | 7.818966e-01 | 0.107 | 0 | 0 |
| NF-kB is activated and signals survival | R-HSA-209560 | 7.818966e-01 | 0.107 | 0 | 0 |
| Sema4D mediated inhibition of cell attachment and migration | R-HSA-416550 | 7.818966e-01 | 0.107 | 0 | 0 |
| Proton-coupled monocarboxylate transport | R-HSA-433692 | 7.818966e-01 | 0.107 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 7.848339e-01 | 0.105 | 0 | 0 |
| Diseases of DNA Double-Strand Break Repair | R-HSA-9675136 | 7.848339e-01 | 0.105 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | R-HSA-9701190 | 7.848339e-01 | 0.105 | 0 | 0 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | R-HSA-983170 | 7.848339e-01 | 0.105 | 0 | 0 |
| NPAS4 regulates expression of target genes | R-HSA-9768919 | 7.848339e-01 | 0.105 | 0 | 0 |
| BMAL1:CLOCK,NPAS2 activates circadian expression | R-HSA-1368108 | 7.848339e-01 | 0.105 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 7.873952e-01 | 0.104 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 7.874713e-01 | 0.104 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 7.891213e-01 | 0.103 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 7.902136e-01 | 0.102 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 7.902136e-01 | 0.102 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE | R-HSA-77075 | 7.923970e-01 | 0.101 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | R-HSA-167160 | 7.923970e-01 | 0.101 | 0 | 0 |
| Interleukin-20 family signaling | R-HSA-8854691 | 7.923970e-01 | 0.101 | 0 | 0 |
| Free fatty acids regulate insulin secretion | R-HSA-400451 | 7.923970e-01 | 0.101 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 7.923970e-01 | 0.101 | 0 | 0 |
| Biosynthesis of maresins | R-HSA-9018682 | 7.923970e-01 | 0.101 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 7.964402e-01 | 0.099 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 7.964402e-01 | 0.099 | 0 | 0 |
| PERK regulates gene expression | R-HSA-381042 | 7.981841e-01 | 0.098 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 7.981841e-01 | 0.098 | 0 | 0 |
| Presynaptic phase of homologous DNA pairing and strand exchange | R-HSA-5693616 | 7.981841e-01 | 0.098 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 7.997468e-01 | 0.097 | 0 | 0 |
| Phosphorylation and nuclear translocation of the CRY:PER:kinase complex | R-HSA-9931530 | 8.029614e-01 | 0.095 | 0 | 0 |
| RUNX3 regulates NOTCH signaling | R-HSA-8941856 | 8.029614e-01 | 0.095 | 0 | 0 |
| GRB2 events in EGFR signaling | R-HSA-179812 | 8.029614e-01 | 0.095 | 0 | 0 |
| Biosynthesis of DPAn-3-derived protectins and resolvins | R-HSA-9026286 | 8.029614e-01 | 0.095 | 0 | 0 |
| Trafficking and processing of endosomal TLR | R-HSA-1679131 | 8.029614e-01 | 0.095 | 0 | 0 |
| Activated NTRK2 signals through FRS2 and FRS3 | R-HSA-9028731 | 8.029614e-01 | 0.095 | 0 | 0 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | R-HSA-975144 | 8.029614e-01 | 0.095 | 0 | 0 |
| IRAK1 recruits IKK complex | R-HSA-937039 | 8.029614e-01 | 0.095 | 0 | 0 |
| Reversal of alkylation damage by DNA dioxygenases | R-HSA-73943 | 8.029614e-01 | 0.095 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 8.036027e-01 | 0.095 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 8.044149e-01 | 0.095 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 8.044149e-01 | 0.095 | 0 | 0 |
| Translocation of ZAP-70 to Immunological synapse | R-HSA-202430 | 8.076265e-01 | 0.093 | 0 | 0 |
| Processing of Capped Intronless Pre-mRNA | R-HSA-75067 | 8.076265e-01 | 0.093 | 0 | 0 |
| Mitochondrial RNA degradation | R-HSA-9836573 | 8.076265e-01 | 0.093 | 0 | 0 |
| Complex III assembly | R-HSA-9865881 | 8.076265e-01 | 0.093 | 0 | 0 |
| Retrograde transport at the Trans-Golgi-Network | R-HSA-6811440 | 8.077883e-01 | 0.093 | 0 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 8.084100e-01 | 0.092 | 0 | 0 |
| Triglyceride catabolism | R-HSA-163560 | 8.108335e-01 | 0.091 | 0 | 0 |
| G1/S-Specific Transcription | R-HSA-69205 | 8.108335e-01 | 0.091 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 8.165167e-01 | 0.088 | 0 | 0 |
| Metabolism of polyamines | R-HSA-351202 | 8.182802e-01 | 0.087 | 0 | 0 |
| NGF-stimulated transcription | R-HSA-9031628 | 8.186150e-01 | 0.087 | 0 | 0 |
| PI-3K cascade:FGFR2 | R-HSA-5654695 | 8.218520e-01 | 0.085 | 0 | 0 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | R-HSA-5693554 | 8.218520e-01 | 0.085 | 0 | 0 |
| Acyl chain remodelling of PS | R-HSA-1482801 | 8.218520e-01 | 0.085 | 0 | 0 |
| Laminin interactions | R-HSA-3000157 | 8.218520e-01 | 0.085 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 8.218520e-01 | 0.085 | 0 | 0 |
| Hyaluronan degradation | R-HSA-2160916 | 8.218520e-01 | 0.085 | 0 | 0 |
| PIWI-interacting RNA (piRNA) biogenesis | R-HSA-5601884 | 8.218520e-01 | 0.085 | 0 | 0 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | R-HSA-9659787 | 8.219928e-01 | 0.085 | 0 | 0 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | R-HSA-9661069 | 8.219928e-01 | 0.085 | 0 | 0 |
| Acyl chain remodeling of DAG and TAG | R-HSA-1482883 | 8.219928e-01 | 0.085 | 0 | 0 |
| Processing of SMDT1 | R-HSA-8949664 | 8.219928e-01 | 0.085 | 0 | 0 |
| Replication of the SARS-CoV-1 genome | R-HSA-9682706 | 8.219928e-01 | 0.085 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 8.277371e-01 | 0.082 | 0 | 0 |
| Homologous DNA Pairing and Strand Exchange | R-HSA-5693579 | 8.341245e-01 | 0.079 | 0 | 0 |
| SLC-mediated transport of inorganic anions | R-HSA-9958790 | 8.341245e-01 | 0.079 | 0 | 0 |
| MET activates PTK2 signaling | R-HSA-8874081 | 8.351255e-01 | 0.078 | 0 | 0 |
| Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes | R-HSA-9931510 | 8.351255e-01 | 0.078 | 0 | 0 |
| TRP channels | R-HSA-3295583 | 8.351255e-01 | 0.078 | 0 | 0 |
| Activated NOTCH1 Transmits Signal to the Nucleus | R-HSA-2122948 | 8.351255e-01 | 0.078 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 8.367905e-01 | 0.077 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 8.367905e-01 | 0.077 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 8.373826e-01 | 0.077 | 0 | 0 |
| Azathioprine ADME | R-HSA-9748787 | 8.387609e-01 | 0.076 | 0 | 0 |
| cGMP effects | R-HSA-418457 | 8.391871e-01 | 0.076 | 0 | 0 |
| CLEC7A (Dectin-1) induces NFAT activation | R-HSA-5607763 | 8.391871e-01 | 0.076 | 0 | 0 |
| Regulation of CDH1 mRNA translation by microRNAs | R-HSA-9764562 | 8.391871e-01 | 0.076 | 0 | 0 |
| CRMPs in Sema3A signaling | R-HSA-399956 | 8.391871e-01 | 0.076 | 0 | 0 |
| Hydrolysis of LPC | R-HSA-1483115 | 8.391871e-01 | 0.076 | 0 | 0 |
| Biosynthesis of E-series 18(R)-resolvins | R-HSA-9023661 | 8.391871e-01 | 0.076 | 0 | 0 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | R-HSA-5684264 | 8.391871e-01 | 0.076 | 0 | 0 |
| Signaling by FGFR4 in disease | R-HSA-5655291 | 8.391871e-01 | 0.076 | 0 | 0 |
| Physiological factors | R-HSA-5578768 | 8.391871e-01 | 0.076 | 0 | 0 |
| Prolactin receptor signaling | R-HSA-1170546 | 8.391871e-01 | 0.076 | 0 | 0 |
| Respiratory syncytial virus genome transcription | R-HSA-9828642 | 8.391871e-01 | 0.076 | 0 | 0 |
| Malate-aspartate shuttle | R-HSA-9856872 | 8.391871e-01 | 0.076 | 0 | 0 |
| Acyl chain remodeling of CL | R-HSA-1482798 | 8.391871e-01 | 0.076 | 0 | 0 |
| SARS-CoV-1 Genome Replication and Transcription | R-HSA-9679514 | 8.391871e-01 | 0.076 | 0 | 0 |
| RAS processing | R-HSA-9648002 | 8.448150e-01 | 0.073 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 8.448150e-01 | 0.073 | 0 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 8.448150e-01 | 0.073 | 0 | 0 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | R-HSA-8866652 | 8.474980e-01 | 0.072 | 0 | 0 |
| ER Quality Control Compartment (ERQC) | R-HSA-901032 | 8.474980e-01 | 0.072 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 8.514931e-01 | 0.070 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 8.537265e-01 | 0.069 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 8.537265e-01 | 0.069 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 8.538031e-01 | 0.069 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 8.546210e-01 | 0.068 | 0 | 0 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | R-HSA-8948700 | 8.547214e-01 | 0.068 | 0 | 0 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 8.547214e-01 | 0.068 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 8.547214e-01 | 0.068 | 0 | 0 |
| Protein lipoylation | R-HSA-9857492 | 8.547214e-01 | 0.068 | 0 | 0 |
| p38MAPK events | R-HSA-171007 | 8.547214e-01 | 0.068 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 8.547214e-01 | 0.068 | 0 | 0 |
| Lysosphingolipid and LPA receptors | R-HSA-419408 | 8.547214e-01 | 0.068 | 0 | 0 |
| Other semaphorin interactions | R-HSA-416700 | 8.547214e-01 | 0.068 | 0 | 0 |
| STAT3 nuclear events downstream of ALK signaling | R-HSA-9701898 | 8.547214e-01 | 0.068 | 0 | 0 |
| DNA Damage Reversal | R-HSA-73942 | 8.547214e-01 | 0.068 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 8.549022e-01 | 0.068 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 8.549022e-01 | 0.068 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 8.569955e-01 | 0.067 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 8.582757e-01 | 0.066 | 0 | 0 |
| PINK1-PRKN Mediated Mitophagy | R-HSA-5205685 | 8.590198e-01 | 0.066 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 8.590198e-01 | 0.066 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 8.616304e-01 | 0.065 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 8.644113e-01 | 0.063 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 8.680623e-01 | 0.061 | 0 | 0 |
| Phosphorylation of the APC/C | R-HSA-176412 | 8.687560e-01 | 0.061 | 0 | 0 |
| Class I peroxisomal membrane protein import | R-HSA-9603798 | 8.687560e-01 | 0.061 | 0 | 0 |
| Atorvastatin ADME | R-HSA-9754706 | 8.687560e-01 | 0.061 | 0 | 0 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | R-HSA-210744 | 8.687560e-01 | 0.061 | 0 | 0 |
| Fructose catabolism | R-HSA-70350 | 8.687560e-01 | 0.061 | 0 | 0 |
| Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells) | R-HSA-9942503 | 8.687560e-01 | 0.061 | 0 | 0 |
| Differentiation of T cells | R-HSA-9945266 | 8.687560e-01 | 0.061 | 0 | 0 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | R-HSA-1362300 | 8.687560e-01 | 0.061 | 0 | 0 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | R-HSA-399955 | 8.687560e-01 | 0.061 | 0 | 0 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | R-HSA-6803207 | 8.687560e-01 | 0.061 | 0 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 8.687560e-01 | 0.061 | 0 | 0 |
| tRNA modification in the nucleus and cytosol | R-HSA-6782315 | 8.691728e-01 | 0.061 | 0 | 0 |
| mRNA Capping | R-HSA-72086 | 8.697396e-01 | 0.061 | 0 | 0 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 8.697396e-01 | 0.061 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 8.697396e-01 | 0.061 | 0 | 0 |
| Intra-Golgi traffic | R-HSA-6811438 | 8.733674e-01 | 0.059 | 0 | 0 |
| SLC-mediated transport of neurotransmitters | R-HSA-442660 | 8.733674e-01 | 0.059 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 8.758288e-01 | 0.058 | 0 | 0 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 8.797049e-01 | 0.056 | 0 | 0 |
| Energy dependent regulation of mTOR by LKB1-AMPK | R-HSA-380972 | 8.797049e-01 | 0.056 | 0 | 0 |
| Neurotransmitter clearance | R-HSA-112311 | 8.797049e-01 | 0.056 | 0 | 0 |
| Glycine degradation | R-HSA-6783984 | 8.814355e-01 | 0.055 | 0 | 0 |
| Fibronectin matrix formation | R-HSA-1566977 | 8.814355e-01 | 0.055 | 0 | 0 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 8.814355e-01 | 0.055 | 0 | 0 |
| Transcriptional regulation of testis differentiation | R-HSA-9690406 | 8.814355e-01 | 0.055 | 0 | 0 |
| Regulation of innate immune responses to cytosolic DNA | R-HSA-3134975 | 8.814355e-01 | 0.055 | 0 | 0 |
| Biosynthesis of maresin-like SPMs | R-HSA-9027307 | 8.814355e-01 | 0.055 | 0 | 0 |
| tRNA modification in the mitochondrion | R-HSA-6787450 | 8.814355e-01 | 0.055 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 8.832176e-01 | 0.054 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 8.835165e-01 | 0.054 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 8.882299e-01 | 0.051 | 0 | 0 |
| Respiratory syncytial virus (RSV) attachment and entry | R-HSA-9820960 | 8.889613e-01 | 0.051 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 8.897200e-01 | 0.051 | 0 | 0 |
| Late SARS-CoV-2 Infection Events | R-HSA-9772573 | 8.911891e-01 | 0.050 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 8.917636e-01 | 0.050 | 0 | 0 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | R-HSA-176407 | 8.928907e-01 | 0.049 | 0 | 0 |
| Biosynthesis of aspirin-triggered D-series resolvins | R-HSA-9020265 | 8.928907e-01 | 0.049 | 0 | 0 |
| Elevation of cytosolic Ca2+ levels | R-HSA-139853 | 8.928907e-01 | 0.049 | 0 | 0 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | R-HSA-164938 | 8.928907e-01 | 0.049 | 0 | 0 |
| Replication of the SARS-CoV-2 genome | R-HSA-9694686 | 8.928907e-01 | 0.049 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 8.945706e-01 | 0.048 | 1 | 0 |
| Synthesis of PA | R-HSA-1483166 | 8.950406e-01 | 0.048 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 8.958543e-01 | 0.048 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 8.971653e-01 | 0.047 | 0 | 0 |
| DAG1 glycosylations | R-HSA-8931838 | 8.975528e-01 | 0.047 | 0 | 0 |
| Developmental Lineage of Multipotent Pancreatic Progenitor Cells | R-HSA-9937080 | 8.975528e-01 | 0.047 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 9.017939e-01 | 0.045 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 9.018553e-01 | 0.045 | 0 | 0 |
| Biosynthesis of Lipoxins (LX) | R-HSA-2142700 | 9.032398e-01 | 0.044 | 0 | 0 |
| Regulation of TP53 Activity through Methylation | R-HSA-6804760 | 9.032398e-01 | 0.044 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9679504 | 9.032398e-01 | 0.044 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 9.041549e-01 | 0.044 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 9.055214e-01 | 0.043 | 0 | 0 |
| Cardiogenesis | R-HSA-9733709 | 9.055214e-01 | 0.043 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 9.067579e-01 | 0.043 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 9.075750e-01 | 0.042 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 9.107121e-01 | 0.041 | 0 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 9.107121e-01 | 0.041 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 9.107121e-01 | 0.041 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 9.107761e-01 | 0.041 | 0 | 0 |
| Pre-NOTCH Processing in Golgi | R-HSA-1912420 | 9.125894e-01 | 0.040 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Cyclin B | R-HSA-174048 | 9.125894e-01 | 0.040 | 0 | 0 |
| Germ layer formation at gastrulation | R-HSA-9754189 | 9.125894e-01 | 0.040 | 0 | 0 |
| Signaling by FGFR2 IIIa TM | R-HSA-8851708 | 9.125894e-01 | 0.040 | 0 | 0 |
| Specification of the neural plate border | R-HSA-9834899 | 9.125894e-01 | 0.040 | 0 | 0 |
| Synthesis of 5-eicosatetraenoic acids | R-HSA-2142688 | 9.125894e-01 | 0.040 | 0 | 0 |
| Other interleukin signaling | R-HSA-449836 | 9.125894e-01 | 0.040 | 0 | 0 |
| SARS-CoV-2 Genome Replication and Transcription | R-HSA-9694682 | 9.125894e-01 | 0.040 | 0 | 0 |
| Acyl chain remodelling of PC | R-HSA-1482788 | 9.129072e-01 | 0.040 | 0 | 0 |
| Vitamin B5 (pantothenate) metabolism | R-HSA-199220 | 9.129072e-01 | 0.040 | 0 | 0 |
| Sphingolipid de novo biosynthesis | R-HSA-1660661 | 9.133295e-01 | 0.039 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 9.136131e-01 | 0.039 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 9.168592e-01 | 0.038 | 0 | 0 |
| Synthesis of PC | R-HSA-1483191 | 9.168592e-01 | 0.038 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 9.187145e-01 | 0.037 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 9.197485e-01 | 0.036 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 9.197485e-01 | 0.036 | 0 | 0 |
| Hyaluronan metabolism | R-HSA-2142845 | 9.197485e-01 | 0.036 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 9.197554e-01 | 0.036 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 9.197680e-01 | 0.036 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 9.197680e-01 | 0.036 | 0 | 0 |
| Regulation of PD-L1(CD274) translation | R-HSA-9909620 | 9.210362e-01 | 0.036 | 0 | 0 |
| Formation of ATP by chemiosmotic coupling | R-HSA-163210 | 9.210362e-01 | 0.036 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 9.210362e-01 | 0.036 | 0 | 0 |
| Mitochondrial iron-sulfur cluster biogenesis | R-HSA-1362409 | 9.210362e-01 | 0.036 | 0 | 0 |
| Acyl chain remodelling of PI | R-HSA-1482922 | 9.210362e-01 | 0.036 | 0 | 0 |
| Common Pathway of Fibrin Clot Formation | R-HSA-140875 | 9.210362e-01 | 0.036 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 9.230790e-01 | 0.035 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 9.238879e-01 | 0.034 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 9.245201e-01 | 0.034 | 0 | 0 |
| Acyl chain remodelling of PE | R-HSA-1482839 | 9.260814e-01 | 0.033 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 9.260814e-01 | 0.033 | 0 | 0 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 9.260814e-01 | 0.033 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 9.282955e-01 | 0.032 | 0 | 0 |
| MyD88 deficiency (TLR2/4) | R-HSA-5602498 | 9.286672e-01 | 0.032 | 0 | 0 |
| Biosynthesis of E-series 18(S)-resolvins | R-HSA-9018896 | 9.286672e-01 | 0.032 | 0 | 0 |
| Intrinsic Pathway of Fibrin Clot Formation | R-HSA-140837 | 9.286672e-01 | 0.032 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in apoptosis | R-HSA-9824594 | 9.286672e-01 | 0.032 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 9.286672e-01 | 0.032 | 0 | 0 |
| Phenylalanine metabolism | R-HSA-8964208 | 9.286672e-01 | 0.032 | 0 | 0 |
| Vitamin C (ascorbate) metabolism | R-HSA-196836 | 9.286672e-01 | 0.032 | 0 | 0 |
| Acyl chain remodelling of PG | R-HSA-1482925 | 9.286672e-01 | 0.032 | 0 | 0 |
| Activation of gene expression by SREBF (SREBP) | R-HSA-2426168 | 9.287209e-01 | 0.032 | 0 | 0 |
| Formation of Fibrin Clot (Clotting Cascade) | R-HSA-140877 | 9.319403e-01 | 0.031 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 9.344250e-01 | 0.029 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 9.344250e-01 | 0.029 | 0 | 0 |
| Class B/2 (Secretin family receptors) | R-HSA-373080 | 9.351973e-01 | 0.029 | 0 | 0 |
| IRAK4 deficiency (TLR2/4) | R-HSA-5603041 | 9.355611e-01 | 0.029 | 0 | 0 |
| FRS-mediated FGFR3 signaling | R-HSA-5654706 | 9.355611e-01 | 0.029 | 0 | 0 |
| Glutathione synthesis and recycling | R-HSA-174403 | 9.355611e-01 | 0.029 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 9.355611e-01 | 0.029 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 9.356845e-01 | 0.029 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 9.366540e-01 | 0.028 | 0 | 0 |
| TRAF6 mediated IRF7 activation | R-HSA-933541 | 9.373576e-01 | 0.028 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 9.385265e-01 | 0.028 | 0 | 0 |
| Biosynthesis of D-series resolvins | R-HSA-9018676 | 9.417891e-01 | 0.026 | 0 | 0 |
| FRS-mediated FGFR4 signaling | R-HSA-5654712 | 9.417891e-01 | 0.026 | 0 | 0 |
| Neurotoxicity of clostridium toxins | R-HSA-168799 | 9.417891e-01 | 0.026 | 0 | 0 |
| WNT ligand biogenesis and trafficking | R-HSA-3238698 | 9.417891e-01 | 0.026 | 0 | 0 |
| Cellular hexose transport | R-HSA-189200 | 9.417891e-01 | 0.026 | 0 | 0 |
| RAF-independent MAPK1/3 activation | R-HSA-112409 | 9.417891e-01 | 0.026 | 0 | 0 |
| Fructose metabolism | R-HSA-5652084 | 9.417891e-01 | 0.026 | 0 | 0 |
| LDL clearance | R-HSA-8964038 | 9.417891e-01 | 0.026 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9694676 | 9.417891e-01 | 0.026 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 9.453983e-01 | 0.024 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 9.465338e-01 | 0.024 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 9.469215e-01 | 0.024 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | R-HSA-381771 | 9.469882e-01 | 0.024 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 9.469882e-01 | 0.024 | 0 | 0 |
| Regulation of PTEN mRNA translation | R-HSA-8943723 | 9.474155e-01 | 0.023 | 0 | 0 |
| Response of EIF2AK1 (HRI) to heme deficiency | R-HSA-9648895 | 9.474155e-01 | 0.023 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 9.474155e-01 | 0.023 | 0 | 0 |
| Formation of the ureteric bud | R-HSA-9830674 | 9.474155e-01 | 0.023 | 0 | 0 |
| Synthesis of UDP-N-acetyl-glucosamine | R-HSA-446210 | 9.474155e-01 | 0.023 | 0 | 0 |
| Mitochondrial mRNA modification | R-HSA-9937008 | 9.474155e-01 | 0.023 | 0 | 0 |
| Organic anion transport by SLCO transporters | R-HSA-879518 | 9.474155e-01 | 0.023 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 9.485831e-01 | 0.023 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 9.504618e-01 | 0.022 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 9.512574e-01 | 0.022 | 0 | 0 |
| Mitochondrial tRNA aminoacylation | R-HSA-379726 | 9.512574e-01 | 0.022 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 9.516628e-01 | 0.022 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 9.524984e-01 | 0.021 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 9.528714e-01 | 0.021 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 9.543026e-01 | 0.020 | 0 | 0 |
| Aflatoxin activation and detoxification | R-HSA-5423646 | 9.551969e-01 | 0.020 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 9.564866e-01 | 0.019 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 9.570639e-01 | 0.019 | 0 | 0 |
| MicroRNA (miRNA) biogenesis | R-HSA-203927 | 9.570903e-01 | 0.019 | 0 | 0 |
| FRS-mediated FGFR1 signaling | R-HSA-5654693 | 9.570903e-01 | 0.019 | 0 | 0 |
| Glycogen breakdown (glycogenolysis) | R-HSA-70221 | 9.570903e-01 | 0.019 | 0 | 0 |
| Biosynthesis of electrophilic ω-3 PUFA oxo-derivatives | R-HSA-9027604 | 9.570903e-01 | 0.019 | 0 | 0 |
| Formation of the nephric duct | R-HSA-9830364 | 9.570903e-01 | 0.019 | 0 | 0 |
| Synthesis of PIPs at the early endosome membrane | R-HSA-1660516 | 9.570903e-01 | 0.019 | 0 | 0 |
| Scavenging by Class A Receptors | R-HSA-3000480 | 9.588305e-01 | 0.018 | 0 | 0 |
| Potassium Channels | R-HSA-1296071 | 9.596296e-01 | 0.018 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 9.612068e-01 | 0.017 | 0 | 0 |
| Urea cycle | R-HSA-70635 | 9.612385e-01 | 0.017 | 0 | 0 |
| Sphingolipid catabolism | R-HSA-9845614 | 9.612385e-01 | 0.017 | 0 | 0 |
| Synthesis of PIPs at the Golgi membrane | R-HSA-1660514 | 9.612385e-01 | 0.017 | 0 | 0 |
| Incretin synthesis, secretion, and inactivation | R-HSA-400508 | 9.621806e-01 | 0.017 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 9.630264e-01 | 0.016 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 9.630813e-01 | 0.016 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 9.635380e-01 | 0.016 | 0 | 0 |
| Biosynthesis of DPAn-3 SPMs | R-HSA-9025094 | 9.649859e-01 | 0.015 | 0 | 0 |
| Signaling by FGFR3 in disease | R-HSA-5655332 | 9.649859e-01 | 0.015 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | R-HSA-6803204 | 9.649859e-01 | 0.015 | 0 | 0 |
| Triglyceride metabolism | R-HSA-8979227 | 9.657834e-01 | 0.015 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 9.658497e-01 | 0.015 | 0 | 0 |
| RAB geranylgeranylation | R-HSA-8873719 | 9.682981e-01 | 0.014 | 0 | 0 |
| Telomere Extension By Telomerase | R-HSA-171319 | 9.683712e-01 | 0.014 | 0 | 0 |
| FRS-mediated FGFR2 signaling | R-HSA-5654700 | 9.683712e-01 | 0.014 | 0 | 0 |
| ATF4 activates genes in response to endoplasmic reticulum stress | R-HSA-380994 | 9.683712e-01 | 0.014 | 0 | 0 |
| Prednisone ADME | R-HSA-9757110 | 9.683712e-01 | 0.014 | 0 | 0 |
| Pyroptosis | R-HSA-5620971 | 9.683712e-01 | 0.014 | 0 | 0 |
| TP53 Regulates Transcription of Cell Death Genes | R-HSA-5633008 | 9.685340e-01 | 0.014 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 9.706374e-01 | 0.013 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 9.714122e-01 | 0.013 | 1 | 0 |
| Nitric oxide stimulates guanylate cyclase | R-HSA-392154 | 9.714294e-01 | 0.013 | 0 | 0 |
| Biosynthesis of EPA-derived SPMs | R-HSA-9018679 | 9.714294e-01 | 0.013 | 0 | 0 |
| MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 9.714294e-01 | 0.013 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 9.720886e-01 | 0.012 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 9.728126e-01 | 0.012 | 0 | 0 |
| GABA synthesis, release, reuptake and degradation | R-HSA-888590 | 9.741921e-01 | 0.011 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 9.763063e-01 | 0.010 | 0 | 0 |
| Cargo concentration in the ER | R-HSA-5694530 | 9.766877e-01 | 0.010 | 0 | 0 |
| Biosynthesis of DPA-derived SPMs | R-HSA-9018683 | 9.766877e-01 | 0.010 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 9.766877e-01 | 0.010 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 9.770235e-01 | 0.010 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 9.770235e-01 | 0.010 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 9.776504e-01 | 0.010 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 9.776504e-01 | 0.010 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 9.776504e-01 | 0.010 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 9.785170e-01 | 0.009 | 0 | 0 |
| Chemokine receptors bind chemokines | R-HSA-380108 | 9.792784e-01 | 0.009 | 0 | 0 |
| Diseases associated with glycosylation precursor biosynthesis | R-HSA-5609975 | 9.809788e-01 | 0.008 | 0 | 0 |
| Recycling of bile acids and salts | R-HSA-159418 | 9.809788e-01 | 0.008 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 9.810036e-01 | 0.008 | 0 | 0 |
| Complex IV assembly | R-HSA-9864848 | 9.825890e-01 | 0.008 | 0 | 0 |
| Miscellaneous transport and binding events | R-HSA-5223345 | 9.828185e-01 | 0.008 | 0 | 0 |
| Heme degradation | R-HSA-189483 | 9.828185e-01 | 0.008 | 0 | 0 |
| Collagen biosynthesis and modifying enzymes | R-HSA-1650814 | 9.829738e-01 | 0.007 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 9.836290e-01 | 0.007 | 0 | 0 |
| RA biosynthesis pathway | R-HSA-5365859 | 9.844803e-01 | 0.007 | 0 | 0 |
| Regulation of TLR by endogenous ligand | R-HSA-5686938 | 9.844803e-01 | 0.007 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 9.845294e-01 | 0.007 | 0 | 0 |
| Amino acids regulate mTORC1 | R-HSA-9639288 | 9.853835e-01 | 0.006 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 9.854652e-01 | 0.006 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 9.865758e-01 | 0.006 | 0 | 0 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | R-HSA-163841 | 9.867562e-01 | 0.006 | 0 | 0 |
| HS-GAG biosynthesis | R-HSA-2022928 | 9.873377e-01 | 0.006 | 0 | 0 |
| FGFR2 mutant receptor activation | R-HSA-1839126 | 9.873377e-01 | 0.006 | 0 | 0 |
| Paracetamol ADME | R-HSA-9753281 | 9.877395e-01 | 0.005 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 9.881753e-01 | 0.005 | 1 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 9.884871e-01 | 0.005 | 0 | 0 |
| NCAM1 interactions | R-HSA-419037 | 9.885626e-01 | 0.005 | 0 | 0 |
| Phenylalanine and tyrosine metabolism | R-HSA-8963691 | 9.885626e-01 | 0.005 | 0 | 0 |
| Lysine catabolism | R-HSA-71064 | 9.885626e-01 | 0.005 | 0 | 0 |
| Collagen chain trimerization | R-HSA-8948216 | 9.885626e-01 | 0.005 | 0 | 0 |
| Metabolism of folate and pterines | R-HSA-196757 | 9.885626e-01 | 0.005 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 9.894073e-01 | 0.005 | 0 | 0 |
| Transcriptional regulation of pluripotent stem cells | R-HSA-452723 | 9.896692e-01 | 0.005 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 9.899945e-01 | 0.004 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 9.900909e-01 | 0.004 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 9.905946e-01 | 0.004 | 0 | 0 |
| Pentose phosphate pathway | R-HSA-71336 | 9.906687e-01 | 0.004 | 0 | 0 |
| Amino acid transport across the plasma membrane | R-HSA-352230 | 9.913933e-01 | 0.004 | 0 | 0 |
| Maturation of TCA enzymes and regulation of TCA cycle | R-HSA-9854311 | 9.915716e-01 | 0.004 | 0 | 0 |
| Glycogen metabolism | R-HSA-8982491 | 9.915716e-01 | 0.004 | 0 | 0 |
| Tryptophan catabolism | R-HSA-71240 | 9.915716e-01 | 0.004 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 9.917100e-01 | 0.004 | 0 | 0 |
| SLC-mediated transport of organic anions | R-HSA-9955298 | 9.923561e-01 | 0.003 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 9.934269e-01 | 0.003 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 9.938829e-01 | 0.003 | 0 | 0 |
| CD22 mediated BCR regulation | R-HSA-5690714 | 9.944913e-01 | 0.002 | 0 | 0 |
| Synthesis of Leukotrienes (LT) and Eoxins (EX) | R-HSA-2142691 | 9.949333e-01 | 0.002 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 9.953994e-01 | 0.002 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 9.953994e-01 | 0.002 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 9.953994e-01 | 0.002 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 9.954220e-01 | 0.002 | 0 | 0 |
| SLC-mediated transport of amino acids | R-HSA-9958863 | 9.957933e-01 | 0.002 | 0 | 0 |
| Plasma lipoprotein remodeling | R-HSA-8963899 | 9.966282e-01 | 0.001 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 9.966753e-01 | 0.001 | 0 | 0 |
| Glyoxylate metabolism and glycine degradation | R-HSA-389661 | 9.969547e-01 | 0.001 | 0 | 0 |
| Peptide hormone metabolism | R-HSA-2980736 | 9.970548e-01 | 0.001 | 0 | 0 |
| Diseases associated with O-glycosylation of proteins | R-HSA-3906995 | 9.970695e-01 | 0.001 | 0 | 0 |
| Interconversion of nucleotide di- and triphosphates | R-HSA-499943 | 9.973237e-01 | 0.001 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 9.974616e-01 | 0.001 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 9.974616e-01 | 0.001 | 0 | 0 |
| Aspirin ADME | R-HSA-9749641 | 9.975561e-01 | 0.001 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 9.978139e-01 | 0.001 | 0 | 0 |
| Citric acid cycle (TCA cycle) | R-HSA-71403 | 9.979630e-01 | 0.001 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 9.979718e-01 | 0.001 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 9.979718e-01 | 0.001 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 9.983064e-01 | 0.001 | 0 | 0 |
| Bile acid and bile salt metabolism | R-HSA-194068 | 9.983393e-01 | 0.001 | 0 | 0 |
| Interleukin-10 signaling | R-HSA-6783783 | 9.984512e-01 | 0.001 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 9.985841e-01 | 0.001 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 9.986243e-01 | 0.001 | 0 | 0 |
| Dectin-2 family | R-HSA-5621480 | 9.986518e-01 | 0.001 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 9.986696e-01 | 0.001 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 9.988039e-01 | 0.001 | 1 | 0 |
| Biosynthesis of DHA-derived SPMs | R-HSA-9018677 | 9.988237e-01 | 0.001 | 0 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 9.989004e-01 | 0.000 | 0 | 0 |
| Heparan sulfate/heparin (HS-GAG) metabolism | R-HSA-1638091 | 9.989004e-01 | 0.000 | 0 | 0 |
| Synthesis of bile acids and bile salts | R-HSA-192105 | 9.989698e-01 | 0.000 | 0 | 0 |
| Glutathione conjugation | R-HSA-156590 | 9.990069e-01 | 0.000 | 0 | 0 |
| Signaling by Retinoic Acid | R-HSA-5362517 | 9.990069e-01 | 0.000 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 9.990525e-01 | 0.000 | 0 | 0 |
| Collagen degradation | R-HSA-1442490 | 9.991031e-01 | 0.000 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 9.992098e-01 | 0.000 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 9.992222e-01 | 0.000 | 0 | 0 |
| Complex I biogenesis | R-HSA-6799198 | 9.992685e-01 | 0.000 | 0 | 0 |
| Digestion and absorption | R-HSA-8963743 | 9.992685e-01 | 0.000 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 9.993063e-01 | 0.000 | 0 | 0 |
| Xenobiotics | R-HSA-211981 | 9.993394e-01 | 0.000 | 0 | 0 |
| Nicotinate metabolism | R-HSA-196807 | 9.995134e-01 | 0.000 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 9.995720e-01 | 0.000 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 9.996017e-01 | 0.000 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 9.996194e-01 | 0.000 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 9.996319e-01 | 0.000 | 0 | 0 |
| Fatty acyl-CoA biosynthesis | R-HSA-75105 | 9.996417e-01 | 0.000 | 0 | 0 |
| Metabolism of porphyrins | R-HSA-189445 | 9.996764e-01 | 0.000 | 0 | 0 |
| FCGR activation | R-HSA-2029481 | 9.996781e-01 | 0.000 | 0 | 0 |
| Purine catabolism | R-HSA-74259 | 9.997078e-01 | 0.000 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 9.997293e-01 | 0.000 | 0 | 0 |
| Diseases of carbohydrate metabolism | R-HSA-5663084 | 9.997361e-01 | 0.000 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 9.997585e-01 | 0.000 | 0 | 0 |
| ROS and RNS production in phagocytes | R-HSA-1222556 | 9.997617e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation elongation | R-HSA-5389840 | 9.997784e-01 | 0.000 | 0 | 0 |
| Iron uptake and transport | R-HSA-917937 | 9.997848e-01 | 0.000 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 9.998009e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation initiation | R-HSA-5368286 | 9.998162e-01 | 0.000 | 0 | 0 |
| Developmental Lineage of Pancreatic Acinar Cells | R-HSA-9925561 | 9.998569e-01 | 0.000 | 0 | 0 |
| Mitochondrial ribosome-associated quality control | R-HSA-9937383 | 9.998851e-01 | 0.000 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 9.999139e-01 | 0.000 | 0 | 0 |
| Peroxisomal lipid metabolism | R-HSA-390918 | 9.999141e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation termination | R-HSA-5419276 | 9.999406e-01 | 0.000 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 9.999580e-01 | 0.000 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 9.999641e-01 | 0.000 | 0 | 0 |
| Mitochondrial Fatty Acid Beta-Oxidation | R-HSA-77289 | 9.999772e-01 | 0.000 | 0 | 0 |
| Sensory perception of sweet, bitter, and umami (glutamate) taste | R-HSA-9717207 | 9.999870e-01 | 0.000 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 9.999894e-01 | 0.000 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 9.999897e-01 | 0.000 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 9.999901e-01 | 0.000 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 9.999909e-01 | 0.000 | 1 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 9.999940e-01 | 0.000 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 9.999946e-01 | 0.000 | 0 | 0 |
| Sensory perception of taste | R-HSA-9717189 | 9.999950e-01 | 0.000 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 9.999956e-01 | 0.000 | 0 | 0 |
| O-linked glycosylation | R-HSA-5173105 | 9.999975e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation | R-HSA-5368287 | 9.999977e-01 | 0.000 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 9.999977e-01 | 0.000 | 0 | 0 |
| Biosynthesis of specialized proresolving mediators (SPMs) | R-HSA-9018678 | 9.999987e-01 | 0.000 | 0 | 0 |
| Regulation of Complement cascade | R-HSA-977606 | 9.999993e-01 | 0.000 | 0 | 0 |
| Arachidonate metabolism | R-HSA-2142753 | 9.999995e-01 | 0.000 | 0 | 0 |
| Nucleotide catabolism | R-HSA-8956319 | 9.999996e-01 | 0.000 | 0 | 0 |
| Synthesis of substrates in N-glycan biosythesis | R-HSA-446219 | 9.999997e-01 | 0.000 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 9.999998e-01 | 0.000 | 0 | 0 |
| Metabolism of water-soluble vitamins and cofactors | R-HSA-196849 | 9.999998e-01 | 0.000 | 0 | 0 |
| Glycosaminoglycan metabolism | R-HSA-1630316 | 9.999999e-01 | 0.000 | 0 | 0 |
| Complement cascade | R-HSA-166658 | 9.999999e-01 | 0.000 | 0 | 0 |
| Infection with Enterobacteria | R-HSA-9640148 | 1.000000e+00 | 0.000 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 1.000000e+00 | 0.000 | 0 | 0 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | R-HSA-446193 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 1.000000e+00 | 0.000 | 0 | 0 |
| Cytochrome P450 - arranged by substrate type | R-HSA-211897 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 1.000000e+00 | 0.000 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase II - Conjugation of compounds | R-HSA-156580 | 1.000000e+00 | 0.000 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 1.000000e+00 | 0.000 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 1.000000e+00 | 0.000 | 0 | 0 |
| Expression and translocation of olfactory receptors | R-HSA-9752946 | 1.000000e+00 | -0.000 | 0 | 0 |
| Olfactory Signaling Pathway | R-HSA-381753 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000e+00 | -0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 1.000000e+00 | -0.000 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 1.000000e+00 | -0.000 | 0 | 0 |